U.S. patent application number 14/733615 was filed with the patent office on 2015-10-01 for pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases.
This patent application is currently assigned to PTC THERAPEUTICS, INC.. The applicant listed for this patent is PTC THERAPEUTICS, INC.. Invention is credited to Neil Almstead, Jeffrey A. Campbell, Guangming Chen, Gary M. Karp, Hongyu Ren, Ellen Welch, Richard Wilde.
Application Number | 20150274674 14/733615 |
Document ID | / |
Family ID | 35517967 |
Filed Date | 2015-10-01 |
United States Patent
Application |
20150274674 |
Kind Code |
A1 |
Almstead; Neil ; et
al. |
October 1, 2015 |
PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF
A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES
Abstract
The present invention relates to methods, compounds, and
compositions for treating or preventing diseases associated with
nonsense mutations in an mRNA by administering the compounds or
compositions of the present invention. More particularly, the
present invention relates to methods, compounds, and compositions
for suppressing premature translation termination associated with a
nonsense mutation in an mRNA.
Inventors: |
Almstead; Neil; (Princeton,
NJ) ; Karp; Gary M.; (Princeton Junction, NJ)
; Wilde; Richard; (Somerville, NJ) ; Welch;
Ellen; (Califon, NJ) ; Campbell; Jeffrey A.;
(Bethlehem, PA) ; Ren; Hongyu; (Dayton, NJ)
; Chen; Guangming; (Bridgewater, NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
PTC THERAPEUTICS, INC. |
South Plainfield |
NJ |
US |
|
|
Assignee: |
PTC THERAPEUTICS, INC.
South Plainfield
NJ
|
Family ID: |
35517967 |
Appl. No.: |
14/733615 |
Filed: |
June 8, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11577177 |
May 2, 2008 |
9051342 |
|
|
PCT/US2005/036761 |
Oct 13, 2005 |
|
|
|
14733615 |
|
|
|
|
60617633 |
Oct 13, 2004 |
|
|
|
60617634 |
Oct 13, 2004 |
|
|
|
60617655 |
Oct 13, 2004 |
|
|
|
60617670 |
Oct 13, 2004 |
|
|
|
60617653 |
Oct 13, 2004 |
|
|
|
60624170 |
Nov 3, 2004 |
|
|
|
Current U.S.
Class: |
514/236.5 ;
514/249; 514/255.05; 514/256; 514/314; 514/341; 514/406; 544/140;
544/333; 544/353; 544/405; 546/167; 546/275.4; 548/364.4;
548/364.7; 548/377.1 |
Current CPC
Class: |
C07D 249/08 20130101;
C07D 307/68 20130101; C07D 271/10 20130101; C07D 231/12 20130101;
A61P 25/28 20180101; C07D 263/32 20130101; A61P 43/00 20180101;
A61P 13/12 20180101; A61P 19/02 20180101; C07D 413/12 20130101;
C07F 9/65306 20130101; A61P 9/10 20180101; A61P 3/10 20180101; A61P
35/00 20180101; C07D 403/04 20130101; C07D 333/24 20130101; C07D
271/06 20130101; A61P 37/06 20180101; A61P 5/14 20180101; A61P
37/00 20180101; A61P 11/00 20180101; A61P 1/16 20180101; C07D
251/24 20130101; C07D 413/06 20130101; C07D 409/04 20130101; C07D
405/04 20130101; A61P 3/06 20180101; A61P 7/04 20180101; C07D
271/107 20130101; A61P 21/00 20180101; C07D 417/04 20130101; A61P
19/08 20180101; C07D 233/64 20130101; A61P 7/00 20180101; A61P
25/00 20180101; C07D 261/08 20130101; C07D 277/30 20130101; A61P
9/00 20180101; A61P 25/16 20180101; A61P 27/02 20180101; A61P 35/02
20180101; C07D 401/04 20130101; C07D 285/12 20130101; A61P 3/04
20180101; A61P 19/00 20180101; A61P 29/00 20180101; A61P 37/02
20180101; C07D 413/04 20130101 |
International
Class: |
C07D 231/12 20060101
C07D231/12; C07D 413/04 20060101 C07D413/04; C07D 409/04 20060101
C07D409/04; C07D 401/04 20060101 C07D401/04; C07D 405/04 20060101
C07D405/04; C07D 403/04 20060101 C07D403/04 |
Claims
1-64. (canceled)
65. A compound of Formula 1-C or 1-D ##STR00547## wherein: Ar.sub.1
is selected from the group consisting of: ##STR00548## ##STR00549##
##STR00550## ##STR00551## ##STR00552## ##STR00553## ##STR00554##
wherein * indicates the bond of attachment of Ar.sub.1 to the
5-membered ring of Formula 1-C or 1-D; Ar.sub.2 is absent; Ar.sub.3
is absent; R.sub.1 is carboxy, cyano, or a carbonyl group which is
optionally substituted with a C.sub.1-C.sub.4 alkoxy group, or a
pharmaceutically acceptable salt, hydrate or solvate, clathrate,
racemate, stereoisomer or polymorph thereof.
66. The compound of claim 65, wherein the compound of Formula 1-C
is selected from the group consisting of: ##STR00555## ##STR00556##
##STR00557## ##STR00558## ##STR00559## ##STR00560## ##STR00561##
##STR00562## ##STR00563## ##STR00564## and a pharmaceutically
acceptable salt, hydrate, solvate, clathrate, polymorph, racemate
or stereoisomer thereof.
67. The compound of claim 65, wherein the compound of Formula 1-D
is selected from the group consisting of: ##STR00565## ##STR00566##
##STR00567## ##STR00568## ##STR00569## ##STR00570## ##STR00571##
##STR00572## and a pharmaceutically acceptable salt, hydrate,
solvate, clathrate, polymorph, racemate or stereoisomer
thereof.
68. A compound selected from the group consisting of: ##STR00573##
##STR00574## ##STR00575## ##STR00576## ##STR00577## ##STR00578##
##STR00579## ##STR00580## ##STR00581## ##STR00582## ##STR00583##
##STR00584## ##STR00585## ##STR00586## ##STR00587## ##STR00588##
##STR00589## ##STR00590## and a pharmaceutically acceptable salt,
hydrate, clathrate, polymorph, racemate or stereoisomer
thereof.
69. A method for preventing or treating a disease associated with a
gene having a nonsense mutation encoding a premature stop codon in
mRNA in a patient in need thereof, comprising administering to said
patient a compound of Formula 1-C or 1-D ##STR00591## wherein:
Ar.sub.1 is selected from the group consisting of: ##STR00592##
##STR00593## ##STR00594## ##STR00595## ##STR00596## ##STR00597##
##STR00598## wherein * indicates the bond of attachment of Ar.sub.1
to the 5-membered ring of Formula 1-C or 1-D; Ar.sub.2 is absent;
Ar.sub.3 is absent; R.sub.1 is carboxy, cyano, or a carbonyl group
which is optionally substituted with a C.sub.1-C.sub.4 alkoxy
group, or a pharmaceutically acceptable salt, hydrate or solvate,
clathrate, racemate, stereoisomer or polymorph thereof, wherein the
premature stop codon results in either or both premature mRNA
translation termination or nonsense-mediated mRNA decay, and
wherein the disease is selected from cancer, a lysosomal storage
disorder, an autoimmune disease, a blood disease, a collagen
disease, diabetes, a cardiovascular disease, a pulmonary disease,
an inflammatory disease, a central nervous system disease, heart
disease, kidney disease, a muscular dystrophy, macular
degeneration, retinitis pigmentosa, amyloidosis, giantism,
dwarfism, hypothyroidism, hyperthyroidism, aging or obesity.
70. The method of claim 69, wherein the autoimmune disease is
immunodeficiency, severe combined immunodeficiency, rheumatoid
arthritis or graft versus host disease; wherein the blood disease
is familial polycythemia, hemophilia, Von Willebrand disease,
ataxia-telangiectasia or .beta.-thalassemia; wherein the collagen
disease is epidermolysis bullosa, Marfan syndrome, osteogenesis
imperfecta or cirrhosis; wherein the inflammatory disease is
arthritis, rheumatoid arthritis or osteoarthritis; wherein the
central nervous system disease is multiple sclerosis, classical
late infantile neuronal ceroid lipofuscinosis, Alzheimer's disease
or Tay Sachs disease; wherein the lysosomal storage disorder is
tuberous sclerosis, Niemann Pick disease, mucopolysaccharidosis
type VII, metachromatic leukodystrophy, Sandhoff disease,
mucopolysaccharidosis type IIIA or mucopolysaccharidosis type VI;
wherein the kidney disease is kidney stones; wherein the
cardiovascular disease is familial hypercholesterolemia or
atherosclerosis; wherein the pulmonary disease is cystic fibrosis;
and, wherein the muscular dystrophy is Duchenne muscular
dystrophy.
71. The method of claim 69, wherein the disease is cancer
associated with a genetic or a somatic nonsense mutation in a tumor
suppressor gene in a human subject in need thereof.
72. The method of claim 71, wherein the tumor suppressor gene is
selected from the group consisting of PTEN, BRCA1, BRCA2, Rb, and
p53.
73. The method of claim 71, wherein the cancer is of the head and
neck, eye, skin, mouth, throat, esophagus, chest, bone, blood,
lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries,
kidney, liver, pancreas, brain, intestine, heart or adrenals.
74. The method of claim 71, wherein the cancer is a solid tumor
cancer selected from sarcoma, carcinoma, fibrosarcoma, myxosarcoma,
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma,
angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer,
squamous cell carcinoma, basal cell carcinoma, adenocarcinoma,
sweat gland carcinoma, sebaceous gland carcinoma, papillary
carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary
carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma,
bile duct carcinoma, choriocarcinoma, seminoma, embryonal
carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung
carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic
neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma or
retinoblastoma.
75. The method of claim 71, wherein the cancer is a blood-born
tumor selected from acute lymphoblastic leukemia, acute
lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia,
acute myeloblastic leukemia, acute promyelocytic leukemia, acute
monoblastic leukemia, acute erythroleukemic leukemia, acute
megakaryoblastic leukemia, acute myelomonocytic leukemia, acute
nonlymphocytic leukemia, acute undifferentiated leukemia, chronic
myelocytic leukemia, chronic lymphocytic leukemia, hairy cell
leukemia, or multiple myeloma.
76. The method of claim 69, for inhibiting the growth of a cancer
cell or for selectively producing a protein in a mammal by the
suppression of a genetic or somatic nonsense mutation.
77. The method of claim 69, wherein the compound of Formula 1-C is
selected from the group consisting of: ##STR00599## ##STR00600##
##STR00601## ##STR00602## ##STR00603## ##STR00604## ##STR00605##
##STR00606## ##STR00607## ##STR00608## and a pharmaceutically
acceptable salt, hydrate, solvate, clathrate, polymorph, racemate
or stereoisomer thereof.
78. The method of claim 69, wherein the compound of Formula 1-D is
selected from the group consisting of: ##STR00609## ##STR00610##
##STR00611## ##STR00612## ##STR00613## ##STR00614## ##STR00615##
##STR00616## and a pharmaceutically acceptable salt, hydrate,
solvate, clathrate, polymorph, racemate or stereoisomer
thereof.
79. A method for preventing or treating a disease associated with a
gene having a nonsense mutation encoding a premature stop codon in
mRNA in a patient in need thereof, comprising administering to said
patient a compound selected from the group consisting of:
##STR00617## ##STR00618## ##STR00619## ##STR00620## ##STR00621##
##STR00622## ##STR00623## ##STR00624## ##STR00625## ##STR00626##
##STR00627## ##STR00628## ##STR00629## ##STR00630## ##STR00631##
##STR00632## and a pharmaceutically acceptable salt, hydrate,
solvate, clathrate, polymorph, racemate or stereoisomer thereof,
wherein the premature stop codon results in either or both
premature mRNA translation termination or nonsense-mediated mRNA
decay, and wherein the disease is selected from cancer, a lysosomal
storage disorder, an autoimmune disease, a blood disease, a
collagen disease, diabetes, a cardiovascular disease, a pulmonary
disease, an inflammatory disease, a central nervous system disease,
heart disease, kidney disease, a muscular dystrophy, macular
degeneration, retinitis pigmentosa, amyloidosis, giantism,
dwarfism, hypothyroidism, hyperthyroidism, aging or obesity.
80. The method of claim 79, wherein the autoimmune disease is
immunodeficiency, severe combined immunodeficiency, rheumatoid
arthritis or graft versus host disease; wherein the blood disease
is familial polycythemia, hemophilia, Von Willebrand disease,
ataxia-telangiectasia or .beta.-thalassemia; wherein the collagen
disease is epidermolysis bullosa, Marfan syndrome, osteogenesis
imperfecta or cirrhosis; wherein the inflammatory disease is
arthritis, rheumatoid arthritis or osteoarthritis; wherein the
central nervous system disease is multiple sclerosis, classical
late infantile neuronal ceroid lipofuscinosis, Alzheimer's disease
or Tay Sachs disease; wherein the lysosomal storage disorder is
tuberous sclerosis, Niemann Pick disease, mucopolysaccharidosis
type VII, metachromatic leukodystrophy, Sandhoff disease,
mucopolysaccharidosis type IIIA or mucopolysaccharidosis type VI;
wherein the kidney disease is kidney stones; wherein the
cardiovascular disease is familial hypercholesterolemia or
atherosclerosis; wherein the pulmonary disease is cystic fibrosis;
and, wherein the muscular dystrophy is Duchenne muscular
dystrophy.
81. The method of claim 79, wherein the disease is cancer
associated with a genetic or a somatic nonsense mutation in a tumor
suppressor gene in a human subject in need thereof.
82. The method of claim 81, wherein the tumor suppressor gene is
selected from the group consisting of PTEN, BRCA1, BRCA2, Rb, and
p53.
83. The method of claim 81, wherein the cancer is of the head and
neck, eye, skin, mouth, throat, esophagus, chest, bone, blood,
lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries,
kidney, liver, pancreas, brain, intestine, heart or adrenals.
84. The method of claim 81, wherein the cancer is a solid tumor
cancer selected from sarcoma, carcinoma, fibrosarcoma, myxosarcoma,
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma,
angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer,
squamous cell carcinoma, basal cell carcinoma, adenocarcinoma,
sweat gland carcinoma, sebaceous gland carcinoma, papillary
carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary
carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma,
bile duct carcinoma, choriocarcinoma, seminoma, embryonal
carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung
carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic
neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma or
retinoblastoma.
85. The method of claim 81, wherein the cancer is a blood-born
tumor selected from acute lymphoblastic leukemia, acute
lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia,
acute myeloblastic leukemia, acute promyelocytic leukemia, acute
monoblastic leukemia, acute erythroleukemic leukemia, acute
megakaryoblastic leukemia, acute myelomonocytic leukemia, acute
nonlymphocytic leukemia, acute undifferentiated leukemia, chronic
myelocytic leukemia, chronic lymphocytic leukemia, hairy cell
leukemia, or multiple myeloma.
Description
RELATED APPLICATIONS
[0001] This application claims priority to and the benefit under 35
U.S.C. .sctn.119 of U.S. Application Nos. 60/617,633, filed Oct.
13, 2004, 60/617,634, filed Oct. 13, 2004; 60/617,655, filed Oct.
13, 2004, 60/617,670, filed Oct. 13, 2004, all of which
applications are herein incorporated by reference in their
entireties. The present application also claims priority to and the
benefit under 35 U.S.C. 1119 of U.S. Application Nos. 60/617,653,
filed Oct. 13, 2004, and 60/624,170, filed Nov. 3, 2004. U.S.
Application No. 60/624,170, filed Nov. 3, 2004, is herein
incorporated by reference in its entirety. The present application
also incorporates by reference herein in their entireties
International Patent Applications entitled "Compounds for Nonsense
Suppression, and Methods for Their Use," filed on Oct. 13, 2005 and
identified as Attorney Docket Numbers 19025.040, 19025.041,
19025.042, and 19025.044.
FIELD OF THE INVENTION
[0002] The present invention relates to methods, compounds, and
compositions for treating or preventing diseases associated with
nonsense mutations in an mRNA by administering the compounds or
compositions of the present invention. More particularly, the
present invention relates to methods, compounds, and compositions
for suppressing premature translation termination associated with a
nonsense mutation in an mRNA.
BACKGROUND OF THE INVENTION
[0003] Gene expression in cells depends upon the sequential
processes of transcription and translation. Together, these
processes produce a protein from the nucleotide sequence of its
corresponding gene.
[0004] Transcription involves the synthesis of mRNA from DNA by RNA
polymerase. Transcription begins at a promoter region of the gene
and continues until termination is induced, such as by the
formation of a stem-loop structure in the nascent RNA or the
binding of the rho gene product.
[0005] Protein is then produced from mRNA by the process of
translation, occurring on the ribosome with the aid of tRNA, tRNA
synthetases and various other protein and RNA species. Translation
comprises the three phases of initiation, elongation and
termination. Translation is initiated by the formation of an
initiation complex consisting of protein factors, mRNA, tRNA,
cofactors and the ribosomal subunits that recognize signals on the
mRNA that direct the translation machinery to begin translation on
the mRNA. Once the initiation complex is formed, growth of the
polypeptide chain occurs by the repetitive addition of amino acids
by the peptidyl transferase activity of the ribosome as well as
tRNA and tRNA synthetases. The presence of one of the three
termination codons (UAA, UAG, UGA) in the A site of the ribosome
signals the polypeptide chain release factors (RFs) to bind and
recognize the termination signal. Subsequently, the ester bond
between the 3' nucleotide of the tRNA located in the ribosome's P
site and the nascent polypeptide chain is hydrolyzed, the completed
polypeptide chain is released, and the ribosome subunits are
recycled for another round of translation.
[0006] Mutations of the DNA sequence in which the number of bases
is altered are categorized as insertion or deletion mutations
(e.g., frameshift mutations) and can result in major disruptions of
the genome. Mutations of the DNA that change one base into another
and result in an amino acid substitution are labeled missense
mutations. Base substitutions are subdivided into the classes of
transitions (one purine to another purine, or one pyrimidine to
another pyrimidine) and transversions (a purine to a pyrimidine, or
a pyrimidine to a purine).
[0007] Transition and transversion mutations can result in a
nonsense mutation changing an amino acid codon into one of the
three stop codons. These premature stop codons can produce aberrant
proteins in cells as a result of premature translation termination.
A nonsense mutation in an essential gene can be lethal and can also
result in a number of human diseases, such as, cancers, lysosomal
storage disorders, the muscular dystrophies, cystic fibrosis and
hemophilia, to name a few.
[0008] The human p53 gene is the most commonly mutated gene in
human cancer (Zambetti, G. P. and Levine, A., FASEB 7:855-865
(1993)). Found in both genetic and spontaneous cancers, over 50
different types of human cancers contain p53 mutations and
mutations of this gene occur in 50-55% of all human cancers
(Hollstein, M., et al., Nucleic Acids Res. 22:3551-55 (1994);
International Agency for Research on Cancer (IARC) database).
Approximately 70% of colorectal cancer, 50% of lung cancer and 40%
of breast cancers contain mutant p53 (Koshland, D., Science
262:1953 (1993)). Aberrant forms of p53 are associated with poor
prognosis, more aggressive tumors, metastasis, and lower 5 year
survival rates (Id). p53's role in the induction of cell growth
arrest and/or apoptosis upon DNA damage is believed to be essential
for the destruction of mutated cells that would have otherwise
gained a growth advantage. In addition, p53 sensitizes rapidly
dividing cells to apoptotic signals. Of greater than 15,000
reported mutations in the p53 gene, approximately 7% are nonsense
mutations. Accordingly, there is a need for a safe and effective
treatment directed to p53 nonsense mutations.
[0009] In bacterial and eukaryotic strain with nonsense mutations,
suppression of the nonsense mutation can arise as a result of a
mutation in one of the tRNA molecules so that the mutant tRNA can
recognize the nonsense codon, as a result of mutations in proteins
that are involved in the translation process, as a result of
mutations in the ribosome (either the ribosomal RNA or ribosomal
proteins), or by the addition of compounds known to alter the
translation process (for example, cycloheximide or the
aminoglycoside antibiotics). The result is that an amino acid will
be incorporated into the polypeptide chain, at the site of the
nonsense mutation, and translation will not prematurely terminate
at the nonsense codon. The inserted amino acid will not necessarily
be identical to the original amino acid of the wild-type protein,
however, many amino acid substitutions do not have a gross effect
on protein structure or function. Thus, a protein produced by the
suppression of a nonsense mutation would be likely to possess
activity close to that of the wild-type protein. This scenario
provides an opportunity to treat diseases associated with nonsense
mutations by avoiding premature termination of translation through
suppression of the nonsense mutation.
[0010] The ability of aminoglycoside antibiotics to promote
read-through of eukaryotic stop codons has attracted interest in
these drugs as potential therapeutic agents in human diseases
caused by nonsense mutations. One disease for which such a
therapeutic strategy may be viable is classical late infantile
neuronal ceroid lipofuscinosis (LINCL), a fatal childhood
neurodegenerative disease with currently no effective treatment.
Premature stop codon mutations in the gene CLN2 encoding the
lysosomal tripeptidyl-peptidase 1 (TPP-I) are associated with
disease in approximately half of children diagnosed with LINCL. The
ability of the aminoglycoside gentamicin to restore TPP-I activity
in LINCL cell lines has been examined. In one patient-derived cell
line that was compound heterozygous for a commonly seen nonsense
mutation (Arg208Stop) and a different rare nonsense mutation,
approximately 7% of normal levels of TPP-I were maximally restored
with gentamicin treatment. These results suggest that
pharmacological suppression of nonsense mutations by
aminoglycosides or functionally similar pharmaceuticals may have
therapeutic potential in LINCL (Sleat et. al., Eur. J. Ped. Neurol.
5:Suppl A 57-62 (2001)).
[0011] In cultured cells having premature stop codons in the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) gene, treatment
with aminoglycosides led to the production of full-length CFTR
(Bedwell et. al., Nat. Med. 3:1280-1284 (1997); Howard et. al. Nat.
Med. 2: 467-469 (1996)). In mouse models for Duchenne muscular
dystrophy, gentamicin sulfate was observed to suppress
translational termination at premature stop codons resulting in
full-length dystrophin (Barton-Davis et. al., J. Clin. Invest.
104:375-381 (1999)). A small increase in the amount of full-length
dystrophin provided protection against contraction-induced damage
in the mdx mice. The amino acid inserted at the site of the
nonsense codon was not determined in these studies.
[0012] Accordingly, small molecule therapeutics or prophylactics
that suppress premature translation termination by mediating the
misreading of the nonsense codon would be useful for the treatment
of a number of diseases. The discovery of small molecule drugs,
particularly orally bioavailable drugs, can lead to the
introduction of a broad spectrum of selective therapeutics or
prophylactics to the public which can be used against disease
caused by nonsense mutations is just beginning.
[0013] Clitocine
(6-Amino-5-nitro-4-(.beta.-D-ribo-furanosylamino)pyrimidine) is a
naturally occurring exocyclic amino nucleoside that was first
isolated from the mushroom Clitocybe inversa (Kubo et al., Tet.
Lett. 27: 4277 (1986)). The total synthesis of clitocine has also
been reported. (Moss et al., J. Med. Chem. 31:786-790 (1988) and
Kamikawa et al., J. Chem. Sec. Chem. Commun. 195 (1988)). Clitocine
has been reported to possess insecticidal activity and cytostatic
activity against leukemia cell lines (Kubo et al., Tet. Lett. 27:
4277 (1986) and Moss et al., J. Med. Chem. 31:786-790 (1988)).
However, the use of clitocine as a therapeutic for diseases
associated with a nonsense mutation has not been disclosed until
now. Nor has anyone reported the development of an analogue or
derivative of clitocine that has utility as a therapeutic for
cancer or a disease associated with a nonsense mutation.
[0014] Thus, there remains a need to develop characterize and
optimize lead molecules for the development of novel drugs for
treating or preventing diseases associated with nonsense mutations
of mRNA. Accordingly, it is an object of the present invention to
provide such compounds.
[0015] All documents referred to herein are incorporated by
reference into the present application as though fully set forth
herein.
SUMMARY OF THE INVENTION
[0016] In accordance with the present invention, compounds that
suppress premature translation termination associated with a
nonsense mutation in mRNA have been identified, and methods for
their use provided.
[0017] In one aspect of the invention, compounds of Formula (1) are
provided which are useful for suppressing premature translation
termination associated with a nonsense mutation in mRNA, and for
treating diseases associated with nonsense mutations in mRNA:
##STR00001##
wherein:
[0018] A.sub.1 is C, CH or N;
[0019] V and X are independently selected from N or C;
[0020] W is selected from N, C or CH;
[0021] wherein at least one of V, W, or X is N, and wherein if W is
N, at least one of V or X also N;
[0022] Y and Z are independently selected from N, C, C--R.sub.c,
C.dbd.O, C.dbd.S, wherein R.sub.c is H, CH.sub.3, or NH.sub.2; with
the proviso that when one of Y or Z is C.dbd.O or C.dbd.S, the
other may also be selected from NH, S, or O;
[0023] R.sub.1 is carboxy, cyano, or a carbonyl group which is
optionally substituted with a C.sub.1-C.sub.4 alkoxy group,
[0024] R.sub.2 is absent or a nitro;
[0025] Ar.sub.1 is a C.sub.1 to C.sub.4 alkyl which is optionally
substituted with a R group; a C.sub.6 to C.sub.10 aryl which is
optionally substituted with one, two or three independently
selected R groups; a five to ten membered heterocycle which is
optionally substituted with one, two or three independently
selected R groups; together with Ar.sub.2 and the heterocycle to
which Ar.sub.1 and Ar.sub.2 are attached form a ring structure
selected from Ar.sub.1-2; or together with Ar.sub.3 and the
heterocycle to which Ar.sub.1 and Ar.sub.3 are attached form a ring
structure selected from Ar.sub.1-3;
[0026] Ar.sub.2 is absent or together with Ar.sub.1 and the
heterocycle to which Ar.sub.1 and Ar.sub.2 are attached form a ring
structure selected from Ar.sub.1-2;
[0027] Ar.sub.3 is absent or together with Ar.sub.1 and the
heterocycle to which Ar.sub.1 and Ar.sub.3 are attached form a ring
structure selected from Ar.sub.1-3;
[0028] Ar.sub.4 is absent or is a C.sub.1-C.sub.4 alkyl, a
C.sub.1-C.sub.4 alkoxy, or a C.sub.1-C.sub.4 thioalkyl, any of
which together with A.sub.1 forms a four to seven membered
carbocycle or heterocycle;
[0029] R is hydrogen; a --R.sub.a group; or two R groups, where R
may also include an oxy group, together with the phenyl or
heterocycle to which they are attached form a ring structure
selected from RR;
[0030] wherein:
[0031] Ar.sub.1-2 and Ar.sub.1-3 are selected from an eleven to
fourteen membered hetero-tricycle ring structure optionally
substituted with one or more halogens, C.sub.1-C.sub.4 alkyl
groups, C.sub.1-C.sub.4 haloalkyl groups, C.sub.1-C.sub.4 alkoxy
groups optionally substituted with a halogen or a C.sub.1-C.sub.4
alkoxy group, C.sub.1-C.sub.4 haloalkoxy groups, or amino groups
optionally substituted with a carbonyl group which is substituted
with a C.sub.1-C.sub.4 alkyl group;
[0032] RR is a nine to ten membered bicyclic ring structure
optionally substituted with one or more halogens, C.sub.1-C.sub.4
alkyl groups, C.sub.1-C.sub.4 haloalkyl groups, C.sub.1-C.sub.4
alkoxy groups, oxo groups, or C.sub.1-C.sub.4 haloalkoxy
groups;
[0033] R.sub.a is selected from the group consisting of: a hydroxy
group; a halogen; a C.sub.1-C.sub.4 alkyl which is optionally
substituted with one or more independently selected halogen or
hydroxy groups; a C.sub.1-C.sub.4 alkoxy which is optionally
substituted with one or more independently selected halogen or
phenyl groups; a C.sub.4-C.sub.8 cycloalkyl which is optionally
substituted with one or more independently selected C.sub.1-C.sub.4
alkyl groups; an --R.sub.b group; a --O--R.sub.b group; a four to
six-membered heterocycle which is optionally substituted with one
or more independently selected C.sub.1-C.sub.4 alkyl, oxo, or
--R.sub.b groups; a nine to ten membered heterocycle having two
ring structures; a carbonyl which is optionally substituted with a
hydroxy, a C.sub.1-C.sub.4 alkyl, or a C.sub.1-C.sub.4 alkoxy
group; a carbamoyl which is optionally substituted with one or two
C.sub.1-C.sub.4 alkyl groups; a nitro group; a cyano group; a thio
which is optionally substituted with a hydroxy, a C.sub.1-C.sub.4
alkyl, or --R.sub.b group; a sulfonyl which is optionally
substituted with a hydroxy, a C.sub.1-C.sub.4 alkyl, or --R.sub.b
group; or an amino which is optionally substituted with one or two
independently selected C.sub.1-C.sub.4 alkyl, sulfonyl, or carbonyl
groups, wherein the aminosulfonyl group is optionally substituted
with a hydroxy, a C.sub.1-C.sub.4 alkyl, or --R.sub.b group and
wherein the aminocarbonyl group is optionally substituted with a
C.sub.1-C.sub.4 alkyl, a C.sub.1-C.sub.4 haloalkyl, a benzoxy, or
an amino group which is optionally substituted with an --R.sub.b
group; [0034] wherein --R.sub.b is a C.sub.6-C.sub.8 aryl which is
optionally substituted with one or more of the following: a
hydroxy, a halogen, a C.sub.1-C.sub.4 alkyl group, a
C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 alkoxy group, or
an amino group which is optionally substituted with one or more
C.sub.1-C.sub.4 alkyl groups;
[0035] or a pharmaceutically acceptable salt, hydrate, solvate,
clathrate, racemate, stereoisomer, or polymorph of said compound of
Formula 1.
[0036] In another aspect of the invention, methods are provided for
the suppression of premature translation termination associated
with a nonsense mutation, and for the prevention or treatment of
diseases associated with nonsense mutations of mRNA. Such diseases
include, but are not limited to, genetic diseases caused by
premature translation termination associated with a nonsense
mutation, such as a CNS disease, an inflammatory disease, a
neurodegenerative disease, an autoimmune disease, a cardiovascular
disease, or a pulmonary disease; more preferably the disease is
cancer (or other proliferative diseases), amyloidosis, Alzheimer's
disease, atherosclerosis, giantism, dwarfism, hypothyroidism,
hyperthyroidism, cystic fibrosis, aging, obesity, Parkinson's
disease, Niemann Pick's disease, familial hypercholesterolemia,
retinitis pigmentosa, Marfan syndrome, lysosomal storage disorders,
the muscular dystrophies, cystic fibrosis, hemophilia, or classical
late infantile neuronal ceroid lipofuscinosis (LINCL).
[0037] In one embodiment, the invention is directed to methods for
suppressing premature translation termination associated with a
nonsense mutation in mRNA comprising administering a
nonsense-suppressing amount of at least one compound of the
invention to a subject in need thereof.
[0038] In yet another embodiment, methods for treating cancer,
lysosomal storage disorders, a muscular dystrophy, cystic fibrosis,
hemophilia, or classical late infantile neuronal ceroid
lipofuscinosis are provided comprising administering a
therapeutically effective amount of at least one compound of the
invention to a subject in need thereof.
[0039] These and other aspects of the invention will be more
clearly understood with reference to the following preferred
embodiments and detailed description.
CERTAIN EMBODIMENTS
[0040] 1. A method of treating or preventing a disease resulting
from a somatic mutation comprising administering to a patient in
need thereof an effective amount of a compound of Formula 1:
##STR00002##
wherein:
[0041] A.sub.1 is C, CH or N;
[0042] V and X are independently selected from N or C;
[0043] W is selected from N, C or CH;
[0044] wherein at least one of V, W, or X is N, and wherein if W is
N, at least one of V or X is also N;
[0045] Y and Z are independently selected from N, C, C--R.sub.c,
C.dbd.O, C.dbd.S, wherein R.sub.c is H, CH.sub.3, or NH.sub.2; with
the proviso that when one of Y or Z is C.dbd.O or C.dbd.S, the
other may also be selected from NH, S, or O;
[0046] R.sub.1 is carboxy, cyano, or a carbonyl group which is
optionally substituted with a C.sub.1-C.sub.4 alkoxy group,
[0047] R.sub.2 is absent or a nitro;
[0048] Ar.sub.1 is a C.sub.1 to C.sub.4 alkyl which is optionally
substituted with an R group; a C.sub.6 to C.sub.10 aryl which is
optionally substituted with one, two or three independently
selected R groups; a five to ten membered heterocycle which is
optionally substituted with one, two or three independently
selected R groups; together with Ar.sub.2 and the heterocycle to
which Ar.sub.1 and Ar.sub.2 are attached form a ring structure
selected from Ar.sub.1-2; or together with Ar.sub.3 and the
heterocycle to which Ar.sub.1 and Ar.sub.3 are attached form a ring
structure selected from Ar.sub.1-3;
[0049] Ar.sub.2 is absent or together with Ar.sub.1 and the
heterocycle to which Ar.sub.1 and Ar.sub.2 are attached form a ring
structure selected from Ar.sub.1-2
[0050] Ar.sub.3 is absent or together with Ar.sub.1 and the
heterocycle to which Ar.sub.1 and Ar.sub.3 are attached form a ring
structure selected from Ar.sub.1-3;
[0051] Ar.sub.4 is absent; or is a C.sub.1-C.sub.4 alkyl, a
C.sub.1-C.sub.4 alkoxy, or a C.sub.1-C.sub.4 thioalkyl, any of
which together with A.sub.1 forms a four to seven membered
carbocycle or heterocycle;
[0052] R is hydrogen; a --R.sub.a group; or two R groups, where R
may also include an oxy group, together with the phenyl or
heterocycle to which they are attached form a ring structure
selected from RR;
[0053] wherein:
[0054] Ar.sub.1-2 and Ar.sub.1-3 are selected from an eleven to
fourteen membered hetero-tricycle ring structure optionally
substituted with one or more halogens, C.sub.1-C.sub.4 alkyl
groups, C.sub.1-C.sub.4 haloalkyl groups, C.sub.1-C.sub.4 alkoxy
groups optionally substituted with a halogen or a C.sub.1-C.sub.4
alkoxy group, C.sub.1-C.sub.4 haloalkoxy groups, or amino groups
optionally substituted with a carbonyl group which is substituted
with a C.sub.1-C.sub.4 alkyl group;
[0055] RR is a nine to ten membered bicyclic ring structure
optionally substituted with one or more halogens, C.sub.1-C.sub.4
alkyl groups, C.sub.1-C.sub.4 haloalkyl groups, C.sub.1-C.sub.4
alkoxy groups, oxo groups, or C.sub.1-C.sub.4 haloalkoxy
groups;
[0056] R.sub.a is selected from the group consisting of: a hydroxy
group; a halogen; a C.sub.1-C.sub.4 alkyl which is optionally
substituted with one or more independently selected halogen or
hydroxy groups; a C.sub.1-C.sub.4 alkoxy which is optionally
substituted with one or more independently selected halogen or
phenyl groups; a C.sub.4-C.sub.8 cycloalkyl which is optionally
substituted with one or more independently selected C.sub.1-C.sub.4
alkyl groups; an --R.sub.b group; a --O--R.sub.b group; a four to
six-membered heterocycle which is optionally substituted with one
or more independently selected C.sub.1-C.sub.4 alkyl, oxo, or
--R.sub.b groups; a nine to ten membered heterocycle having two
ring structures; a carbonyl which is optionally substituted with a
hydroxy, a C.sub.1-C.sub.4 alkyl, or a C.sub.1-C.sub.4 alkoxy
group; a carbamoyl which is optionally substituted with one or two
C.sub.1-C.sub.4 alkyl groups; a nitro group; a cyano group; a thio
which is optionally substituted with a hydroxy, a C.sub.1-C.sub.4
alkyl, or --R.sub.b group; a sulfonyl which is optionally
substituted with a hydroxy, a C.sub.1-C.sub.4 alkyl, or --R.sub.b
group; or an amino which is optionally substituted with one or two
independently selected C.sub.1-C.sub.4 alkyl, sulfonyl, or carbonyl
groups, wherein the aminosulfonyl group is optionally substituted
with a hydroxy, a C.sub.1-C.sub.4 alkyl, or --R.sub.b group and
wherein the aminocarbonyl group is optionally substituted with a
C.sub.1-C.sub.4 alkyl, a C.sub.1-C.sub.4 haloalkyl, a benzoxy, or
an amino group which is optionally substituted with an --R.sub.b
group;
[0057] wherein --R.sub.b is a C.sub.6-C.sub.1 aryl which is
optionally substituted with one or more of the following: a
hydroxy, a halogen, a C.sub.1-C.sub.4 alkyl group, a
C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 alkoxy group, or
an amino group which is optionally substituted with one or more
C.sub.1-C.sub.4 alkyl groups;
[0058] or a pharmaceutically acceptable salt, hydrate, solvate,
clathrate, racemate, stereoisomer, or polymorph of said compound of
Formula 1.
[0059] 2. The method of embodiment 1, wherein the compound, or a
pharmaceutically acceptable salt, hydrate, solvate, clathrate
polymorph, racemate, stereoisomer, or polymorph thereof, is
administered as a composition comprising the compound and a
pharmaceutically acceptable carrier or diluent.
[0060] 3. The method of embodiment 1, wherein the administration is
intravenous.
[0061] 4. The method of embodiment 1, wherein Ar.sub.1-2 is
selected from the following:
##STR00003##
[0062] wherein the * indicates the bond of attachment of Ar.sub.1-2
to the 6-membered ring of Formula 1.
[0063] Ar.sub.1-3 is selected from the following:
##STR00004##
[0064] wherein the * indicates the bond of attachment of Ar.sub.1-3
to the 6-membered ring of Formula 1.
[0065] and RR is selected from the following: a quinoline group; a
napthyl group; a benzo[1,3]dioxole group; a benzo[1,4]dioxole
group; an indolyl group; or a quinoxaline group;
##STR00005##
[0066] wherein the * indicates the bond of attachment of RR to the
5-membered ring of Formula 1.
[0067] 5. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-A:
##STR00006##
[0068] wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4, and A.sub.5 are
independently selected from N, C and CH; Ar.sub.3 is absent or
hydrogen and n is 0, 1, or 2.
[0069] 6. The method of embodiment 5, wherein R.sub.2 is absent and
A.sub.1, A.sub.2, A.sub.3, A.sub.4, and A.sub.5 are independently
selected from C and CH.
[0070] 7. The method of embodiment 5, wherein R.sub.1 is a carboxy
group.
[0071] 8. The method embodiment 1, wherein the compound of Formula
1 is a compound of Formula 1-B:
##STR00007##
[0072] 9. The method of embodiment 8, wherein R.sub.1 is a carboxy
group.
[0073] 10. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-C:
##STR00008##
[0074] 11. The method of embodiment 10, wherein Ar.sub.1 is a
thienyl group.
[0075] 12. The method of embodiment 10, wherein R.sub.1 is a
carboxy group.
[0076] 13. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-D:
##STR00009##
[0077] 14. The method of embodiment 13, wherein Ar.sub.2 is
absent.
[0078] 15. The method of embodiment 13, wherein Ar.sub.3 is
hydrogen.
[0079] 16. The method of embodiment 13, wherein R.sub.1 is a
carboxy group.
[0080] 17. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-E:
##STR00010##
[0081] 18. The method of embodiment 17, wherein Ar.sub.1 is a
phenyl group optionally substituted with one or two R groups.
[0082] 19. The method of embodiment 18, wherein the one or two R
groups are independently selected from a C.sub.1-C.sub.4 alkyl
group and a halogen.
[0083] 20. The method of embodiment 17, wherein R.sub.1 is a
carboxy group.
[0084] 21. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-F:
##STR00011##
[0085] 22. The method of embodiment 21, wherein Ar.sub.1 is a
phenyl group optionally substituted with one or two R groups.
[0086] 23. The method of embodiment 22, wherein the one or two R
groups are independently selected from a C.sub.1-C.sub.4 alkyl
group, a halogen, C.sub.1-C.sub.4 haloalkyl, and a methanesulfonyl
group, or two R groups together form a quinoline group.
[0087] 24. The method of embodiment 21, wherein R.sub.1 is a
carboxy group.
[0088] 25. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-G:
##STR00012##
[0089] 26. The method of embodiment 25, wherein Ar.sub.1 is a
phenyl group optionally substituted with one or two R groups.
[0090] 27. The method of embodiment 26, wherein the one or two R
groups are independently selected from a C.sub.1-C.sub.4 alkyl
group and a cyano group.
[0091] 28. The method of embodiment 25, wherein R.sub.1 is a
carboxy group.
[0092] 29. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-H:
##STR00013##
[0093] 30. The method of embodiment 29, wherein Ar.sub.1 is a
phenyl group optionally substituted with one or two R groups.
[0094] 31. The method of embodiment 30, wherein the one or two R
groups are C.sub.1-C.sub.4 alkyl groups.
[0095] 32. The method of embodiment 29, wherein R.sub.1 is a
carboxy group.
[0096] 33. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-I:
##STR00014##
[0097] 34. The method of embodiment 33, wherein Ar.sub.1 is a
phenyl group optionally substituted with one or two R groups.
[0098] 35. The method of embodiment 34, wherein the one or two R
groups are C.sub.1-C.sub.4 alkyl groups.
[0099] 36. The method of embodiment 33, wherein R.sub.1 is a
carboxy group.
[0100] 37. The method of embodiment 1, wherein the compound of
Formula 1 is a compound of Formula 1-J:
##STR00015##
[0101] 38. The method of embodiment 37, wherein Ar.sub.1 is a
phenyl group optionally substituted with one or two R groups.
[0102] 39. The method of embodiment 38, wherein the one or two R
groups are C.sub.1-C.sub.4 alkyl groups.
[0103] 40. The method of embodiment 37, wherein R.sub.1 is a
carboxy group.
[0104] 41. A method of treating or preventing an autoimmune
disease, a blood disease, a collagen disease, diabetes, a
neurodegenerative disease, a cardiovascular disease, a pulmonary
disease, or an inflammatory disease or central nervous system
disease comprising administering to a patient in need thereof an
effective amount of a compound of Formula 1, or a pharmaceutically
acceptable salt, hydrate, solvate, clathrate, racemate,
stereoisomer, or polymorph thereof.
[0105] 42. The method of embodiment 41, wherein the administration
is intravenous.
[0106] 43. The method of embodiment 41, wherein the autoimmune
disease is rheumatoid arthritis or graft versus host disease.
[0107] 44. The method of embodiment 41, wherein the inflammatory
disease is arthritis.
[0108] 45. The method of embodiment 41, wherein the central nervous
system disease is multiple sclerosis, muscular dystrophy, Duchenne
muscular dystrophy, Alzheimer's disease, a neurodegenerative
disease or Parkinson's disease.
[0109] 46. The method of embodiment 41, wherein the blood disorder
is hemophilia, Von Willebrand disease, or .beta.-thalassemia.
[0110] 47. The method of embodiment 41, wherein the collagen
disease is osteogenesis imperfecta or cirrhosis.
[0111] 48. A method of treating or preventing familial
polycythemia, immunodeficiency, kidney disease, cystic fibrosis,
familial hypercholesterolemia, retinitis pigmentosa, amyloidosis,
hemophilia, Alzheimer's disease, Tay Sachs disease, Niemann Pick
disease, Parkinson's disease, atherosclerosis, giantism, dwarfism,
hyperthyroidism, aging, obesity, Duchenne muscular dystrophy or
Marfan syndrome comprising administering to a patient in need
thereof an effective amount of a compound of Formula 1, or a
pharmaceutically acceptable salt, hydrate, solvate, clathrate,
racemate, stereoisomer, or polymorph thereof.
[0112] 49. The method of embodiment 48, wherein the administration
is intravenous.
[0113] 50. A method of treating or preventing cancer in a human
comprising administering to a human in need thereof an effective
amount of a compound of Formula 1, or a pharmaceutically acceptable
salt, hydrate, solvate, clathrate, racemate, stereoisomer, or
polymorph thereof.
[0114] 51. The method of embodiment 50, wherein the administration
is intravenous.
[0115] 52. The method of embodiment 50, wherein the cancer is of
the head and neck, eye, skin, mouth, throat, esophagus, chest,
bone, blood, lung, colon, sigmoid, rectum, stomach, prostate,
breast, ovaries, kidney, liver, pancreas, brain, intestine, heart
or adrenals.
[0116] 53. The method of embodiment 50, wherein the compound, or a
pharmaceutically acceptable salt, hydrate, solvate, clathrate or
stereoisomer thereof, comprises a pharmaceutically acceptable
carrier or diluent.
[0117] 54. The method of embodiment 50, wherein the cancer is a
solid tumor.
[0118] 55. The method of embodiment 50, wherein the cancer is
sarcoma, carcinoma, fibrosarcoma, myxosarcoma, liposarcoma,
chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,
endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,
synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,
rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast
cancer, ovarian cancer, prostate cancer, squamous cell carcinoma,
basal cell carcinoma, adenocarcinoma, sweat gland carcinoma,
sebaceous gland carcinoma, papillary carcinoma, papillary
adenocarcinomas, cystadenocarinoma, medullary carcinoma,
bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms'
tumor, cervical cancer, testicular tumor, lung carcinoma, small
cell lung carcinoma, bladder carcinoma, epithelial carcinoma,
glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic
neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma,
retinoblastoma, a blood-born tumor or multiple myeloma.
[0119] 56. The method of embodiment 50, wherein the cancer is acute
lymphoblastic leukemia, acute lymphoblastic B-cell leukemia, acute
lymphoblastic T-cell leukemia, acute myeloblastic leukemia, acute
promyelocytic leukemia, acute monoblastic leukemia, acute
erythroleukemic leukemia, acute megakaryoblastic leukemia, acute
myelomonocytic leukemia, acute nonlymphocytic leukemia, acute
undifferentiated leukemia, chronic myelocytic leukemia, chronic
lymphocytic leukemia, hairy cell leukemia, or multiple myeloma.
[0120] 57. A method of treating or preventing a disease associated
with a mutation of the p53 gene comprising administering to a
patient in need thereof an effective amount of a compound of
Formula 1, or a pharmaceutically acceptable salt, hydrate, solvate,
clathrate, racemate, stereoisomer, or polymorph thereof.
[0121] 58. The method of embodiment 57, wherein the administration
is intravenous.
[0122] 59. The method of embodiment 57, wherein the disease is
sarcoma, carcinomas, fibrosarcoma, myxosarcoma, liposarcoma,
chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,
endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,
synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,
rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast
cancer, ovarian cancer, prostate cancer, squamous cell carcinoma,
basal cell carcinoma, adenocarcinoma, sweat gland carcinoma,
sebaceous gland carcinoma, papillary carcinoma, papillary
adenocarcinomas, cystadenocarcinoma, medullary carcinoma,
bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms'
tumor, cervical cancer, testicular tumor, lung carcinoma, small
cell lung carcinoma, bladder carcinoma, epithelial carcinoma,
glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic
neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma or
retinoblastoma.
[0123] 60. A method of inhibiting the growth of a cancer cell
comprising contacting the cancer cell with an effective amount of a
compound of Formula 1, or a pharmaceutically acceptable salt,
hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph
thereof.
[0124] 61. A method for selectively producing a protein in a mammal
comprising, transcribing a gene containing a nonsense mutation in
the mammal; and providing an effective amount of a compound of the
present invention to maid mammal, wherein said protein is produced
from said gene containing a nonsense mutation.
BRIEF DESCRIPTION OF THE DRAWINGS
[0125] FIG. 1 provides schematic representations of constructs for
luciferase based assays to evaluate the suppression of a nonsense
mutation.
[0126] FIG. 2 provides schematic representations of the luciferase
constructs engineered to harbor one or more epitope tags in the
N-terminus of the luciferase protein.
[0127] FIG. 3 provides schematic representations of constructs for
luciferase based assays to evaluate readthrough efficiency.
DETAILED DESCRIPTION OF THE INVENTION
[0128] Premature translation termination can produce aberrant
proteins which can be lethal or can cause a number of diseases,
including as non-limiting examples, cancers, lysosomal storage
disorders, the muscular dystrophies, cystic fibrosis and
hemophilia. In accordance with the present invention, compounds
that suppress nonsense mutations have been identified, and methods
for their use provided.
[0129] A. Compounds of the Invention
[0130] In one aspect of the invention, compounds of the invention
are provided which are useful in suppression of a nonsense
mutation. In certain embodiments, the compounds of the invention
specifically suppresses a nonsense mutation, while in other
embodiments, the compounds of the invention suppress a nonsense
mutation as well as treat a disease, including as non-limiting
examples, cancers, lysosomal storage disorders, the muscular
dystrophies, cystic fibrosis and hemophilia.
[0131] Preferred compounds of the present invention useful in the
suppression of a nonsense mutation include those of Formula (1) as
shown below.
##STR00016##
wherein.
[0132] A.sub.1 is C, CH or N;
[0133] V and X are independently selected from N or C;
[0134] W is selected from N, C or CH:
[0135] wherein at least one of V, W, or X is N, and wherein if W is
N, at least one of V or X is also N;
[0136] Y and Z are independently selected from N, C, C--R.sub.c,
C.dbd.O, C.dbd.S, wherein R.sub.c is H, CH.sub.3, or NH.sub.2; with
the proviso that when one of Y or Z is C.dbd.O or C.dbd.S, the
other may also be selected from NH, S, or O;
[0137] R.sub.1 is carboxy, cyano, or a carbonyl group which is
optionally substituted with a C.sub.1-C.sub.4 alkoxy group,
[0138] R.sub.2 is absent or a nitro;
[0139] Ar.sub.1 is a C.sub.1 to C.sub.4 alkyl which is optionally
substituted with an R group; a C.sub.5 to C.sub.10 aryl which is
optionally substituted with one, two or three independently
selected R groups; a five to ten membered heterocycle which is
optionally substituted with one, two or three independently
selected R groups; together with Ar.sub.2 and the heterocycle to
which Ar.sub.1 and Ar.sub.2 are attached form a ring structure
selected from Ar.sub.1-2; or together with Ar.sub.3 and the
heterocycle to which Ar.sub.1 and Ar.sub.3 are attached form a ring
structure selected from Ar.sub.1-3;
[0140] Ar.sub.2 is absent or together with Ar.sub.1 and the
heterocycle to which Ar.sub.1 and Ar.sub.2 are attached form a ring
structure selected from Ar.sub.1-2
[0141] Ar.sub.3 is absent or together with Ar.sub.1 and the
heterocycle to which Ar.sub.1 and Ar.sub.3 are attached form a ring
structure selected from Ar.sub.1-3;
[0142] Ar.sub.4 is absent; or is a C.sub.1-C.sub.4 alkyl, a
C.sub.1-C.sub.4 alkoxy, or a C.sub.1-C.sub.4 thioalkyl, any of
which together with A.sub.1 form a four to seven membered
carbocycle or heterocycle;
[0143] R is hydrogen; a --R.sub.a group; or two R groups, where R
may also include an oxy group, together with the phenyl or
heterocycle to which they are attached form a ring structure
selected from RR;
[0144] wherein:
[0145] Ar.sub.1-2 and Ar.sub.1-3 are selected from an eleven to
fourteen membered hetero-tricycle ring structure optionally
substituted with one or more halogens, C.sub.1-C.sub.4 alkyl
groups, C.sub.1-C.sub.4 haloalkyl groups, C.sub.1-C.sub.4 alkoxy
groups optionally substituted with a halogen or a C.sub.1-C.sub.4
alkoxy group. C.sub.1-C.sub.4 haloalkoxy groups, or amino groups
optionally substituted with a carbonyl group which is substituted
with a C.sub.1-C.sub.4 alkyl group;
[0146] RR is a nine to ten membered bicyclic ring structure
optionally substituted with one or more halogens, C.sub.1-C.sub.4
alkyl groups, C.sub.1-C.sub.4 haloalkyl groups, C.sub.1-C.sub.4
alkoxy groups, oxo groups, or C.sub.1-C.sub.4 haloalkoxy
groups;
[0147] R.sub.a is selected from the group consisting of: a hydroxy
group; a halogen; a C.sub.1-C.sub.4 alkyl which is optionally
substituted with one or more independently selected halogen or
hydroxy groups; a C.sub.1-C.sub.4 alkoxy which is optionally
substituted with one or more independently selected halogen or
phenyl groups; a C.sub.4-C.sub.8 cycloalkyl which is optionally
substituted with one or more independently selected C.sub.1-C.sub.4
alkyl groups; an --R.sub.b group; a --O--R.sub.b group; a four to
six-membered heterocycle which is optionally substituted with one
or more independently selected C.sub.1-C.sub.4 alkyl, oxo, or
--R.sub.b groups; a nine to ten membered heterocycle having two
ring structures; a carbonyl which is optionally substituted with a
hydroxy, a C.sub.1-C.sub.4 alkyl, or a C.sub.1-C.sub.4 alkoxy
group; a carbamoyl which is optionally substituted with one or two
C.sub.1-C.sub.4 alkyl groups; a nitro group; a cyano group; a thio
which is optionally substituted with a hydroxy, a C.sub.1-C.sub.4
alkyl, or --R.sub.b group; a sulfonyl which is optionally
substituted with a hydroxy, a C.sub.1-C.sub.4 alkyl, or --R.sub.b
group; or an amino which is optionally substituted with one or two
independently selected C.sub.1-C.sub.4 alkyl, sulfonyl, or carbonyl
groups, wherein the aminosulfonyl group is optionally substituted
with a hydroxy, a C.sub.1-C.sub.4 alkyl, or --R.sub.b group and
wherein the aminocarbonyl group is optionally substituted with a
C.sub.1-C.sub.4 alkyl, a C.sub.1-C.sub.4 haloalkyl, a benzoxy, or
an amino group which is optionally substituted with an --R.sub.b
group;
[0148] wherein --R.sub.b is a C.sub.6-C.sub.8 aryl which is
optionally substituted with one or more of the following: a
hydroxy, a halogen, a C.sub.1-C.sub.4 alkyl group, a
C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 alkoxy group, or
an amino group which is optionally substituted with one or more
C.sub.1-C.sub.4 alkyl groups;
[0149] or a pharmaceutically acceptable salt, hydrate, solvate,
clathrate, racemate, stereoisomer, or polymorph of said compound of
Formula 1.
[0150] In a preferred embodiment of Formula 1, Ar.sub.1-2 is
selected from the following, optionally substituted as in Formula
1:
##STR00017##
[0151] wherein the * indicates the bond of attachment of Ar.sub.1-2
to the 6-membered ring of Formula 1.
[0152] In another preferred embodiment of Formula 1, Ar.sub.1-3 is
selected from the following, optionally substituted as in Formula
1:
##STR00018##
[0153] wherein the * indicates the bond of attachment of Ar.sub.1-3
to the 6-membered ring of Formula 1.
[0154] In another preferred embodiment of Formula 1,
Ar.sub.4-A.sub.1 may, together with the A.sub.1 and V/W/X/Y/Z
containing rings to which Ar.sub.4-A.sub.1 is joined, form a three,
four or five membered fused ring structure. In a preferred
embodiment of Formula 1. Ar.sub.4-A.sub.1, together with the
A.sub.1 and V/W/X/Y/Z containing rings to which it is joined, form
a heterotricycle which may be optionally substituted as described
herein.
[0155] In yet another preferred embodiment of Formula 1,
Ar.sub.4-A.sub.1, together with the A.sub.1 and V/W/X/Y/Z
containing rings to which Ar.sub.4-A.sub.1 is joined, may be
selected from.
##STR00019##
[0156] wherein the * indicates the bond of attachment to Ar.sub.1
of a tricycle formed between Ar.sub.4-A.sub.1, the A, containing
ring and the V/W/X/Y/Z containing ring of Formula 1.
[0157] In yet another preferred embodiment of Formula 1, RR is
selected from the following: a quinoline group; a napthyl group; a
benzo[1,3]dioxole group; a benzo[1,4]dioxole group; an indolyl
group; or a quinoxaline group;
##STR00020##
[0158] wherein the * indicates the bond of attachment of RR to the
5-membered ring of Formula 1.
[0159] In yet another preferred embodiment of Formula 1, Ar.sub.1-2
may be selected from:
##STR00021## ##STR00022## ##STR00023##
[0160] wherein the * indicates the bond of attachment of Ar.sub.1-2
to the 6-membered ring of Formula 1.
[0161] In yet another preferred embodiment of Formula 1. Ar.sub.1-3
may be selected from:
##STR00024##
[0162] wherein the * indicates the bond of attachment of Ar.sub.1-3
to the 6-membered ring of Formula 1.
[0163] In yet another preferred embodiment of Formula 1,
Ar.sub.4-A.sub.1, together with the A.sub.1 and V/W/X/Y/Z
containing rings to which Ar.sub.4-A.sub.1 is joined, may be
selected from:
##STR00025##
[0164] wherein the * indicates the bond of attachment to Ar.sub.1
of a tricycle formed between Ar.sub.4-A.sub.1, the A.sub.1
containing ring and the V/W/X/Y/Z containing ring of Formula 1.
[0165] In yet another preferred embodiment of Formula 1, RR may be
selected from:
##STR00026##
[0166] In yet other preferred embodiments of Formula 1, Ar.sub.1
may be selected from:
##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031##
##STR00032## ##STR00033##
[0167] wherein the * indicates the bond of attachment of Ar.sub.1
to the 5-membered ring of Formula 1.
[0168] As recognized by one of skill in the art, certain compounds
of the invention may include at least one chiral center, and as
such may exist as racemic mixtures or as enantiomerically pure
compositions. As used herein, "enantiomerically pure" refers to
compositions consisting substantially of a single isomer,
preferably consisting of 90%, 92%, 95%, 98%, 99%, or 100% of a
single isomer.
[0169] As used herein, the term "alkyl" generally refers to
saturated hydrocarbyl radicals of straight, branched or cyclic
configuration including methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl,
cyclohexyl, n-heptyl, octyl, n-octyl, and the like. In some
embodiments, alkyl substituents may be C.sub.1 to C.sub.8, C.sub.3
to C.sub.8, C.sub.1 to C.sub.6, or C.sub.1 to C.sub.4 alkyl groups.
In certain embodiments, the alkyl group may be optionally
substituted with one or more halogen or alkoxy groups. For
instance, the alkyl group may include one or more halogen
substituents to form a haloalkyl, including monohaloalkyl,
dihaloalkyl, and trihaloalkyl.
[0170] As used herein, "alkenyl" generally refers to linear,
branched or cyclic alkene radicals having one or more carbon-carbon
double bonds, such as C.sub.2 to C.sub.6 alkylene groups including
3-propenyl.
[0171] As used herein, "aryl" refers to a carbocyclic aromatic ring
structure. Included in the scope of aryl groups are aromatic rings
having from five to twenty carbon atoms. Aryl ring structures
include compounds having one or more ring structures, such as
mono-, bi-, or tricyclic compounds. Examples of aryl groups that
include phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl,
phenanthrenyl (i.e., phenanthrene), and napthyl (i.e., napthalene)
ring structures. In certain embodiments, the aryl group may be
optionally substituted.
[0172] As used herein. "heterocycle" refers to cyclic ring
structures in which one or more atoms in the ring, the
heteroatom(s), is an element other than carbon. Heteroatoms are
typically O, S or N atoms. Included within the scope of
heterocycle, and independently selectable, are O, N, and S
heterocycle ring structures. The ring structure may include
compounds having one or more ring structures, such as mono-, bi-,
or tricyclic compounds, and may be aromatic, i.e., the ring
structure may be a heteroaryl. Example of heterocyclo groups
include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl,
piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl,
tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl,
tetrahydropyrimidinyl, tetrahydrothiophenyl or
tetrahydrothiopyranyl and the like. In certain embodiments, the
heterocycle may optionally be substituted. As used herein,
"heteroaryl" refers to cyclic aromatic ring structures in which one
or more atoms in the ring, the heteroatom(s) is an element other
than carbon. Heteroatoms are typically O, S or N atoms. Included
within the scope of heteroaryl, and independently selectable O, N,
and S heteroaryl ring structures. The ring structure may include
compounds having one or more ring structures, such as mono-, bi-,
or tricyclic compounds. In some embodiments, the heteroaryl groups
may be selected from heteroaryl groups that contain two or more
heteroatoms, three or more heteroatoms, or four or more
heteroatoms. Heteroaryl ring structures may be selected from those
that contain five or more atoms, six or more atoms, or eight or
more atoms. In a preferred embodiment, the heteroaryl including
five to ten atoms. Examples of heteroaryl ring structures include:
acridine, benzimidazole, benzoxazole, benzodioxole, benzofuran,
1,3-diazine, 1,2-diazine, 1,2-diazole, 1,4-diazanaphthalene, furan,
furazan, imidazole, indole, isoxazole, isoquinoline, isothiazole,
oxazole, purine, pyridazine, pyrazole, pyridine, pyrazine,
pyrimidine, pyrrole, quinoline, quinoxaline, thiazole, thiophene,
1,3,5-triazine, 1,2,4-triazine, 1,2,3-triazine, tetrazole and
quinazoline.
[0173] As used herein, "alkoxy" generally refers to a group with
the structure --O--R. In certain embodiments, R may be an alkyl
group, such as a C.sub.1 to C.sub.8, C.sub.1 to C.sub.6 alkyl
group, or C.sub.1 to C.sub.4 alkyl group. In certain embodiments,
the R group of the alkoxy may optionally be substituted with at
least one halogen. For example, the R group of the alkoxy may be a
haloalkyl, i.e., haloalkoxy.
[0174] Halogen substituents may be independently selected from the
halogens such as fluorine, chlorine, bromine, iodine, and
astatine.
[0175] For the purposes of this invention, where one or more
functionalities or substituents are incorporated into a compound of
the invention, including preferred embodiments, each functionality
or substituent appearing at any location within the disclosed
compounds may be independently selected, and as appropriate,
independently substituted. Further, where a more generic
substituent is set forth for any position in the molecules of the
present invention, it is understood that the generic substituent
may be replaced with more specific substituents and the resulting
molecules are within the scope of the molecules of the present
invention.
[0176] With reference to Formula 1, in an embodiment, R is
preferably in a meta and/or para position and is preferably a
halogen, a C.sub.1-C.sub.4 alkyl, a C.sub.1-C.sub.4 haloalkyl, a
C.sub.1-C.sub.4 alkoxy, a C.sub.1-C.sub.4 haloalkoxy, an amino
which is optionally substituted with one or more C.sub.1-C.sub.4
alkyl groups, an --R group, a pyrrolyl group, an imidazolyl group,
or two R groups together with the phenyl ring to which they are
attached form a benzo[1,3]dioxole or 2,3-dihydro-benzo[1,4]dioxinyl
group. Particularly preferred R groups include those shown in the
table above.
[0177] In a preferred embodiment, compounds of Formula 1 includes
those of Formula 1-A:
##STR00034##
[0178] With reference to Formula 1-A, in an embodiment, A.sub.1,
A.sub.2, A.sub.3, A.sub.4, and A.sub.5 are independently selected
from N, C and CH, and n is 0, 1, or 2. In a preferred embodiment.
R.sub.2 is absent and A.sub.1, A.sub.2, A.sub.3, A.sub.4, and
A.sub.5 are independently selected from C and CH. R.sub.1 is
preferably a carboxy group, and is preferably located in a meta or
para position. In a further embodiment of Formula 1-A, R may be
independently selected from: hydrogen; a hydroxy group; a
C.sub.1-C.sub.4 alkyl group; a halogen; a C.sub.1-C.sub.4 haloalkyl
group; a C.sub.1-C.sub.4 alkoxy group; a C.sub.1-C.sub.4 haloalkoxy
group; a phenyloxy group; a benzyloxy group; a C.sub.6-C.sub.5 aryl
which is optionally substituted with one or more independently
selected halogens, C.sub.1-C.sub.4 alkyl groups, and/or
C.sub.1-C.sub.4 alkoxy groups; an amino group which is optionally
substituted with one or two independently selected C.sub.1-C.sub.4
alkyl groups; a cyano group; a --C(O)--R.sub.d group, wherein RP is
a hydroxy group, a C.sub.1-C.sub.4 alkyl group or a C.sub.1-C.sub.4
alkoxy group; a methanesulfonyl group; a nitro group; a
benzofuranyl group; a pyrrolidinyl group; a pyrrolidinonyl group; a
azetidinonyl group; a morpholinyl group; or two R groups together
with the phenyl or heterocycle to which they are attached form a
ring structure selected from RR.
[0179] In a preferred embodiment of Formula 1-A, V, W, and Y are
each N, while X is C and Z is C--R.sub.c. R.sub.c is preferably
hydrogen or a methyl group. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-1 as
follows:
##STR00035##
[0180] With reference to Formula 1-A-1, in an embodiment, R.sub.1
is preferably a carboxy group, and is preferably located in a meta
or para position. In an embodiment, R.sub.2 is preferably absent.
In another embodiment, R.sub.c is preferably hydrogen or a methyl
group. In a further embodiment, R is preferably independently
selected from: a halogen; a C.sub.1-C.sub.4 alkyl; a
C.sub.1-C.sub.4 haloalkyl; a C.sub.1-C.sub.4 alkoxy which is
optionally substituted with one or more halogens; a C.sub.6-C.sub.8
aryl which is optionally substituted with one or more
C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl or C.sub.1-C.sub.4
alkoxy groups; a benzofuryl group; a pyrolidinyl group; a
pyrrolidinonyl group; and/or a azetidinonyl group. Further, n is
preferably 0, 1, or 2, and the R groups are preferably located at
the meta and/or para positions.
[0181] In another preferred embodiment of Formula 1-A, W, X and Z
are each N, while V is C and Y is C--R.sub.c. R.sub.c is preferably
hydrogen or a methyl group. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-2 as
follows:
##STR00036##
[0182] With reference to Formula 1-A-2, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or par position.
In an embodiment, R.sub.2 is preferably absent. In another
embodiment, R is preferably independently selected from: a hydroxy,
a halogen; a C.sub.1-C.sub.4 alkoxy; and/or a benzyloxy group. In a
further embodiment of Formula 1-A-2, n is preferably 0 or 1, and
the R group is preferably located at the meta or para
positions.
[0183] In another preferred embodiment of Formula 1-A, X, Y and Z
are each N, while V is C and W is CH. In a particularly preferred
embodiment, compounds of Formula 1-A include the compounds of
Formula 1-A-3 as follows:
##STR00037##
[0184] With reference to Formula 1-A-3, in an embodiment, R.sub.1
is preferably a carboxy group, and is preferably located in a meta
or para position. In an embodiment, R.sub.2 is preferably absent.
In another embodiment of Formula 1-A-3, R is preferably
independently selected from: a halogen; a C.sub.1-C.sub.4 alkyl; a
C.sub.1-C.sub.4 haloalkyl; a C.sub.1-C.sub.4 alkoxy which is
optionally substituted with one or more halogens; and/or two R
groups together with the six membered aryl to which they are
attached form a napthyl group which is optionally substituted with
one or more C.sub.1-C.sub.4 alkoxy groups. In a further embodiment,
n is preferably 0, 1, or 2, and the R groups are preferably located
at the meta and/or para positions.
[0185] In another preferred embodiment of Formula 1-A, X and Z are
both N, while V is C, W is CH, and Y is C--R.sub.c. R.sub.c is
preferably hydrogen or an amino group. In a particularly preferred
embodiment, compounds of Formula 1-A include the compounds of
Formula 1-A-4 as follows:
##STR00038##
[0186] With reference to Formula 1-A-4, in an embodiment. R.sub.1
is preferably a carboxy group, and is preferably located in a meta
or para position. In an embodiment, R.sub.2 is preferably absent.
In another embodiment of Formula 1-A-4, R.sub.c is preferably
hydrogen or an amino group. In another embodiment, R is preferably
independently selected from C.sub.1-C.sub.4 alkyl groups. In a
further embodiment of Formula 1-A-4, n is preferably 0 or 1, and
the R group is preferably located at the meta and/or para
positions.
[0187] In another preferred embodiment of Formula 1-A, V and W are
both N, while X is C, and Y and Z am both C--R.sub.c. R.sub.c is
preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-5 as
follows:
##STR00039##
[0188] With reference to Formula 1-A-S, in an embodiment, R.sub.1
is preferably a carboxy group or cyano, and is preferably located
in a meta or para position. In another preferred embodiment of
Formula 1-A-5, R.sub.1 is preferably a carboxy group and is
preferably located in a meta or para position. In an embodiment,
R.sub.2 is preferably absent. In another embodiment of Formula
1-A-5, R is preferably independently selected from: hydroxy; a
halogen; a C.sub.1-C.sub.4 alkyl; a C.sub.1-C.sub.4 haloalkyl; a
C.sub.1-C.sub.4 alkoxy which is optionally substituted with one or
more halogens; a benzyloxy group; a nitro group; an amino group
which is optionally substituted with one or two C.sub.1-C.sub.4
alkyl groups; and/or two R groups together with the six membered
aryl to which they are attached form a benzo[1,3]dioxole group or
an indolyl group. In a further embodiment, n is preferably 0, 1, or
2, and the R groups are preferably located at the meta and/or para
positions.
[0189] In another preferred embodiment of Formula 1-A, V and Y are
both N, while X is C, W is CH, and Z is C--R.sub.c. In an
embodiment, R.sub.c is preferably hydrogen. In a particularly
preferred embodiment, compounds of Formula 1-A include the
compounds of Formula 1-A-6 as follows:
##STR00040##
[0190] With reference to Formula 1-A-6, in an embodiment, R.sub.1
is preferably a carboxy group, and is preferably located in a meta
or para position. In another embodiment, R.sub.2 is preferably
absent. In an embodiment of Formula 1-A-6, R is preferably
independently selected from C.sub.1-C.sub.4 alkyl groups. In a
further embodiment, n is preferably 0 or 1, and the R group is
preferably located at the meta and/or para positions.
[0191] In another preferred embodiment of Formula 1-A, V and Z are
both N, while X is C, W is CH, and Y is C--R.sub.c. R.sub.c is
preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-7 as
follows:
##STR00041##
[0192] With reference to Formula 1-A-7, in an embodiment, R.sub.1
is preferably a carboxy or cyano group, and is preferably located
in a meta or para position. In another embodiment, R.sub.2 is
preferably absent or a nitro group. When R.sub.2 is present, it is
preferably located in an ortho position. In an embodiment of
Formula 1-A-7, R is preferably independently selected from:
hydroxy; a halogen; a C.sub.1-C.sub.4 alkyl; a C.sub.1-C.sub.4
haloalkyl; a C.sub.1-C.sub.4 alkoxy which is optionally substituted
with one or more halogens; a --C(O--OCH.sub.3 group; and/or two R
groups together with the six membered aryl to which they me
attached form a benzo[1,3]dioxole group. In a further embodiment of
Formula 1-A-7, n is preferably 0, 1, or 2, and the R groups are
preferably located at the meta and/or para position.
[0193] In mother preferred embodiment of Formula 1-A, W and X are
both N, while V is C, and Y and Z e both C--R.sub.c. R.sub.c is
preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-8 as
follows:
##STR00042##
[0194] With reference to Formula 1-A-8, in an embodiment, R.sub.1
is preferably a carboxy or --C(O)--OCH.sub.3 group, and is
preferably located in a meta or para position. In another
embodiment. R.sub.2 is preferably absent. In another embodiment, R
is preferably independently selected from: hydroxy; a halogen; a
C.sub.1-C.sub.4 alkyl; a C.sub.1-C.sub.4 haloalkyl; a
C.sub.1-C.sub.4 alkoxy which is optionally substituted with one or
more halogens; a cyano group; and/or a morpholinyl group. In a
further embodiment of Formula 1-A-8, n is preferably 0, 1, or 2,
and the R groups are preferably located at the meta and/or par
positions.
[0195] In another preferred embodiment of Formula 1-A. X and Y are
both N, while V is C, W is CH and Z is C--R.sub.c. R.sub.c is
preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-9 as
follows:
##STR00043##
[0196] With reference to Formula 1-A-9, in an embodiment, R.sub.1
is preferably a carboxy group, and is preferably located in a meta
or para position. In another embodiment, R.sub.2 is preferably
absent. In a further embodiment of Formula 1-A-9, R is preferably
independently selected from: hydroxy; a halogen; a C.sub.1-C.sub.4
alkyl; a C.sub.1-C.sub.4 haloalkyl; a C.sub.1-C.sub.4 alkoxy which
is optionally substituted with one or more halogens; a phenyloxy
group; a nitro group; an amino group which is optionally
substituted with one or two C.sub.1-C.sub.4 alkyl groups; and/or
two R groups together with the six membered aryl to which they are
attached form a benzo[1,3]dioxole group, a quinoline group, or a
quinoxaline group. Further, n is preferably 0, 1, or 2, and the R
groups are preferably located at the meta and/or para
positions.
[0197] In another preferred embodiment of Formula 1-A, V is N,
while X is C, W is CH, and Y and Z are both C--R.sub.c. R.sub.c is
preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-10 as
follows:
##STR00044##
[0198] With reference to Formula 1-A-10, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. R.sub.2 is preferably absent. R is preferably
independently selected from: a halogen; a C.sub.1-C.sub.4 alkyl; a
C.sub.1-C.sub.4 haloalkyl; a C.sub.1-C.sub.4 alkoxy which is
optionally substituted with one or more halogens; a benzyloxy
group; and/or two R groups together with the six membered aryl to
which they are attached form a benzo[1,4]dioxole group. Further, n
is preferably 0, 1, or 2, and the R groups are preferably located
at the meta and/or pare positions.
[0199] In another preferred embodiment of Formula 1-A, X is N,
while V is C, W is CH, and Y and Z are both C--R.sub.c. R.sub.c is
preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-11 as
follows:
##STR00045##
[0200] With reference to Formula 1-A-11. R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. R.sub.2 is preferably absent. R is preferably
independently selected from C.sub.1-C.sub.4 alkyl groups. Further,
n is preferably 0 or 1, and the R group is preferably located at
the meta and/or para positions.
[0201] In another preferred embodiment of Formula 1-A, W is N,
while X and V are both C, and Y and Z are both C--R.sub.c. R.sub.c
is preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-12 as
follows:
##STR00046##
[0202] With reference to Formula 1-A-12, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. R.sub.2 is preferably absent. R is preferably
independently selected from C.sub.1-C.sub.4 alkyl groups. Further,
n is preferably 0 or 1, and the R group is preferably located at
the meta and/or para positions.
[0203] In another preferred embodiment of Formula 1-A, Z is N,
while V and X are C, W is CH, and Y is C--R.sub.c. R.sub.c is
preferably hydrogen. In a particularly preferred embodiment,
compounds of Formula 1-A include the compounds of Formula 1-A-13 as
follows:
##STR00047##
[0204] With reference to Formula 1-A-13, R.sub.1 is preferably a
carboxy group, and preferably located in a meta or pare position.
R.sub.2 is preferably absent. R is preferably independently
selected from C.sub.1-C.sub.4 alkyl groups. Further, n is
preferably 0 or 1, and the R group is preferably located at the
meta and/or para positions.
[0205] In another preferred embodiment of Formula 1, V, W, and Y
are each N, and X and Z are both C. Further, Ar.sub.1 and Ar.sub.2
together with the heterocycle to which they are attached form a
thirteen membered hetero-tricycle ring structure as follows
(Formula 1-B):
##STR00048##
[0206] With reference to Formula 1-B, R.sub.1 is preferably carboxy
group, and is preferably located in a meta or para position.
[0207] In yet another preferred embodiment of Formula 1, V and W
are both N, X is C, and Y and Z are each CH (Formula 1-C):
##STR00049##
[0208] With reference to Formula 1-C. R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. Further, Ar.sub.1 is preferably a thienyl group.
[0209] In yet another preferred embodiment of Formula 1, X and Y
are both N, V is C, and W and Z are independently C or CH (Formula
1-D):
##STR00050##
[0210] With reference to Formula 1-D, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. Further, Ar.sub.2 and/or Ar.sub.3 am preferably absent.
In another preferred embodiment. Ar.sub.1 is preferably a
benzooxazole grow. In another preferred embodiment of Formula 1-D.
Ar.sub.3 is absent, and Ar.sub.1 and Ar.sub.2 together with the
five membered ring to which they me attached form an Ar.sub.1-2
ring structure. In a preferred embodiment of Formula 1-D,
Ar.sub.1-2 is selected from the following, optionally substituted
as in Formula 1:
##STR00051##
[0211] wherein the * indicates the bond of attachment of Ar.sub.1-2
to the 6-membered ring of Formula 1. In yet another preferred
embodiment of Formula 1-D, Ar.sub.1-2 may be selected from:
##STR00052## ##STR00053##
[0212] In another preferred embodiment of Formula 1-D, Ar.sub.2 is
absent, and Ar.sub.1 and Ar.sub.3 together with the five membered
ring to which they are attached form an Ar.sub.1-3 ring structure.
In a preferred embodiment of Formula 1-D, Ar.sub.1-3 is selected
from the following, optionally substituted as in Formula 1:
##STR00054##
[0213] wherein the * indicates the bond of attachment of Ar.sub.1-3
to the 6-membered ring of Formula 1. In yet another preferred
embodiment of Formula 1, Ar.sub.1-3 may be selected from:
##STR00055##
[0214] wherein the * indicates the bond of attachment of Ar.sub.1-3
to the 6-membered ring of Formula 1.
[0215] In yet another preferred embodiment of Formula 1, V and W
are each N. X is C, Y is NH, and Z is C.dbd.O (Formula 1-E):
##STR00056##
[0216] With reference to Formula 1-E. R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. Further, Ar.sub.2 and/or Ar.sub.3 are preferably absent.
In another preferred embodiment, Ar.sub.1 is preferably a phenyl
group optionally substituted with one or two R groups. Further, the
one or two R groups are preferably independently selected from a
C.sub.1-C.sub.4 alkyl group and a halogen.
[0217] In yet another preferred embodiment of Formula 1, V and W
are each N, X is C, Y is O, and Z is C.dbd.O (Formula 1-F):
##STR00057##
[0218] With reference to Formula 1-F, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. Further, Ar.sub.2 and/or Ar.sub.3 are preferably absent.
In another preferred embodiment. Ar.sub.1 is preferably a phenyl
group optionally substituted with one or two R groups. Further, the
one or two R groups are preferably independently selected from a
C.sub.1-C.sub.4 alkyl group, a halogen, C.sub.1-C.sub.4 haloalkyl,
and a methanesulfonyl group, or two R groups together form a
quinoline group.
[0219] In yet another preferred embodiment of Formula 1, V is C, W
and X are each N, Y is C.dbd.O and Z is O (Formula 1-G):
##STR00058##
[0220] With reference to Formula 1-G, R.sub.1 is preferably a
carboxy group, and is preferably located in a mesa or para
position. Further, Ar.sub.2 and/or Ar.sub.3 are preferably absent.
In another preferred embodiment, Ar.sub.1 is preferably a phenyl
group optionally substituted with one or two R groups. Further, the
one or two R groups are preferably independently selected from a
C.sub.1-C.sub.4 alkyl group and a cyano group.
[0221] In yet another preferred embodiment of Formula 1, V is C, W
and X are each N, Y is C.dbd.O and Z is S (Formula 1-H):
##STR00059##
[0222] With reference to Formula 1-H, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. Further. Ar.sub.2 and/or Ar.sub.3 are preferably absent.
In another preferred embodiment, Ar.sub.1 is preferably a phenyl
group optionally substituted with one or two R groups. Further, the
one or two R groups are preferably independently selected
C.sub.1-C.sub.4 alkyl groups.
[0223] In yet another preferred embodiment of Formula 1, V is C, W
and X are each N, Y is C.dbd.S and Z is S (Formula 1-I):
##STR00060##
[0224] With reference to Formula 1-I, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. Further, Ar.sub.2 and/or Ar.sub.3 are preferably absent.
In another preferred embodiment, Ar.sub.1 is preferably a phenyl
group optionally substituted with one or two R groups. Further, the
one or two R groups are preferably independently selected
C.sub.1-C.sub.4 alkyl groups.
[0225] In yet another preferred embodiment of Formula 1, V is C, W
and X are each N, Y is C.dbd.S and Z is O (Formula 1-J):
##STR00061##
[0226] With reference to Formula 1-J, R.sub.1 is preferably a
carboxy group, and is preferably located in a meta or para
position. Further, Ar.sub.2 and/or Ar.sub.3 re preferably absent.
In another preferred embodiment, Ar.sub.1 is preferably a phenyl
group optionally substituted with one or two R groups. Further, the
one or two R groups are preferably independently selected
C.sub.1-C.sub.4 alkyl groups.
[0227] In another preferred embodiment of Formula 1, Ar.sub.4 is
absent (Formula 1-K):
##STR00062##
[0228] In an embodiment of Formula 1-K, any substituent patterns as
illustrated in Formulas 1-A through I-J may be preferred.
[0229] In an embodiment of Formula 1, Ar.sub.4 is a C.sub.1-C.sub.4
alkyl which together with A.sub.1 forms a four to seven membered
carbocycle or heterocycle (Formula 1-L).
[0230] In a preferred embodiment of Formula 1-L, Ar.sub.4 is a
C.sub.1-C.sub.4 alkyl which together with A.sub.1 forms a four to
seven membered carbocycle. In a preferred embodiment of Formula
1-L, Ar.sub.4 is a C.sub.1-C.sub.4 alkyl which is attached to
A.sub.1 to form a five to six membered carbocycle. In an embodiment
of Formula 1-L, R.sub.1 is preferably a carboxy group, and is
preferably located in a meta or para position. In a preferred
embodiment, Ar.sub.4 is a methylene group. In a further preferred
embodiment of Formula 1-L, Ar.sub.2 and Ar.sub.3 are preferably
absent. In another preferred embodiment, Ar.sub.1 is preferably a
phenyl group optionally substituted with one or two R groups. In a
further preferred embodiment, Ar.sub.1 is a phenyl group optionally
substituted with one or more independently selected halogens,
C.sub.1-C.sub.4 alkyl groups, or C.sub.1-C.sub.4 haloalkoxy groups.
In another preferred embodiment, Ar.sub.1 is a phenyl group
substituted with one or more independently selected halogens,
C.sub.1-C.sub.4 alkyl groups, or C.sub.1-C.sub.4 haloalkoxy groups.
In a further preferred embodiment, Ar.sub.1 is a phenyl group
substituted with a halogen and a C.sub.1-C.sub.4 alkyl group. In
another preferred embodiment, Ar.sub.1 is a phenyl group
substituted with a fluorine and a methyl group. In a preferred
embodiment, Ar.sub.1 is a phenyl group substituted with a
C.sub.1-C.sub.4 haloalkoxy group. In another preferred embodiment,
Ar.sub.1 is a phenyl group substituted with a trifluoromethoxy
group.
[0231] In an embodiment of Formula 1, Ar.sub.4 is a C.sub.1-C.sub.4
alkoxy which is attached to A, to form a four to seven membered
heterocycle (Formula 1-M).
[0232] In a preferred embodiment of Formula 1-M, Ar.sub.4 is a
C.sub.1-C.sub.4 alkoxy which is attached to A.sub.1 to form a five
to six membered heterocycle. In an embodiment of Formula 1-M,
R.sub.1 is preferably a carboxy group, and is preferably located in
a meta or para position. In a preferred embodiment of Formula 1-M,
Ar.sub.4 is a methoxy group. In a further preferred embodiment of
Formula 1-M. Ar.sub.2 and Ar.sub.3 are preferably absent. In
another preferred embodiment, of Formula 1-M, Ar.sub.1 is absent.
In another preferred embodiment of Formula 1-M, Ar.sub.1 is a
phenyl group optionally substituted with one or two R groups.
[0233] In a further preferred embodiment of Formula 1-M, Ar.sub.1
is a phenyl group optionally substituted with one or more
independently selected halogens, C.sub.1-C.sub.4 alkyl groups, or
C.sub.1-C.sub.4 alkoxy, or C.sub.1-C.sub.4 haloalkyl groups. In a
further preferred embodiment of Formula 1-M, Ar.sub.1 is a phenyl
group substituted with one, two or three independently selected
halogens, C.sub.1-C.sub.4 alkyl groups, C.sub.1-C.sub.4 alkoxy, or
C.sub.1-C.sub.4 haloalkyl groups. In another preferred embodiment
of f Formula 1-M, Ar.sub.1 is a phenyl group substituted with one
halogen. C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy,
C.sub.1-C.sub.4 haloalkyl group. In a preferred embodiment of
Formula 1-M, Ar.sub.1 is a phenyl group substituted with one
fluorine, chlorine, methyl, methoxy, or trifluoromethoxy group. In
another preferred embodiment of Formula 1-M. Ar.sub.1 is a phenyl
group substituted with three C.sub.1-C.sub.4 alkoxy groups. In a
further preferred embodiment of Formula 1-M, Ar.sub.1 is a phenyl
group substituted with three methoxy groups.
[0234] In an embodiment of Formula 1, Ar.sub.4 is a C.sub.1-C.sub.4
thioalkyl which is attached to A.sub.1 to form a four to seven
membered heterocycle (Formula 1-N).
[0235] In a preferred embodiment of Formula 1-N, Ar.sub.4 is a
C.sub.1-C.sub.4 thioalkyl which is attached to A.sub.1 to form a
five to six membered heterocycle. In an embodiment of Formula 1-N,
R.sub.1 is preferably a carboxy group, and is preferably located in
a mete or para position. In a preferred embodiment of Formula 1-N,
Ar.sub.4 is a thiomethyl group. In a further preferred embodiment
of Formula 1-N, Ar.sub.2 and Ar.sub.3 are preferably absent.
[0236] In another preferred embodiment of Formula 1-N, Ar.sub.1 is
a phenyl group optionally substituted with one or more R groups. In
another preferred embodiment of Formula 1-N, Ar.sub.1 is a phenyl
group optionally substituted with one R group. In another preferred
embodiment of Formula 1-N, Ar.sub.1 is a phenyl group substituted
with a C.sub.1-C.sub.4 alkyl group. In another preferred embodiment
of Formula 1-N, Ar.sub.1 is a phenyl group substituted with a
methyl group.
[0237] Preferred compounds of the invention include the compounds
in Table X as follows:
TABLE-US-00001 TABLE X Compound ##STR00063## 1 ##STR00064## 2
##STR00065## 3 ##STR00066## 4 ##STR00067## 5 ##STR00068## 6
##STR00069## 8 ##STR00070## 9 ##STR00071## 10 ##STR00072## 11
##STR00073## 12 ##STR00074## 13 ##STR00075## 14 ##STR00076## 15
##STR00077## 16 ##STR00078## 17 ##STR00079## 18 ##STR00080## 19
##STR00081## 20 ##STR00082## 21 ##STR00083## 22 ##STR00084## 23
##STR00085## 24 ##STR00086## 25 ##STR00087## 26 ##STR00088## 27
##STR00089## 28 ##STR00090## 29 ##STR00091## 30 ##STR00092## 31
##STR00093## 32 ##STR00094## 33 ##STR00095## 34 ##STR00096## 35
##STR00097## 36 ##STR00098## 37 ##STR00099## 38 ##STR00100## 39
##STR00101## 40 ##STR00102## 41 ##STR00103## 42 ##STR00104## 43
##STR00105## 44 ##STR00106## 45 ##STR00107## 46 ##STR00108## 47
##STR00109## 48 ##STR00110## 49 ##STR00111## 50 ##STR00112## 51
##STR00113## 52 ##STR00114## 53 ##STR00115## 54 ##STR00116## 55
##STR00117## 56 ##STR00118## 57 ##STR00119## 58 ##STR00120## 59
##STR00121## 60 ##STR00122## 61 ##STR00123## 62 ##STR00124## 63
##STR00125## 64 ##STR00126## 65 ##STR00127## 66 ##STR00128## 67
##STR00129## 68 ##STR00130## 69 ##STR00131## 70 ##STR00132## 71
##STR00133## 72 ##STR00134## 73 ##STR00135## 74 ##STR00136## 75
##STR00137## 76 ##STR00138## 77 ##STR00139## 78 ##STR00140## 79
##STR00141## 80 ##STR00142## 81 ##STR00143## 82 ##STR00144## 83
##STR00145## 84 ##STR00146## 85 ##STR00147## 86 ##STR00148## 87
##STR00149## 88 ##STR00150## 89 ##STR00151## 90 ##STR00152## 91
##STR00153## 92 ##STR00154## 93 ##STR00155## 94 ##STR00156## 95
##STR00157## 96 ##STR00158## 97 ##STR00159## 98 ##STR00160## 99
##STR00161## 100 ##STR00162## 101 ##STR00163## 102 ##STR00164## 103
##STR00165## 104 ##STR00166## 105 ##STR00167## 106 ##STR00168## 107
##STR00169## 108 ##STR00170## 109 ##STR00171## 110 ##STR00172## 111
##STR00173## 112 ##STR00174## 113 ##STR00175## 114 ##STR00176## 115
##STR00177## 116 ##STR00178## 117 ##STR00179## 118 ##STR00180## 119
##STR00181## 120 ##STR00182## 121 ##STR00183## 122 ##STR00184## 123
##STR00185## 124
##STR00186## 125 ##STR00187## 126 ##STR00188## 127 ##STR00189## 128
##STR00190## 129 ##STR00191## 130 ##STR00192## 131 ##STR00193## 132
##STR00194## 133 ##STR00195## 134 ##STR00196## 135 ##STR00197## 136
##STR00198## 137 ##STR00199## 138 ##STR00200## 139 ##STR00201## 140
##STR00202## 141 ##STR00203## 142 ##STR00204## 143 ##STR00205## 144
##STR00206## 145 ##STR00207## 146 ##STR00208## 147 ##STR00209## 148
##STR00210## 149 ##STR00211## 150 ##STR00212## 151 ##STR00213## 152
##STR00214## 153 ##STR00215## 154 ##STR00216## 155 ##STR00217## 156
##STR00218## 157 ##STR00219## 158 ##STR00220## 159 ##STR00221## 160
##STR00222## 161 ##STR00223## 162 ##STR00224## 163 ##STR00225## 164
##STR00226## 165 ##STR00227## 166 ##STR00228## 167 ##STR00229## 168
##STR00230## 169 ##STR00231## 170 ##STR00232## 171 ##STR00233## 172
##STR00234## 173 ##STR00235## 174 ##STR00236## 175 ##STR00237## 176
##STR00238## 177 ##STR00239## 178 ##STR00240## 179 ##STR00241## 180
##STR00242## 181 ##STR00243## 182 ##STR00244## 183 ##STR00245## 184
##STR00246## 185 ##STR00247## 186 ##STR00248## 187 ##STR00249## 188
##STR00250## 189 ##STR00251## 190 ##STR00252## 191 ##STR00253## 192
##STR00254## 193 ##STR00255## 194 ##STR00256## 195 ##STR00257## 196
##STR00258## 197 ##STR00259## 198 ##STR00260## 199 ##STR00261## 200
##STR00262## 201 ##STR00263## 202 ##STR00264## 203 ##STR00265## 204
##STR00266## 205 ##STR00267## 206 ##STR00268## 207 ##STR00269## 208
##STR00270## 209 ##STR00271## 210 ##STR00272## 211 ##STR00273## 212
##STR00274## 213 ##STR00275## 214 ##STR00276## 215 ##STR00277## 216
##STR00278## 217 ##STR00279## 218 ##STR00280## 219 ##STR00281## 220
##STR00282## 221 ##STR00283## 222 ##STR00284## 223 ##STR00285## 224
##STR00286## 225 ##STR00287## 226 ##STR00288## 227 ##STR00289## 228
##STR00290## 229 ##STR00291## 230 ##STR00292## 231 ##STR00293## 232
##STR00294## 233 ##STR00295## 234 ##STR00296## 235 ##STR00297## 236
##STR00298## 237 ##STR00299## 238 ##STR00300## 239 ##STR00301## 240
##STR00302## 241 ##STR00303## 242 ##STR00304## 243 ##STR00305## 244
##STR00306## 245 ##STR00307## 246 ##STR00308## 247 ##STR00309## 248
##STR00310## 249
##STR00311## 250 ##STR00312## 251 ##STR00313## 252 ##STR00314## 253
##STR00315## 254 ##STR00316## 255 ##STR00317## 256 ##STR00318## 257
##STR00319## 258 ##STR00320## 259 ##STR00321## 260 ##STR00322## 261
##STR00323## 262 ##STR00324## 263 ##STR00325## 264 ##STR00326## 265
##STR00327## 266 ##STR00328## 267 ##STR00329## 268 ##STR00330## 269
##STR00331## 270 ##STR00332## 271 ##STR00333## 272 ##STR00334## 273
##STR00335## 274 ##STR00336## 275 ##STR00337## 276 ##STR00338## 277
##STR00339## 278 ##STR00340## 279 ##STR00341## 280 ##STR00342## 281
##STR00343## 282 ##STR00344## 283 ##STR00345## 284 ##STR00346## 285
##STR00347## 286 ##STR00348## 287 ##STR00349## 288 ##STR00350## 289
##STR00351## 290 ##STR00352## 291 ##STR00353## 292 ##STR00354## 293
##STR00355## 294 ##STR00356## 295 ##STR00357## 296 ##STR00358## 297
##STR00359## 298 ##STR00360## 299 ##STR00361## 300 ##STR00362## 301
##STR00363## 302 ##STR00364## 303 ##STR00365## 304 ##STR00366## 305
##STR00367## 306 ##STR00368## 307 ##STR00369## 308 ##STR00370## 309
##STR00371## 310 ##STR00372## 311 ##STR00373## 312 ##STR00374## 313
##STR00375## 314 ##STR00376## 315 ##STR00377## 316 ##STR00378## 317
##STR00379## 318 ##STR00380## 319 ##STR00381## 320 ##STR00382## 321
##STR00383## 322 ##STR00384## 323 ##STR00385## 324 ##STR00386## 325
##STR00387## 326 ##STR00388## 327 ##STR00389## 328 ##STR00390## 329
##STR00391## 330 ##STR00392## 331 ##STR00393## 332 ##STR00394## 333
##STR00395## 334 ##STR00396## 335 ##STR00397## 336 ##STR00398## 337
##STR00399## 338 ##STR00400## 339 ##STR00401## 340 ##STR00402## 341
##STR00403## 342 ##STR00404## 343 ##STR00405## 344 ##STR00406## 345
##STR00407## 346 ##STR00408## 347 ##STR00409## 348 ##STR00410## 349
##STR00411## 350 ##STR00412## 351 ##STR00413## 352 ##STR00414## 353
##STR00415## 354 ##STR00416## 355 ##STR00417## 356 ##STR00418## 357
##STR00419## 358 ##STR00420## 359 ##STR00421## 360 ##STR00422## 361
##STR00423## 362 ##STR00424## 363 ##STR00425## 364 ##STR00426## 365
##STR00427## 366 ##STR00428## 367 ##STR00429## 368 ##STR00430## 369
##STR00431## 370 ##STR00432## 371 ##STR00433## 372 ##STR00434## 373
##STR00435## 374 ##STR00436## 375
##STR00437## 376 ##STR00438## 377 ##STR00439## 378 ##STR00440## 379
##STR00441## 380 ##STR00442## 381 ##STR00443## 382 ##STR00444## 383
##STR00445## 384 ##STR00446## 385 ##STR00447## 386 ##STR00448## 387
##STR00449## 388 ##STR00450## 389 ##STR00451## 390 ##STR00452## 391
##STR00453## 392 ##STR00454## 393 ##STR00455## 394 ##STR00456## 395
##STR00457## 396 ##STR00458## 397 ##STR00459## 398 ##STR00460## 399
##STR00461## 400 ##STR00462## 401 ##STR00463## 402 ##STR00464## 403
##STR00465## 404 ##STR00466## 405 ##STR00467## 406 ##STR00468## 407
##STR00469## 408 ##STR00470## 409 ##STR00471## 410 ##STR00472## 411
##STR00473## 412 ##STR00474## 413 ##STR00475## 414 ##STR00476## 415
##STR00477## 416 ##STR00478## 417 ##STR00479## 418 ##STR00480## 419
##STR00481## 420 ##STR00482## 421 ##STR00483## 422 ##STR00484## 423
##STR00485## 424 ##STR00486## 425 ##STR00487## 426 ##STR00488## 427
##STR00489## 428 ##STR00490## 429 ##STR00491## 430 ##STR00492## 431
##STR00493## 432 ##STR00494## 433 ##STR00495## 434 ##STR00496## 435
##STR00497## 436 ##STR00498## 437 ##STR00499## 438 ##STR00500## 439
##STR00501## 440 ##STR00502## 441 ##STR00503## 442 ##STR00504## 443
##STR00505## 444 ##STR00506## 445 ##STR00507## 446 ##STR00508## 447
##STR00509## 448 ##STR00510## 449 ##STR00511## 450 ##STR00512## 451
##STR00513## 452 ##STR00514## 453 ##STR00515## 454 ##STR00516## 455
##STR00517## 456 ##STR00518## 457 ##STR00519## 458 ##STR00520## 459
##STR00521## 460 ##STR00522## 461 ##STR00523## 462 ##STR00524## 463
##STR00525## 464 ##STR00526## 465 ##STR00527## 466 ##STR00528## 467
##STR00529## 468 ##STR00530## 469 ##STR00531## 470 ##STR00532## 471
##STR00533## 472 ##STR00534## 473 ##STR00535## 474
[0238] As illustrated in Table X: As used herein, Compound 12 is
the same structure as Compound 292. As used herein, Compound 13 is
the same structure as Compound 293. As used herein. Compound 14 is
the same structure as Compound 294. As used herein, Compound 15 is
the same structure as Compound 295. As used herein, Compound 16 is
the same structure as Compound 296. As used herein, Compound 17 is
the same structure as Compound 297. As used herein, Compound 18 is
the same structure as Compound 298. As used herein, Compound 19 is
the same structure as Compound 299. As used herein, Compound 20 is
the same structure as Compound 300. As used herein, Compound 21 is
the same structure as Compound 301. As used herein, Compound 22 is
the same structure as Compound 302. As used herein, Compound 23 is
the same structure as Compound 303. As used herein, Compound 24 is
the same structure as Compound 304. As used herein, Compound 25 is
the same structure a Compound 305. As used herein, Compound 26 is
the same structure as Compound 306. As used herein, Compound 27 is
the same structure as Compound 307. As used herein, Compound 28 is
the same structure as Compound 308. As used herein, Compound 29 is
the same structure as Compound 309. As used herein. Compound 30 is
the same structure as Compound 310. As used herein, Compound 31 is
the same structure as Compound 311. As used herein, Compound 32 is
the same structure as Compound 312. As used herein, Compound 33 is
the same structure as Compound 313. As used herein, Compound 34 is
the same structure as Compound 314. As used herein, Compound 35 is
the same structure as Compound 315. As used herein, Compound 36 is
the same structure as Compound 316. As used herein, Compound 37 is
the same structure as Compound 317. As used herein, Compound 38 is
the same structure as Compound 318. As used herein, Compound 39 is
the same structure as Compound 319. As used herein, Compound 40 is
the same structure as Compound 320. As used herein, Compound 41 is
the same structure as Compound 321. As used herein, Compound 42 is
the same structure as Compound 322. As used herein, Compound 43 is
the same structure as Compound 323. As used herein, Compound 44 is
the same structure as Compound 324. As used herein, Compound 45 is
the same structure as Compound 325. As used herein, Compound 46 is
the same structure as Compound 326.
[0239] Particularly preferred compounds are Compound NOs: 47, 48,
66, 76, 81, 87, 105, 106, 109, 110, 133, 138, 139, 140, 146, 148,
154, 157, 167, 174, 177, 186, 196, 204. The above compounds are
listed only to provide examples that may be used in the methods of
the invention. Based upon the instant disclosure, the skilled
artisan would recognize other compounds intended to be included
within the scope of the presently claimed invention that would be
useful in the methods recited herein.
[0240] B. Preparation of Compounds of the Invention
[0241] Compounds of the invention may be produced in any manner
known in the art. By way of example, compounds of the invention may
be prepared according to the following general schemes with
reference to the individual azine ring core structures. For
example, compounds of Formula 1 wherein V is N can be prepared by
the method shown in Scheme A.
##STR00536##
[0242] In accordance with Scheme A, an unsubstituted nitrogen atom
on the azole ring of compound A1 can be substituted in a
cross-coupling reaction. This type of reaction may be accomplished
with the use of substrates such as Ar.sub.1-X (where X is a halogen
like bromide or iodide, or a pseudohalide such as methanesulfonate)
or Ar.sub.1-M (where M is a group such as a boronic acid or
trialkoxysilane). Catalysts for the reaction may include copper
salts (such as copper (II) oxide, copper (II) acetate, etc.),
palladium salts (such as palladium (II) acetate,
tetrakistriphenylphosphine palladium, etc.), and other catalytic
transition metal salts with catalytic properties. One specific
example of such a cross-coupling reaction comes from the reports of
Buchwald, et al., J. Am. Chem. Soc. 2001, 123, 7727, which involves
the reaction of aryl bromides or iodides with azoles catalyzed by
the presence of copper iodide with a diamine ligand, also in the
presence of an appropriate base such as potassium phosphate or
potassium carbonate, usually in a higher-boiling solvent such as
1,4-dioxane, dimethoxyethane, toluene, etc. Another specific
example of an azole cross-coupling reaction is the method of Lam,
et al., Tetrahedron Lett. 2001, 42, 3415. This method involves the
reaction of an azole compound such as A1 with an arylboronic acid
reagent in the presence of copper (II) acetate, an amine reagent
(such as pyridine, triethylamine, etc.) and molecular sieves. Such
cross-coupling reactions useful for the synthesis of the compounds
in this invention are not limited to these two specific
examples.
[0243] Certain functional groups may be carried through the
syntheses described in this invention in protected form, then
liberated in a later step. Protecting group strategy is well-known
to those skilled in the art of organic synthesis, and is reviewed
in such texts as Greene, Protective Groups in Organic Synthesis,
John Wiley and Sons, New York. For example, carboxylic acids may be
carried through various organic syntheses as a carboxylic ester
compound, then cleaved at an appropriate point to the carboxylic
acid. The cleavage reaction may involve the reaction with hydroxide
(sodium hydroxide, lithium hydroxide, etc.) in appropriate solvents
(water, ethanol, tetrahydrofuran or mixtures thereof) at
temperatures ranging from ambient to the reflux point of the
solvent. Alternatively, some ester groups may be cleaved by
nucleophilic reagents (lithium iodide, lithium thiophenylate, etc.)
in solvents such as pyridine, dimethylsulfoxide or
dimethylformamide. Another group which is a convenient masked form
of a carboxylate group is cyano. An aryl nitrile compound may be
hydrolyzed under acidic (e.g., concentrated hydrochloric acid or
dry hydrogen chloride gas, followed by alcoholysis/hydrolysis) or
basic (e.g., sodium hydroxide) conditions.
[0244] Traditional heterocyclic syntheses may be employed for the
various embodiments of Formula 1. For example, with reference to
compounds comprising a central pyrrole ring, the arylation
methodology discussed above can be employed for a pyrrole compound
of formula B1 (Scheme B).
##STR00537##
[0245] In accordance with Scheme B, compound B1 may be prepared by
one of two routes. The first involves the cross-coupling of a
compound of formula B2, where X represents a halogen or
pseudohalogen group and Z represents either a hydrogen atom or a
protecting group. Suitable protecting groups include but are not
limited to tert-butoxycarbonyl, trityl, triisopropylsilyl, etc. The
other cross-coupling component consists of a reagent Ar-M, where M
represents a metal or other atom which will undergo the
cross-coupling reaction, and may be chosen from the list consisting
of Mg, Zn, B or Si, the atoms listed here also bonded to various
other groups as fitting the valence of the selected M atom. The
cross-coupling reaction may be performed in the presence of a
catalyst. Suitable catalysts include various compounds containing
Pd, Cu, or Ni. After the coupling reaction, the arylated product
may be deprotected by removing the Z group to form B1. Deprotection
conditions will depend on the chosen Z group and are familiar to
those skilled in the art of organic synthesis. A variation of this
first approach begins with a pyrrole reagent bearing the M group
(B3), and the cross-coupling is performed as described above with a
reagent of the formula Ar--X. One method which uses this route has
the M group as B(OH).sub.2 and X as Br or I; the catalyst of choice
for this reaction is a Pd(0) compound (such as Pd(PPh.sub.3).sub.4)
or a Pd(II) compound (such as Pd(PPh.sub.3).sub.2Cl.sub.2 or
Pd(OAc).sub.2), and a base such as Na.sub.2CO.sub.3 or CsF is
present. A third synthesis of the compound of formula B1 begins
with an olefinic compound of formula B4. This is treated with the
reagent toluenesulfonylmethyl isocyanide (TosMIC) under basic
conditions. The resulting product is the version of compound B1
where R and R are both hydrogen atoms. Compound B1 is then
subjected to the arylation methodology discussed above for Scheme
A.
[0246] For compounds of Formula 1 comprised of a central pyrazole
ring, the arylation methodology discussed above can be employed for
a pyrazole compound of formula C1 (Scheme C).
##STR00538##
[0247] In accordance with Scheme C, compound C1 can be derived from
either a vinylogous amide compound of formula C2 or a dicarbonyl
compound of formula C4. Either substrate can be treated with
hydrazine hydrate in a protic solvent such as ethanol or acetic
acid, optionally in the presence of an acid catalyst such as
hydrochloric acid. The reactions are typically performed at
elevated temperatures. The vinylogous amide compound of formula C2
may be prepared by the condensation of a ketone compound of formula
C3 with an acetal of an amide. This reaction is typically performed
with one or greater equivalents of the acetal reagent neat or in an
appropriate solvent at the reflux temperature of the solvent.
Diketone reagents of the formula C4 may be prepared by the
condensation of an aroyl ester of formula C5 with a ketone of
formula C6. This condensation reaction is usually performed under
basic conditions (for example, sodium hydride) in various solvents,
or the enolate anion of C6 can first be generated under strong base
conditions (e.g., lithium diisopropylamide, low temperatures,
aprotic solvents) and the ester C5 is subsequently added.
[0248] For the variation of the pyrazole class of compounds where
there is one of the aryl groups attached at the 4-position of the
pyrazole ring, the arylation methodology discussed above can be
employed for a compound of formula D1 (Scheme D).
##STR00539##
[0249] In accordance with Scheme D, as above, the N-unsubstituted
pyrazole can be formed by the cyclocondensation reaction of
hydrazine with either a dicarbonyl compound of formula D2 or a
vinylogous amide compound of formula D4. These reagents are in turn
derived from ketones D3 and D5, respectively, analogously to the
method described above. For the case when R.dbd.R.dbd.H, the
methodology of Coppola et al., J. Het. Chem. 1974, 11, 51-56 may be
employed. This involves the treatment of an arylacetic acid reagent
of formula D6 with a preformed mixture of phosphorus oxychloride
and dimethylformamide. Basic workup then affords the formyl enamine
product D4.
[0250] An alternative synthesis oft the reagent of Formula 1 where
one of the aryl groups is attached at the 4-position of the
pyrazole ring is shown in Scheme E.
##STR00540##
[0251] In accordance with Scheme E, the previously-described
compounds D2 and D4 may be condensed directly with an arylhydrazine
compound of formula E2, under similar conditions as employed for
the reaction of unsubstituted hydrazine itself. In the case of
R.noteq.R, the regioselectivity may be controlled by the size of
the R groups, and chromatographic methods familiar to those skilled
in the art may be necessary to separate the products.
[0252] For compounds of Formula 1 comprised of a central imidazole
ring, the arylation methodology discussed above can be employed for
an imidazole compound of formula F1 (Scheme F).
##STR00541##
[0253] In accordance with Scheme F, a reagent of formula F2, where
Y represents a halogen, amine or hydroxyl group, may be converted
to compound F1 through a cyclocondensation reaction. In the case
when R.dbd.H, .alpha.-bromoketones (F2, Y.dbd.Br) may be treated
with formamide at high temperatures (>150.degree. C.) to afford
the imidazole product. The cross-coupling reaction of imidazole F1
may proceed with good to excellent regioselectivity if aryl and R
are different in size; otherwise two regioisomers may result, which
may be separable by chromatography. Imidazoles of this invention
may also be prepared by cyclocondensation reaction of an arylamino
ketone substrate (73) with a reagent such as a nitrile or an
imidate. For compounds with 2-amino substitution, compound 73 may
also be treated with cyanamide to afford a 2-aminoimidazole. The
primary amino group may then be functionalized as one chooses.
[0254] For compounds of Formula 1 comprised of a central
1,2,4-triazole ring, the arylation methodology discussed above can
be employed for a compound of formula G1 (Scheme G).
##STR00542##
[0255] In accordance with Scheme G, another route starts with
nitrile reagent G2, which is first treated in alcohol solvent with
dry acid (gaseous HCl or in situ-generated HCl from an acid
chloride). The intermediate imidate salt is then treated with an
arylhydrazine reagent to afford compound G3. This compound is then
allowed to undergo a cyclocondensation reaction with an orthoester
reagent of formula R--C(OR).sub.3 to afford the product G4, or with
a reagent such as carbonyldiimidazole to give G5. In the case where
compound G5 bears an Ar.sub.1 group with functionality that can
react with the 1,2,4-triazolone oxygen atom (e.g. a CH.sub.2--Br
group at the ortho position of the Ar.sub.1 ring), then another
ring may be formed by such an alkylation reaction. Basic reagents
and/or conditions such as sodium hydride or potassium carbonate in
dimethylformamide solvent at temperatures from ambient to
100.degree. C. may be used to perform this internal alkylation to
provide the compound of formula G6. An ortho-CH.sub.2Br group may
be prepared on the Ar.sub.1 ring by the conversion of a CH.sub.3
group to CH.sub.2Br by free radical bromination. This reaction may
be performed with reagents such as N-bromosuccinimide in a
refluxing solution with a solvent such as carbon tetrachloride or
chloroform. The presence of a catalytic amount of a free-radical
initiator, such as 2,2'azobis(2-methylpropionitrile), may prove
beneficial in this reaction.
[0256] For compounds of Formula 1 comprised of a central
1,23-triazole ring, the following methodology can be employed for a
compound H1 (Scheme H).
##STR00543##
[0257] In accordance with Scheme H., the triazole can be prepared
by the cycloaddition reaction of an azido reagent of formula H2 and
an alkynyl reagent of formula H3. This cycloaddition reaction may
be performed thermally, in appropriate aprotic solvents at elevated
temperatures (in sealed vessels if necessary). Alternatively, the
reaction may be performed in the presence of a catalyst, such as
copper sulfate pentahydrate-ascorbic acid, according to the method
of Sharpless et al., Angew. Chem., Int. Ed. Engl. 2002, 41
2596-2599. These conditions allow for higher product yields and
better regioselectivity. Azide compounds may be prepared by first
converting an aniline compound of formula H4 to a diazonium salt
(H5), with the use of such reagents as sodium nitrite/acid or an
alkyl nitrite reagent. The diazonium salt Is then treated with an
azide salt, such as sodium azide, to afford the azido compound H2.
An example of just such a transformation may be found in the work
of Carnazzi et al., J. Med. Chem. 1994, 37, 1841. The alkyne
compound H3 can be prepared by the palladium-catalyzed
cross-coupling reaction of an aryl halide reagent of formula H6 and
a terminal acetylene reagent of formula H7. Catalysts containing
either Pd(0) or Pd(II), such as bis(triphenylphosphine)palladium
dichloride, are useful for this reaction. This coupling reaction is
usually also mediated by the presence of a copper (I) catalyst, and
a mono-, di- or trialkylamine as a copper ligand, usually as a
cosolvent along with a polar solvent such as dimethylformamide. The
reactions may be performed at elevated temperatures as
appropriate.
[0258] Compounds of Formula 1 that contain a central oxadiazoline
ring may be prepared according to the strategy shown in Schemes J
and K (below).
##STR00544##
##STR00545##
[0259] In accordance with Schemes J and K, similar conditions are
used for both variations, beginning with starting materials that
give final products with carboxyl substitution on one side or the
other. An arylhydrazine reagent (J1 or K1) is acylated with a
carboxylic acid reagent (J2 or K2) to give hydrazides J3 or K3.
This condensation may also be performed using the appropriately
substituted aroyl chloride reagent and an organic or inorganic
base. The ring is formed in a cyclocondensation reaction using a
reagent like carbonyldiimidazole, and the resulting ester compound
(J4 or K4) is hydrolyzed to afford the carboxylic acid. Other
non-nucleophilic ester-cleaving conditions may be employed for this
transformation. This methodology may also be performed by attaching
intermediates to a solid support, thus allowing rapid intermediate
isolation and the liberation of pure final product.
[0260] Compounds of Formula 1 with a thiadiazoline core ring are
prepared using the methodology shown in Scheme L.
##STR00546##
[0261] In accordance with Scheme L, the hydrazide intermediates
discussed above in Schemes J and K are treated with Lawesson's
reagent to give an intermediate phosphorus-containing heterocyclic
product (L2). The phosphorus group is removed by treatment with
hydroxide, and the resulting thiohydrazide L3 is cyclocondensed in
a manner analogous to the oxadiazolones to afford the thiadiazolone
L4. The free carboxyl group is then liberated by the method
discussed above.
[0262] In certain preferred embodiments, compounds of the invention
may be resolved to enantiomerically pure compositions or
synthesized as enantiomerically pure compositions using any method
known in art. By way of example, compounds of the invention may be
resolved by direct crystallization of enantiomer mixtures, by
diastereomer salt formation of enantiomers, by the formation and
separation of diasteriomers or by enzymatic resolution of a racemic
mixture.
[0263] These and other reaction methodologies may be useful in
preparing the compounds of the invention, as recognized by one of
skill in the art. Various modifications to the above schemes and
procedures will be apparent to one of skill in the art, and the
invention is not limited specifically by the method of preparing
the compounds of the invention.
[0264] C. Methods of the Invention
[0265] In another aspect of the invention, methods me provided for
the suppression of premature translation termination, which may be
associated with a nonsense mutation, and for the prevention or
treatment of diseases. In a preferred embodiment, such diseases are
associated with mutations of mRNA, especially nonsense mutations.
Exemplary diseases include, but are not limited to, cancer,
lysosomal storage disorders, the muscular dystrophies, cystic
fibrosis, hemophilia, epidermolysis bullosa and classical late
infantile neuronal ceroid lipofuscinosis. In this embodiment,
methods for treating cancer, lysosomal storage disorders, a
muscular dystrophy, cystic fibrosis, hemophilia, or classical late
Infantile neuronal ceroid lipofuscinosis me provided comprising
administering a therapeutically effective amount of at least one
compound of the invention to a subject in need thereof.
[0266] In one embodiment, the present invention is directed to
methods for increasing the expression of one or more specific,
functional proteins. Any compound of the invention can be used to
specifically increase expression of functional protein. In another
embodiment, a specific increase in expression of functional protein
occurs when premature translation termination is suppressed by
administering a therapeutically effective amount of at least one
compound of the invention to a subject in need thereof. In a
preferred embodiment premature translation termination is
associated with a nonsense mutation in mRNA. In another embodiment,
a specific increase in expression of functional protein occurs when
mRNA decay is reduced in a patient. In a preferred embodiment, the
abnormality in a patient is caused by mutation-mediated mRNA decay.
In a particularly preferred embodiment, mutation-mediated mRNA
decay is the result of a nonsense mutation. The methods of the
present invention are not limited by any particular theory.
[0267] The invention encompasses methods of treating and preventing
diseases or disorders ameliorated by the suppression of premature
translation termination, nonsense-mediated mRNA decay, or premature
translation termination and nonsense-mediated mRNA decay in a
patient which comprise administering to a patient in need of such
treatment or prevention a therapeutically effective amount of a
compound of the invention.
[0268] In one embodiment, the present invention encompasses the
treatment or prevention of any disease that is associated with a
gene exhibiting premature translation termination,
nonsense-mediated mRNA decay, or premature translation termination
and nonsense-mediated mRNA decay. In one embodiment, the disease is
due, in part, to the lack of or reduced expression of the gene
resulting from a premature stop codon. Specific examples of genes
which may exhibit premature translation termination and/or
nonsense-mediated mRNA decay and diseases associated with premature
translation termination and/or nonsense-mediated mRNA decay are
found in U.S. Provisional Patent Application No. 60/390,747,
titled: Methods For Identifying Small Molecules That Modulate
Premature Translation Termination And Nonsense Mediated mRNA Decay,
filed Jun. 21, 2002, and International Application PCT/US03/19760,
filed Jun. 23, 2003, both of which are incorporated herein by
reference in their entirety.
[0269] Diseases ameliorated by the suppression of premature
translation termination, nonsense-mediated mRNA decay, or premature
translation termination and nonsense-mediated mRNA decay include,
but are not limited to: genetic diseases, somatic diseases,
cancers, autoimmune diseases, blood diseases, collagen diseases,
diabetes, neurodegenerative diseases, proliferative diseases,
cardiovascular diseases, pulmonary diseases, inflammatory diseases
or central nervous system diseases.
[0270] In one embodiment, diseases to be treated or prevented by
administering to a patient in need thereof an effective amount of a
compound of the invention include, but are not limited to,
amyloidosis, hemophilia, Alzheimer's disease, Tay Sachs disease,
Niemann Pick disease, atherosclerosis, giantism, dwarfism,
hypothyroidism, hyperthyroidism, aging, obesity, Parkinson's
disease, cystic fibrosis, muscular dystrophy, heart disease, kidney
stones, ataxia-telangiectasia, familial hypercholesterolemia,
retinitis pigmentosa, Duchenne muscular dystrophy, epidermolysis
bullosa and Marfan syndrome. In one embodiment, the diseases are
associated with a nonsense mutation.
[0271] In one embodiment, the compounds of the invention are useful
for treating or preventing an autoimmune disease. In one
embodiment, the autoimmune disease is associated with a nonsense
mutation. In a preferred embodiment, the autoimmune disease is
rheumatoid arthritis or graft versus host disease.
[0272] In another embodiment, the compounds of the invention are
useful for treating or preventing a blood disease. In one
embodiment, the blood disease is associated with a nonsense
mutation. In a preferred embodiment, the blood disease is
hemophilia, Von Willebrand disease, .beta.-thalassemia
[0273] In another embodiment, the compounds of the invention are
useful for treating or preventing a collagen disease. In one
embodiment, the collagen disease is associated with a nonsense
mutation. In a preferred embodiment, the collagen disease is
osteogenesis imperfecta or cirrhosis.
[0274] In another embodiment, the compounds of the invention are
useful for treating or preventing diabetes. In one embodiment, the
diabetes is associated with a nonsense mutation.
[0275] In another embodiment, the compounds of the invention are
useful for treating or preventing an inflammatory disease. In one
embodiment, the inflammatory disease is associated with a nonsense
mutation. In a preferred embodiment, the inflammatory disease Is
arthritis, rheumatoid arthritis or osteoarthritis.
[0276] In another embodiment, the compounds of the invention are
useful for treating or preventing a central nervous system disease.
In one embodiment, the central nervous system disease is associated
with a nonsense mutation. In one embodiment, the central nervous
system disease is a neurodegenerative disease. In a preferred
embodiment, the central nervous system disease is multiple
sclerosis, muscular dystrophy, Duchenne muscular dystrophy,
Alzheimer's disease. Tay Sachs disease. Niemann Pick disease, late
infantile neuronal ceroid lipofuscinosis (LINCL) or Parkinson's
disease.
[0277] In another preferred embodiment, the compounds of the
invention are useful for treating or preventing cancer,
particularly in humans. In a preferred embodiment, the cancer is of
the head and neck, eye, skin, mouth, throat, esophagus, chest,
bone, blood, lung, colon, sigmoid, rectum, stomach, prostate,
breast, ovaries, kidney, liver, pancreas, brain, intestine, heart
or adrenals. In one embodiment, the cancer is a solid tumor. In one
embodiment, the cancer is associated with a nonsense mutation. In
another embodiment, the cancer is associated with a genetic
nonsense mutation. In another embodiment, the cancer is associated
with a somatic mutation. Without being limited by any theory, the
use of the compounds of the invention against cancer may relate to
its action against mutations of the p53 gene.
[0278] In one embodiment, the cancer is not a blood cancer. In
another embodiment, the cancer is not leukemia. In another
embodiment, the cancer is not multiple myeloma. In another
embodiment, the cancer is not prostate cancer.
[0279] In another preferred embodiment, the compounds of the
invention are useful for treating or preventing cancer associated
with a mutation of tumor suppressor gene. Such genes include, but
are not limited to PTEN, BRCA1, BRCA2, Rb, and the p53 gene. In one
embodiment, the mutation is a genetic mutation. In another
embodiment, the mutation is a somatic mutation. The methods of the
invention are particularly useful for treating or preventing a
cancer associated with a nonsense mutation in the in a tumor
suppressor gene. In a preferred embodiment, the methods of the
invention are particularly useful for treating or preventing a
cancer associated with a p53 gene due to the role of p53 in
apoptosis. Without being limited by theory, it is thought that
apoptosis can be induced by contacting a cell with an effective
amount of a compound of the invention resulting in suppression of
the nonsense mutation, which, in turn, allows the production of
full-length p53 to occur. Nonsense mutations have been identified
in the p53 gone and have been implicated in cancer. Several
nonsense mutations in the p53 gene have been identified (see, e.g.,
Masuda et al., 2000, Tokai J Exp Clin Med. 25(2):69-77; Oh et al.,
2000, Mol Cells 10(3):275-80; Li et al., 2000, Lab Invest.
80(4):493-9; Yang et al., 1999, Zhonghua Zhong Liu Za Zhi
21(2):1144; Finkelstein et al., 1998, Mol Diagn. 3(1):37-41;
Kajiyama et al., 1998, Dis Esophagus. 11(4):279-83; Kawamura et
al., 1999, Leuk Res. 23(2):115-26; Radig et al., 1998, Hum Pathol.
29(11):1310-6; Schuyer et al., 1998, Int J Cancer 76(3):299-303;
Wang-Gohrke et al., 1998, Oncol Rep. 5(1):65-8; Fulop et al., 1998.
J Reprod Med. 43(2):119-27; Ninomiya et al., 1997, J Dermatol Sci.
14(3):173-8; Hsieh et al., 1996, Cancer Lett. 100(1-2):107-13; Rall
et al., 1996, Pancreas. 12(1):10-7; Fukutomi et al., 1995, Nippon
Rinsho. 53(11):2764-8; Frebourg et al., 1995, Am J Hum Genet.
56(3):608-15; Dove et al., 1995, Cancer Surv. 25:335-55; Adamson et
al., 1995, Br J Hamatol. 89(1):61-6; Orayson et al., 1994, Am J
Pediatr Hematol Oncol. 16(4):341-7; Lepelley et al., 1994,
Leukemia. 8(8):1342-9; McIntyre et al., 1994, J Clin Oncol.
12(5):925-30; Horio et al., 1994, Oncogene. 9(4):1231-5; Nakamura
et al., 1992, Jpn J Cancer Res. 83(12):1293-8; Davidoff et al.,
1992, Oncogene. 7(1):127-33; and Ishioka et al., 1991. Biochem
Biophys Res Commun. 177(3):901.6; the disclosures of which are
hereby incorporated by reference herein in their entireties). Any
disease associated with a p53 gene encoding a premature translation
codon including, but not limited to, the nonsense mutations
described in the references cited above, can be treated or
prevented by compounds of the invention.
[0280] In other embodiments, diseases to be treated or prevented by
administering to a patient in need thereof an effective amount of a
compound of the invention include, but are not limited to, solid
tumors such as sarcoma, carcinomas, fibrosarcoma, myxosarcoma,
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma,
angiosarcoma, endotheliosarcoma, lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer,
squamous cell carcinoma, basal cell carcinoma adenocarcinoma, sweat
gland carcinoma, sebaceous gland carcinoma, papillary carcinoma,
papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma,
bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms'
tumor, cervical cancer, testicular tumor, lung carcinoma, small
cell lung carcinoma, bladder carcinoma, epithelial carcinoma,
glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, Kaposi's sarcoma, pinealoma. hemangioblastoma, acoustic
neuroma. oligodendroglioma, menangioma, melanoma, neuroblastoma,
retinoblastoma, a blood-born tumor or multiple myeloma.
[0281] In another embodiment, diseases to be treated or prevented
by administering to a patient in need thereof an effective amount
of a compound of the invention include, but are not limited to, a
blood-born tumor such as acute lymphoblastic leukemia, acute
lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia,
acute myeloblastic leukemia, acute promyelocytic leukemia, acute
monoblastic leukemia, acute erythroleukemic leukemia, acute
megakaryoblastic leukemia, acute myelomonocytic leukemia, acute
nonlymphocytic leukemia, acute undifferentiated leukemia, chronic
myelocytic leukemia, chronic lymphocytic leukemia, hairy cell
leukemia, or multiple myeloma. See e.g., Harrison's Principles of
Internal Medicine, Eugene Braunwald et al., eds., pp. 491-762 (15th
ed. 2001).
[0282] In yet another embodiment, the invention encompasses the
treatment of a human afflicted with a solid tumor or a blood
tumor.
[0283] In a preferred embodiment, the invention encompasses a
method of treating or preventing a disease ameliorated by
modulation of premature translation termination, nonsense-mediated
mRNA decay, or premature translation termination and nonsense.
mediated mRNA decay, or ameliorating one or more symptoms
associated therewith comprising contacting a cell with a
therapeutically effective amount of a compound of the invention.
Cells encompassed by the present methods include animal cells,
mammalian cells, bacterial cells, and virally infected cells. In
one embodiment, the nonsense mutation is a genetic mutation (i.e.,
the nonsense codon was present in the progenitor DNA). In another
embodiment, the nonsense mutation is a somatic mutation (i.e., the
nonsense codon arose spontaneously or from mutagenesis).
[0284] In certain embodiments, a compound of the invention is
administered to a subject, including but not Limited to a plant,
reptile. avian, amphibian or preferably a mammal, more preferably a
human, as a preventative measure against a disease associated with
premature translation termination, nonsense-mediated mRNA decay, or
premature translation termination and nonsense-mediated mRNA
decay.
[0285] In a preferred embodiment, it is first determined that the
patient is suffering from a disease associated with premature
translation termination and/or nonsense-mediated mRNA decay. In
another embodiment, the patient has undergone a screening process
to determine the presence of a nonsense mutation comprising the
steps of screening a subject, or cells extracted therefrom, by an
acceptable nonsense mutation screening assay. In a preferred
embodiment, the DNA of the patient can be sequenced or subjected to
rern Blot, polymerase chain reaction (PCR), use of the Short Tandem
Repeat (STR), or polymorphic length restriction fragments (RFLP)
analysis to determine if a nonsense mutation is present in the DNA
of the patient. In one embodiment, it is determined whether the
nonsense mutation is a genetic mutation or a somatic mutation by
comparison of progenitor DNA. Alternatively, it can be determined
if altered levels of the protein with the nonsense mutation are
expressed in the patient by western blot or other immunoassays. In
another embodiment, the patient is an unborn child who has
undergone screening in utero for the presence of a nonsense
mutation. Administration of a compound of the invention can occur
either before or after birth. In a related embodiment, the therapy
is personalized in that the patient is screened for a nonsense
mutation screening assay and treated by the administration of one
or more compounds of the invention; particularly, the patient may
be treated with a compound particularly suited for the mutations in
question; e.g., depending upon the disease type. cell type, and the
gene in question. Such methods are well known to one of skill in
the art.
[0286] In another embodiment, the cells (e.g., animal cells,
mammalian cells, bacterial cells, plant cells and virally infected
cells) are screened for premature translation termination and/or
nonsense-mediated mRNA decay with a method such as that described
above (i.e., the DNA of the cell can be sequenced or subjected to
Southern Blot, polymerase chain reaction (PCR), use of the Short
Tandem Repeat (STR), or polymorphic length restriction fragments
(RFLP) analysis to determine if a nonsense mutation is present in
the DNA of the cell; the RNA of the cell can be subjected to
quantitative real time PCR to determine transcript abundance).
[0287] Specific methods of the invention further comprise the
administration of an additional therapeutic agent (i.e., a
therapeutic agent other than a compound of the invention). In
certain embodiments of the present invention, the compounds of the
invention can be used in combination with at least one other
therapeutic agent. Therapeutic agents include, but are not limited
to non-opioid analgesics; non-steroid anti-inflammatory agents;
steroids, antiemetics; .beta.-adrenergic blockers; anticonvulsants;
antidepressants; Ca.sup.2+-channel blockers; anticancer agent(s)
and antibiotics and mixtures thereof.
[0288] In certain embodiments, the compounds of the invention can
be administered or formulated in combination with anticancer
agents. Suitable anticancer agents include, but are not limited to:
alkylating agents; nitrogen mustards; folate antagonists; purine
antagonists; pyrimidine antagonists; spindle poisons; topoisomerase
inhibitors; apoptosis inducing agents; angiogenesis inhibitors;
podophyllotoxins; nitrosoureas; cisplatin; carboplatin; interferon;
asparaginase; tamoxifen; leuprolide; flutamide; megestrol;
mitomycin; bleomycin; doxorubicin; irinotecan and taxol.
[0289] In certain embodiments, the compounds of the invention can
be administered or formulated in combination with antibiotics. In
certain embodiments, the antibiotic is an aminoglycoside (e.g.,
tobramycin), a cephalosporin (e.g., cephalexin, cephradine,
cefuroxime. cefprozil, cefaclor, cefixime or cefadroxil), a
clarithromycin (e.g., clarithromycin), a macrolide (e.g.,
erythromycin), a penicillin (e.g., penicillin V) or a quinolone
(e.g., ofloxacin, ciprofloxacin or norfloxacin). In a preferred
embodiment, the antibiotic is active against Pseudomonas
aeruginosa.
[0290] Without intending to be limited by theory, it is believed
that the methods of the present invention act through a combination
of mechanisms that suppress nonsense mutations. In preferred
embodiments, the methods of the invention comprise administering a
therapeutically effective amount of at least one compound of the
invention, e.g., a compound of Formula 1. Relative activity of the
compounds of the invention may be determined by any method known in
the sat, including the assay described in Example 2 herein.
[0291] Compounds of the invention can be characterized with an in
vitro luciferase nonsense suppression assay. Luciferase assays are
included in the methods of the present invention. Luciferase can be
used as a functional reporter gene assay (light is only produced if
the protein is functional), and luciferase is extremely sensitive
(Light intensity is proportional to luciferase concentration in the
nM range). In one embodiment, an assay of the present invention is
a cell-based luciferase reporter assay. in a preferred cell-based
luciferase reporter assay, a luciferase reporter construct
containing a premature termination codon (UGA, UAA, or UAG) is
stably transfected in 293 Human Embryonic Kidney cells.
[0292] In another assay of the present invention, a preferred assay
is a biochemical assay consisting of rabbit reticulocyte lysate and
a nonsense-containing luciferase reporter mRNA. In another assay of
the present invention, the assay is a biochemical assay consisting
of prepared and optimized cell extract (Lie & Macdonald, 1999,
Development 126(22):4989-4996 and Lie & Macdonald, 2000,
Biochem. Biophys. Res. Commun. 270(2):473-481. In the biochemical
assay. mRNA containing a premature termination codon (UGA. UAA, or
UAG) is used as a reporter in an in vitro translation reaction
using rabbit reticulocyte lysate supplemented with tRNA, hemin,
creatine kinase, amino acids. KOAc, Mg(OAc)2, and creatine
phosphate. Translation of the mRNA is initiated within a virus
derived leader sequence, which significantly reduces the cost of
the assay because capped RNA is not required. Synthetic mRNA is
prepared in vitro using the T7 promoter and the MegaScript in vitro
transcription kit (Ambion, Inc.; Austin, Tex.). In assays of the
present invention, addition of gentamicin, an aminoglycoside known
to allow readthrough of premature termination codon, results in
increased luciferase activity and can be used as an internal
standard. Assays of the present invention can be used in
high-throughput screens. Hundreds of thousands of compounds can be
screened in cell-based and biochemical assays of the present
invention. In a preferred aspect. a functional cell-based assay
similar to the one described.
[0293] Compounds of the present invention include compounds capable
of increasing specific, functional protein expression from mRNA
molecules comprising premature termination codons. In one
embodiment, compounds of the present invention can preferentially
suppress premature translation termination. For example, a compound
of the present invention can be capable of suppressing a nonsense
mutation if the mutation results in UAA, but not capable of
suppressing a nonsense mutation if the mutation results in UAG.
Another non-limiting example can occur when a compound of the
present invention can be capable of suppressing a nonsense mutation
if the mutation results in UAA and is followed, in-frame by a
cytosine at the +1 position, but not capable of suppressing a
nonsense mutation if the mutation results in UAA and is followed,
in-frame by an adenine at the +1 position.
[0294] A stable cell line harboring the UGA nonsense-containing
luciferase gene can be treated with a test compound. In this
aspect, cells can be grown in standard medium supplemented with 1%
penicillin-streptomycin (P/S) and 10% fetal bovine serum (FBS) to
70% confluency and split 1:1 the day before treatment. The next
day, cells are trypsinized and 40,000 cells are added to each well
of a 96-well tissue culture dish. Serial dilutions of each compound
are prepared to generate a six-point dose response curve spanning 2
logs (30 .mu.M to 0.3 .mu.M). The final concentration of the DMSO
solvent remains constant at 1% in each well. Cells treated with 1%
DMSO serve as the background standard, and cells treated with
gentamicin serve as a positive control.
[0295] To address the effects of the nonsense-suppressing compounds
on mRNAs altered in specific inherited diseases, a bronchial
epithelial cell line harboring a nonsense codon at amino acid 1282
(W1282X) can be treated with a compound of the invention and CFTR
function is monitored as a cAMP-activated chloride channel using
the SPQ assay (Yang et al., Hum. Mol. Genet. 2(8):1253-1261 (1993)
and Howard et al., Nat. Med 2(4):467-469(1996)). The increase in
SPQ fluorescence in cells treated with a compound of the invention
is compared to those treated with cAMP and untreated cells. An
increase in SPQ fluorescence in cells is consistent with
stimulation of CFTR-mediated halide efflux and an increase in
readthrough of the nonsense codon. Full-length CFTR expression from
this nonsense-containing allele following treatment with a compound
of the invention demonstrates that cystic fibrosis cell lines
increase chloride channel activity when treated with a compound of
the invention.
[0296] D. Metabolites of the Compounds of the Invention
[0297] Also falling within the scope of the present invention are
the in vivo metabolic products of the compounds described herein.
Such products may result for example from the oxidation, reduction,
hydrolysis, amidation. esterification and the like of the
administered compound, primarily due to enzymatic processes.
Accordingly, the invention includes compounds produced by a process
comprising contacting a compound of this invention with a mammalian
tissue or a mammal for a period of time sufficient to yield a
metabolic product thereof. Such products typically are identified
by preparing a radio-labeled (e.g. C.sup.14 or H.sup.3) compound of
the Invention, administering it in a detectable dose (e.g., greater
than about 0.5 mg/kg) to a mammal such as rat, mouse, guinea pig,
monkey, or to man, allowing sufficient time for metabolism to occur
(typically about 30 seconds to 30 hours), and isolating its
conversion products from urine, blood or other biological samples.
These products are easily isolated since they are labeled (others
are isolated by the use of antibodies capable of binding epitopes
surviving in the metabolite). The metabolite structures are
determined in conventional fashion, e.g., by MS or NMR analysis. In
general, analysis of metabolites may be done in the same way as
conventional drug metabolism studies well-known to those skilled in
the art. The conversion products, so long as they are not otherwise
found in vive, are useful in diagnostic assays for therapeutic
dosing of the compounds of the invention even if they possess no
biological activity of their own.
[0298] E. Pharmaceutical Compostions of the Invention
[0299] While it is possible for the compounds of the present
invention to be administered neat, it may be preferable to
formulate the compounds as pharmaceutical compositions. As such, in
yet another aspect of the invention, pharmaceutical compositions
useful in the methods of the invention are provided. The
pharmaceutical compositions of the invention may be formulated with
pharmaceutically acceptable excipients such as carriers, solvents,
stabilizers, adjuvants, diluents, etc., depending upon the
particular mode of administration and dosage form. The
pharmaceutical compositions should generally be formulated to
achieve a physiologically compatible pH, and may range from a pH of
about 3 to a pH of about 11, preferably about pH 3 to about pH 7.
depending on the formulation and route of administration. In
another embodiment, the pharmaceutical compositions of the
invention may be formulated in a pH range from about pH 4 to about
pH 7. In alternative embodiments, it may be preferred that the pH
is adjusted to a range from about pt 5 to about pH 8.
[0300] More particularly, the pharmaceutical compositions of the
invention comprise a therapeutically or prophylactically effective
amount of at least one compound of the present invention, together
with one or more pharmaceutically acceptable excipients.
Optionally, the pharmaceutical compositions of the invention may
comprise a combination of compounds of the present invention, or
may include a second active ingredient useful in the treatment of
cancer, diabetic retinopathy, or exudative macular
degeneration.
[0301] Formulations of the present invention, e.g., for parenteral
or oral administration. are most typically solids, liquid
solutions, emulsions or suspensions, while inhalable formulations
for pulmonary administration are generally liquids or powders, with
powder formulations being generally preferred. A preferred
pharmaceutical composition of the invention may also be formulated
as a lyophilized solid that is reconstituted with a physiologically
compatible solvent prior to administration. Alternative
pharmaceutical compositions of the invention may be formulated as
syrup., creams, ointments, tablets, and the like.
[0302] The pharmaceutical compositions of the invention can be
administered to the subject via any drug delivery route known in
the art. Specific exemplary administration routes include oral.
ocular, rectal, buccal, topical, nasal, ophthalmic, subcutaneous,
intramuscular, intravenous (bolus and infusion), intracerebral,
transdermal, and pulmonary.
[0303] The term "pharmaceutically acceptable excipient" refers to
an excipient for administration of a pharmaceutical agent, such as
the compounds of the present invention. The term refers to any
pharmaceutical excipient that may be administered without undue
toxicity. Pharmaceutically acceptable excipients are determined in
part by the particular composition being administered, as well as
by the particular method used to administer the composition.
Accordingly, there exists a wide variety of suitable formulations
of pharmaceutical compositions of the present invention (see, e.g.,
Remington's Pharmaceutical Sciences, 18.sup.th Ed., Mack Publishing
Co., 1990).
[0304] Suitable excipients may be carrier molecules that include
large, slowly metabolized macromolecules such as proteins,
polysaccharides, polylactic acids, polyglycolic acids, polymeric
amino acids, amino acid copolymers, and inactive virus particles.
Other exemplary excipients include antioxidants such as ascorbic
acid; chelating agents such as EDTA; carbohydrates such as dextrin,
hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid;
liquids such as oils, water, saline, glycerol and ethanol; wetting
or emulsifying agents; pH buffering substances; and the like.
Liposomes are also included within the definition of
pharmaceutically acceptable excipients.
[0305] The pharmaceutical compositions of the invention may be
formulated in any form suitable for the intended method of
administration. When intended for oral use for example, tablets,
troches, lozenges, aqueous or oil suspensions, non-aqueous
solutions, dispersible powders or granules (including micronized
particles or nanoparticles), emulsions, hard or soft capsules,
syrups or elixirs may be prepared. Compositions intended for oral
use may be prepared according to any method known to the art for
the manufacture of pharmaceutical compositions, and such
compositions may contain one or more agents including sweetening
agents, flavoring agents, coloring agents and preserving agents, in
order to provide a palatable preparation.
[0306] Pharmaceutically acceptable excipients particularly suitable
for use in conjunction with tablets include, for example, inert
diluents. such as celluloses, calcium or sodium carbonate, lactose,
calcium or sodium phosphate; disintegrating agents, such as
croscarmellose sodium, cross-linked povidone, maize starch, or
alginic acid; binding agents, such as povidone, starch, gelatin or
acacia; and lubricating agents, such as magnesium stearate, stearic
acid or talc. Tablets may be uncoated or may be coated by known
techniques including microencapsulation to delay disintegration and
adsorption in the gastrointestinal tract and thereby provide a
sustained action over a longer period. For example, a time delay
material such as glyceryl monostearate or glyceryl distearate alone
or with a wax may be employed.
[0307] Formulations for oral use may be also presented as hard
gelatin capsules where the active ingredient is mixed with an inert
solid diluent, for example celluloses, lactose, calcium phosphate
or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with non-aqueous or oil medium, such as
glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid
paraffin or olive oil.
[0308] In another embodiment, pharmaceutical compositions of the
invention may be formulated as suspensions comprising a compound of
the present invention in admixture with at least one
pharmaceutically acceptable excipient suitable for the manufacture
of a suspension. In yet another embodiment, pharmaceutical
compositions of the invention may be formulated as dispersible
powders and granules suitable for preparation of a suspension by
the addition of suitable excipients.
[0309] Excipients suitable for use in connection with suspensions
include suspending agents, such as sodium carboxymethylcellulose,
methylcellulose, hydroxypropyl methylcelluose, sodium alginate,
polyvinylpyrrolidone, gum tragacanth, gum acacia. dispersing or
wetting agents such as a naturally occurring phosphatide (e.g.,
lecithin), a condensation product of an alkylene oxide with a fatty
acid (e.g., polyoxyethylene stearate), a condensation product of
ethylene oxide with a long chain aliphatic alcohol (e.g.,
heptadecaethylenooxycethanol), a condensation product of ethylene
oxide with a partial ester derived from a fatty acid and a hexitol
anhydride (e.g., polyoxyethylene sorbitan monoleate); and
thickening agents, such as carbomer, beeswax, hard paraffin or
cetyl alcohol. The suspensions may also contain one or more
preservatives such as acetic acid, methyl and/or n-propyl
p-hydroxy-benzoate; one or more coloring agents; one or more
flavoring agents; and one or more sweetening agents such as sucrose
or saccharin.
[0310] The pharmaceutical compositions of the invention may also be
in the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, such as olive oil or arachis oil, a mineral oil,
such as liquid paraffin, or a mixture of these. Suitable
emulsifying agents include naturally-occurring gums, such as gum
acacia and gum tragacanth; naturally occurring phosphatides, such
as soybean lecithin. esters or partial esters derived from fatty
acids; hexitol anhydrides, such as sorbitan monoleate; and
condensation products of these partial esters with ethylene oxide,
such as polyoxyethylene sorbitan monoleate. The emulsion may also
contain sweetening and flavoring agents. Syrups and elixirs may be
formulated with sweetening agents, such as glycerol, sorbitol or
sucrose. Such formulations may also contain a demulcent, a
preservative, a flavoring or a coloring agent.
[0311] Additionally, the pharmaceutical compositions of the
invention may be in the form of a sterile injectable preparation.
such as a sterile injectable aqueous emulsion or oleaginous
suspension. This emulsion or suspension may be formulated according
to the known art using those suitable dispersing or wetting agents
and suspending agents which have been mentioned above. The sterile
injectable preparation may also be a sterile injectable solution or
suspension in a non-toxic parenterally acceptable diluent or
solvent, such as a solution in 1,2-propane-diol. The sterile
injectable preparation may also be prepared as a lyophilized
powder. Among the acceptable vehicles and solvents that may be
employed are water, Ringer's solution, and isotonic sodium chloride
solution. In addition, sterile fixed oils may be employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid may likewise be used in
the preparation of injectables.
[0312] Generally, the compounds of the present invention useful in
the methods of the present invention are substantially insoluble in
water and are sparingly soluble in most pharmaceutically acceptable
protic solvents and in vegetable oils. However, the compounds are
generally soluble in medium chain fatty acids (e.g., caprylic and
capric acids) or triglycerides and have high solubility in
propylene glycol esters of medium chain fatty acids. Also
contemplated in the invention are compounds which have been
modified by substitutions or additions of chemical or biochemical
moieties which make them more suitable for delivery (e.g. increase
solubility, bioactivity, palatability, decrease adverse reactions,
etc.), for example by esterification, glycosylation, PEGylation,
etc.
[0313] In a preferred embodiment, the compounds of the present
invention may be formulated for oral administration in a
lipid-based formulation suitable for low solubility compounds.
Lipid-based formulations can generally enhance the oral
bioavailability of such compounds. As such, a preferred
pharmaceutical composition of the invention comprises a
therapeutically or prophylactically effective amount of a compound
of the present invention, together with at least one
pharmaceutically acceptable excipient selected from the group
consisting of: medium chain fatty acids or propylene glycol esters
thereof (e.g., propylene glycol esters of edible fatty acids such
as caprylic and capric fatty acids) and pharmaceutically acceptable
surfactants such as polyoxyl 40 hydrogenated castor oil.
[0314] In an alternative preferred embodiment, cyclodextrins may be
added as aqueous solubility enhancers. Preferred cyclodextrins
include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and
maltotriosyl derivatives of .alpha.-, .beta.-, and
.gamma.-cyclodextrin. A particularly preferred cyclodextrin
solubility enhancer is hydroxypropyl-.beta.-cyclodextrin (HPBC),
which may be added to any of the above-described compositions to
further improve the aqueous solubility characteristics of the
compounds of the present invention. In one embodiment the
composition comprises 0.1% to 20%
hydroxypropyl-.beta.-cyclodextrin, more preferably 1% to 15%
hydroxypropyl-.beta.-cyclodextrin, and even more preferably from
2.5% to 10% hydroxypropyl-.beta.-cyclodextrin. The amount of
solubility enhancer employed will depend on the amount of the
compound of the present invention in the composition.
[0315] The therapeutically effective amount, as used herein, refers
to an amount of a pharmaceutical composition of the invention to
treat, ameliorate, or modulate an identified disease or condition,
or to exhibit a detectable therapeutic or inhibitory effect. The
effect can be detected by, for example, assays of the present
invention. The effect can also be the prevention of a disease or
condition where the disease or condition is predicted for an
individual or a high percentage of a population.
[0316] The precise effective amount for a subject will depend upon
the subject's body weight, size, and health; the nature and extent
of the condition; the therapeutic or combination of therapeutics
selected for administration, the protein half-life, the mRNA
half-life and the protein localization. Therapeutically effective
amounts for a given situation can be determined by routine
experimentation that is within the skill and judgment of the
clinician.
[0317] For any compound, the therapeutically effective amount can
be estimated initially either in cell culture assays, e.g., of
neoplastic cells, or in animal models, usually rats, mice, rabbits,
dogs, or pigs. The animal model may also be used to determine the
appropriate concentration range and route of administration. Such
information can then be used to determine useful doses and routes
for administration in humans. Therapeutic/prophylactic efficacy and
toxicity may be determined by standard pharmaceutical procedures in
cell cultures or experimental animals, e.g., ED.sub.50 (the dose
therapeutically effective in 50% of the population) and LD.sub.50
(the dose lethal to 50% of the population). The dose ratio between
toxic and therapeutic effects is the therapeutic index, and it can
be expressed as the ratio, LD.sub.50/ED.sub.50. Pharmaceutical
compositions that exhibit large therapeutic indices are preferred.
The data obtained from cell culture assays and animal studies may
be used in formulating a range of dosage for human use. The dosage
contained in such compositions is preferably within a range of
circulating concentrations that include an ED.sub.50 with little or
no toxicity. The dosage may vary within this range depending upon
the dosage form employed, sensitivity of the patient, and the route
of administration.
[0318] More specifically, the concentration-biological effect
relationships observed with regard to the compound(s) of the
present invention indicate an initial target plasma concentration
ranging from approximately 5 .mu.g/mL to approximately 100
.mu.g/mL, preferably from approximately 10 .mu.g/mL to
approximately 50 .mu.g/mL, more preferably from approximately 10
.mu.g/mL to approximately 25 .mu.g/mL. To achieve such plasma
concentrations. the compounds of the invention may be administered
at doses that vary from 1 mg/kg to 150 mg/g, depending upon the
route of administration. Guidance as to particular dosages and
methods of delivery is provided in the literature and is generally
available to practitioners in the art. In general the dose will be
in the range of about 1 mg/day to about 10 g/day, or about 0.1 g to
about 3 g/day, or about 0.3 g to about 3 g/day, or about 0.5 g to
about 2 g/day, in single, divided, or continuous doses for a
patient weighing between about 40 to about 100 kg (which dose may
be adjusted for patients above or below this weight range,
particularly children under 40 kg).
[0319] The magnitude of a prophylactic or therapeutic dose of a
particular active ingredient of the invention in the acute or
chronic management of a disease or condition will vary, however,
with the nature and severity of the disease or condition, and the
route by which the active ingredient is administered. The dose, and
perhaps the dose frequency, will also vary according to the age,
body weight, and response of the individual patient. Suitable
dosing regimens can be readily selected by those skilled in the art
with due consideration of such factors. In general, the recommended
daily dose range for the conditions described herein lie within the
range of from about 1 mg/kg to about 150 mg/kg per day. In one
embodiment, the compound of the invention is given as a single
once-a-day dose. In another embodiment, the compound of the
invention is given as divided doses throughout a day. More
specifically, the daily dose is administered in a single dose or in
equally divided doses. Preferably, a daily dose range should be
from about 5 mg/kg to about 100 mg/kg per day, more preferably,
between about 10 mg/kg and about 90 mg/kg per day, even more
preferably 20 mg/kg to 60 mg/kg per day. In managing the patient.
the therapy should be initiated at a lower dose, perhaps about 200
mg to about 300 mg, and increased if necessary up to about 600 mg
to about 4000 mg per day as either a single dose or divided doses,
depending on the patient's global response. It may be necessary to
use dosages of the active ingredient outside the ranges disclosed
herein in some cases, as will be apparent to those of ordinary
skill in the art. Furthermore, it is noted that the clinician or
treating physician will know how and when to interrupt, adjust, or
terminate therapy in conjunction with individual patient
response.
[0320] Different therapeutically effective amounts may be
applicable for different diseases and conditions, as will be
readily known by those of ordinary skill in the art. Similarly,
amounts sufficient to treat or prevent such diseases, but
insufficient to cause, or sufficient to reduce, adverse effects
associated with conventional therapies are also encompassed by the
above described dosage amounts and dose frequency schedules.
[0321] As stated before. the exact dosage will be determined by the
practitioner, in light of factors related to the subject that
requires treatment. Dosage and administration are adjusted to
provide sufficient levels of the active agent(s) or to maintain the
desired effect. Factors which may be taken into account include the
severity of the disease state, general health of the subject, ago,
weight, and gender of the subject, diet. time, protein of interest
half-life. RNA of interest half-life, frequency of administration,
drug combination(s), reaction sensitivities, and tolerance/response
to therapy. Long-acting pharmaceutical compositions may be
administered every 3 to 4 days, every week, or once every two weeks
depending on half-life and clearance rate of the particular
formulation.
[0322] F. Combination Therapy
[0323] It is also possible to combine any compound of the present
invention with one or more other active ingredients useful in the
treatment of diseases associated with nonsense mutations of mRNA as
described herein, including compounds in a unitary dosage form. or
in separate dosage forms intended for simultaneous or sequential
administration to a patient in need of treatment. When administered
sequentially, the combination may be administered in two or more
administrations. In an alternative embodiment, it is possible to
administer one or more compounds of the present invention and one
or more additional active ingredients by different routes.
[0324] The skilled artisan will recognize that a variety of active
ingredients may be administered in combination with the compounds
of the present invention that may act to augment or synergistically
enhance the nonsense mutation-suppressing activity of the compounds
of the invention.
[0325] According to the methods of the invention, the combination
of active ingredients may be: (1) co-formulated and administered or
delivered simultaneously in a combined formulation; (2) delivered
by alternation or in parallel as separate formulations; or (3) by
any other combination therapy regimen known in the art. When
delivered in alternation therapy, the methods of the invention may
comprise administering or delivering the active ingredients
sequentially. e.g., in separate solution, emulsion, suspension,
tablets, pills or capsules, or by different injections in separate
syringes. In general, during alternation therapy, an effective
dosage of each active ingredient is administered sequentially,
i.e., serially, whereas in simultaneous therapy, effective dosages
of two or more active ingredients are administered together.
Various sequences of intermittent combination therapy may also be
used.
[0326] G. Gene Therapy
[0327] The compounds of the present invention or other nonsense
compounds can be utilized in combination with gene therapy. In this
embodiment, a gene can be introduced or provided to a mammal,
preferably a human that contains a specified nonsense mutation in
the desired gene. In a preferred aspect, the desired gene is
selected from the group consisting of IGF1, EPO, p53, p19ARF, p21,
PTEN, EI 24 and ApoAI. In order to obtain expression of the
full-length polypeptide in a patient or mammal, the patient or
mammal would be provided with an effective amount of a compound of
the present invention or other nonsense suppression compound when
such polypeptide is desired.
[0328] There are two major approaches to getting nucleic acids that
contain a nonsense mutation (optionally contained in a vector) into
the patient's cells: in vivo and ex vivo. For in vivo delivery the
nucleic acid is injected directly into the patient, usually at the
sites where the polypeptide is required, i.e., the site of
synthesis of the polypeptide, if known, and the site (e.g. solid
tumor) where biological activity of the polypeptide is needed. For
ex vivo treatment, the patient's cells are removed, the nucleic
acid is introduced into these isolated cells, and the modified
cells are administered to the patient either directly or, for
example, encapsulated within porous membranes that are implanted
into the patient (see e.g., U.S. Pat. Nos. 4,892,538 and
5,283,187). There are a variety of techniques available for
introducing nucleic acids into viable cells. The techniques vary
depending upon whether the nucleic acid is transferred into
cultured cells in vitro, or transferred in vivo in the cells of the
intended host. Techniques suitable for the transfer of nucleic acid
into mammalian cells in vitro include the use of liposomes,
electroporation, microinjection, transduction, cell fusion,
DEAE-dextran, the calcium phosphate precipitation method, etc.
Transduction involves the association of a replication-defective,
recombinant viral (preferably retroviral) particle with a cellular
receptor, followed by introduction of the nucleic acids contained
by the particle into the cell. A commonly used vector for ax vivo
delivery of the gene is a retrovirus.
[0329] The currently preferred in vivo nucleic and transfer
techniques include transfection with viral or non-viral vectors
(such as adenovirus, lentivirus. Herpes simplex I virus, or
adeno-associated virus (AAV)) and lipid-based systems (useful
lipids for lipid-mediated transfer of the gene are, for example,
DOTMA, DOPE, and DC-Chol; see, e.g., Tonkinson et al., Cancer
Investigation. 14 (1): 54-65 (1996)). The most preferred vectors
for use in gene therapy are viruses, most preferably adenoviruses,
AAV, lentiviruses, or retroviruses. A viral vector such as a
retroviral vector includes at least one transcriptional
promoter/enhancer or locus-defining element(s), or other elements
that control gene expression by other means such as alternate
splicing, nuclear RNA export, or post-ranslational modification of
messenger. In addition, a viral vector such as a retroviral vector
includes a nucleic acid sequence that, when transcribed with a gene
encoding a polypeptide, is operably linked to the coding sequence
and acts as a translation initiation sequence. Such vector
constructs also include a packaging signal, long terminal repeats
(LTRs) or portions thereof, and positive and negative strand primer
binding sites appropriate to the virus used (if these are not
already present in the viral vector). In addition, such vector
typically includes a signal sequence for secretion of the
polypeptide from a host cell in which it is placed. Preferably the
signal sequence for this purpose is a mammalian signal sequence,
most preferably the native signal sequence for the polypeptide.
Optionally, the vector construct may also include a signal that
directs polyadenylation, as well as one or more restriction sites
and a translation termination sequences. By way of example, such
vectors will typically include a 5' LTR, a tRNA binding site, a
packaging signal, a origin of second-strand DNA synthesis, and a 3'
LTR or a portion thereof. Other vectors can be used that are
non-viral, such as cationic lipids, polylysine, and dendrimers.
[0330] In some situations, it is desirable to provide the nucleic
acid source with an agent that targets the target cells, such as an
antibody specific for a cell-surface membrane protein or the target
cell, a ligand for a receptor on the target cell, etc. Where
liposomes are employed, proteins that bind to a cell-surface
membrane protein associated with endocytosis may be used for
targeting and/or to facilitate uptake, e.g., capsid proteins or
fragments thereof tropic for a particular cell type, antibodies for
proteins that undergo internalization in cycling, and proteins that
target intracellular localization and enhance intracellular
half-life. The technique of recepto-mediated endocytosis is
described, for example, by Wu et al., J. Bid. Chem. 262: 4429-4432
(1987); and Wagner et al., Proc. Natl. Acad. Sci. USA, 87:
3410-3414 (1990). For a review of the currently known gene marking
and gene therapy protocols, see, Anderson et al., Science 256:
808-813 (1992). See also WO 93/25673 and the references cited
therein.
[0331] Suitable gene therapy and methods for making retroviral
particles and structural proteins can be found in, e.g. U.S. Pat.
Nos. 5,681,746; 6,800,604 and 6,800,731.
[0332] To assist in understanding the present invention, the
following Examples are included. The experiments relating to this
invention should not, of course, be construed as specifically
limiting the invention and such variations of the invention, now
known or later developed, which would be within the purview of one
skilled in the at are considered to fall within the scope of the
invention as described herein and hereinafter claimed.
EXAMPLES
[0333] The present invention is described in more detail with
reference to the following non-limiting examples, which are offered
to more fully illustrate the invention, but are not to be construed
as limiting the scope thereof. The examples illustrate the
preparation of certain compounds of the invention, and the testing
of these compounds in vitro and/or in viva. Those of skill in the
art will understand that the techniques described in these examples
represent techniques described by the inventors to function well in
the practice of the invention, and as such constitute preferred
modes for the practice thereof. However, it should be appreciated
that those of skill in the art should in light of the present
disclosure, appreciate that many changes can be made in the
specific methods that are disclosed and still obtain a like or
similar result without departing from the spirit and scope of the
invention.
Example 1
Preparation of Compounds of the Invention
A. Preparation of Pyrroles
[0334] Pyrroles of the invention may be generally prepared as
follows.
Preparation of
3-[1-(4-Trifluoromethyl-phenyl)-]-1H-pyrrol-3-yl]-benzoic acid
sodium salt (Compound 154)
[0335] Part A.
[0336] To a solution of 1-(triisopropylsilyl)pyrrole-3-boronic acid
(prepared according to the method of Alvarez, A.; Guzman, A.; Ruiz,
A.; Velarde, E., J. Org. Chew. 1992, 57, 1653-1656) (6.12 g, 22.9
mmol) in anhydrous dimethoxyethane (76 mL) is added methyl
4-iodobenzoate (96.61 g, 25.2 mmol),
dichlorobis(triphenylphosphine)palladium(II) (0.484 g, 0.69 mmol)
and cesium fluoride (6.96 g, 45.8 mmol). The mixture is heated at
reflux under a nitrogen atmosphere for 17 h. The reaction mixture
is cooled to room temperature, diluted with water (100 mL) and
extracted with ethyl acetate (4.times.25 mL). The extract is washed
with water, dried over MgSO.sub.4 and concentrated to give the
crude product. The product is purified by silica gel chromatography
(5-15% ethyl acetate/hexane) to give 2.69 g of methyl
4-(1H-pyrrol-3-yl)-benzoate as a white solid (58% yield). .sup.1H
NMR (300 MHz, DMSO-d.sub.6): .delta. 3.83 (s, 3H), 6.53 (m, 1H),
6.83 (m, 1H), 7.35 (m, 1H), 7.66 (d, 2H, J=8.4 Hz), 7.86 (d, 2H,
J=0.4 Hz), 11.11 (brs, 1H).
[0337] Part B.
[0338] To a solution of methyl 4-(1H-pyrrol-3-yl)-benzoate in
anhydrous dioxane (67 mL) is added 4-iodobenzofluoride (4.39 g,
16.1 mmol), cuprous iodide (0.255 g, 1.34 mmol), ethylenediamine
(81 mg, 1.35 mmol) and potassium phosphate (10.16 g, 44.1 mmol).
The reaction mixture is heated at reflux for 20 h. under a nitrogen
atmosphere, then cooled to room temperature. The solid is filtered,
washed with ethyl acetate and discarded. The filtrate is
concentrated to give a dark solid which is diluted with water (50
mL) and extracted with ethyl acetate (3.times.20 mL). The extracts
are washed with water (2.times.20 mL), combined, dried over
MgSO.sub.4 and concentrated to give the crude product. The crude
product is purified by silica gel chromatography (5-20% ethyl
acetate) to give 2.00 g of methyl
3-[1-(4-trifluoromethyl-phenyl)-1H-pyrrol-3-yl]-benzoate as a white
solid (73% yield). .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
3.93 (s, 3H), 6.75 (m, 1H), 7.19 (m, 1H), 7.50 (m, 1H), 7.55 (d,
2H, J=8.7 Hz), 7.63 (d, 2H, J=6.6 Hz), 7.73 (d, 2H, J=8.4 Hz), 8.04
(d, 2H, J=6.6 Hz).
[0339] Part C.
[0340] To a suspension of methyl
3-[1-(4-trifluoromethyl-phenyl)-1H-pyrrol-3-yl]-benzoate (1.24 g,
3.59 mmol) in tert-butanol (4 mL) and water (16 mL) is added sodium
hydroxide (0.215 g, 5.38 mmol). The reaction mixture is heated at
reflux for 4 h, then cooled to room temperature. The solid is
filtered, washed with water (3.times.4 mL) and dried to give 0.90 g
of the tide product as a gray solid (71% yield). MS (ES+): m/z
332.61.
[0341] Part D.
[0342] A portion of the sodium salt of
3-[1-(4-trifluoromethyl-phenyl)-1H-pyrrol-3-yl]-benzoic acid is
neutralized with 1N aq. HCl to afford. after filtration, water
washing and drying under vacuum. the free acid: m.p.
224-226.degree. C. MS (ES+): m/s 332.28 (100). MS (ES-): m/e 330.31
(100).
Preparation of
4-[1-(4-Trifluoromethyl-phenyl)-1H-pyrrol-3-yl]-benzoic acid
(Compound 105)
[0343] Part A.
[0344] To a slurry of methyltriphenylphosphonium bromide (10.88 g,
30.46 mmol, 1 eq.) and potassium tert-butoxide (31 mL, 1 M solution
in THF, 30.46 mmol 1 eq.) in THF is added methyl-4-formylbenzoate
(5.0 g, 30.46 mmol, 1 eq.). The bright yellow reaction mixture is
stirred at room temperature for 5 hrs. Hexane is added and after
stirring for 10 minutes, the mixture is filtered and washed twice
with hexanes. Solvent is removed in vacuum and the crude oily
residue is purified by silica gel chromatography (0-14% ethyl
acetate/hexanes) to give 3.76 g of a white oily solid, methyl
4-vinylbenzoate (23.21 mmol, 76.2% yield). .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 7.99 (2H, d, J=9 Hz), 7.45 (2H, d, J=9 Hz),
6.76 (1H, dd, J=17, 11 Hz), 5.86 (1H, d, J=17 Hz), 5.37 (1H, d,
J=11 Hz), 3.91 (3H, s).
[0345] Part B.
[0346] Sodium tert-butoxide (3.681 g, 38.3 mmol 2.0 eq.) is
suspended in anhydrous DMSO under nitrogen. To this a solution of
methyl 4-vinylbenzoate (3.11 g 19.15 mmol, 1.0 eq.) and tosylmethyl
isocyanide (4.86 g, 24.89 mmol, 1.3 eq.) in anhydrous DMSO is
transferred via cannula. The dark brown mixture is stirred at room
temperature for 16 hrs. The mixture is adjusted to pH 6 by addition
of 10% HCl solution, diluted with water and extracted with ethyl
acetate (3.times.50 mL). The combined organic extract is washed
with water (2.times.50 mL) and brine, dried over sodium sulfate and
concentrated. The crude residue is purified by silica gel
chromatography (20-40% ethyl acetate/hexanes) to give 990 mg (4.92
mmol, 25.7%) of methyl 4-(1H-pyrrol-3-yl)-benzoate as a cream
colored solid. MS (ES+): m/e 201.08. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.39 (1H, br s), 8.00 (2H, d, J=9 Hz), 7.58
(2H, d, J=9 Hz), 7.20 (1H, m), 6.85 (1H, m), 6.60 (1H, m), 3.91
(3H, s).
[0347] Part C.
[0348] To a stirred solution of methyl 4-1H-pyrrol-3-yl)-benzoate
(402 mg, 1.997 mmol, 1.0 eq.) and 4-trifluoromethyl-1-iodobenzene
(652 mg, 2.39 mmol, 1.2 eq.) in anhydrus 1,4-dioxane (15 mL) is
added copper(I) iodide (38 mg, 0.199 mmol, 0.1 eq.).
ethylenediamine (13 .mu.L, 0.199 mmol, 0.1 eq.) and potassium
triphosphate (762 mg, 1.66 mmol, 3.31 eq.). The reaction mixture is
degassed, flushed with nitrogen and heated to reflux for 18 hr. The
reaction mixture is cooled, filtered and washed with ethyl acetate.
The filtrate is concentrated and purified by silica gel
chromatography (10% ethyl acetate/hexane) to get a white powder,
methyl 4-[1-(4-trifluoromethyl-phenyl)-1H-pyrrol-3-yl]-benzoate
(363.2 mg, 1.05 mmol, 52.7%). MS (ES+): m/e 345.11. .sup.1H NMR
(300 MHz, CDCl.sub.3): .delta. 8.04 (2H, d, J=8 Hz), 7.72 (2H, d,
J=8 Hz), 7.63 (21H, d, J=8 Hz), 7.54 (2H, d, J=8 Hz), 7.50 (1H, m),
7.18 (1H, m), 6.75 (1H, m), 3.93 (3H, s).
[0349] Part D.
[0350] Methyl
4-[1-(4-trifluoromethylphenyl)-1H-pyrrol-3-yl)benzoate (150 mg,
0.434 mmol, 1 eq.) is suspended in 10 mL of 75% EtOH/water.
Potassium hydroxide (73 .mu.L of 1 M solution, 3.0 eq.) is added
and the mixture heated to 60.degree. C. for 16 hrs. The mixture is
diluted with water and washed with chloroform (2.times.3 mL). The
aqueous layer is acidified to pH 3 and the resulting precipitate is
filtered and washed with water. The white solid is dried under high
vacuum to give 121 mg (0.365 mmol, 84.15%) of the title product,
m.p. 315-317.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.03 (1H, m), 7.90 (2H, d, J=8 Hz), 7.83-7.76 (4H, m), 7.58
(1H, m), 7.52 (2H, d, J=8 Hz), 6.76 (1H, m). MS (ES+): m/e 332.24
(100). MS (ES-): m/e 330.25 (100).
[0351] Using modifications of the procedures detailed above, the
following compounds may be prepared.
[0352] Compound 6
[0353] 3-[1-(4-Isopropyl-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
210-215.degree. C. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.30
(1H, s), 7.92 (1H, d, J=8 Hz), 7.80 (1H, d, J=8 Hz), 7.46 (1H, t,
J=8 Hz), 7.44 (1H, s), 7.37 (2H, d, J=8 Hz), 7.31 (2H, d, J=8 Hz),
7.11 (1H, d, J=2 Hz), 6.69 (1H, d, J=2 Hz), 2.96 (1H, heptet, J=7
Hz), 1.29 (6H, d, J=7 Hz). MS (ES+): m/e 306 (100).
[0354] Compound 106
[0355] 4-[1-(4-Isopropyl-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
240-243.degree. C. MS (ES+): m/e 306.35 (100). MS (ES-): m/e 304.26
(100).
[0356] Compound 125
[0357] 3-[1-(4-Ethyl-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
190-192.degree. C. MS (ES+): m/e 292.36 (100). MS (ES-): m/e 290.37
(100).
[0358] Compound 126
[0359] 4-[1-(4-Methoxy-phenyl)-1H-pyrol-3-yl]-benzoic acid: m.p.
178-180.degree. C. MS (ES+): m/e 294.26 (100). MS (ES-): m/e 292.26
(100).
[0360] Compound 127
[0361] 4-[1-(3,4-Difluoro-phenyl)-1H-pyrrol-3-yl]-benzoic acid:
m.p. 231-233.degree. C. MS (ES+): m/e 300.27 (100). MS (ES-): m/e
298.27 (100).
[0362] Compound 128
[0363] 4-[1-(3-Triflouromethyl-phenyl)-1H-pyrrol-3-yl]-benzoic
acid: m.p. 209-211.degree. C. MS (ES+): m/e 332.34 (100). MS (ES-):
m/e 330.35 (100).
[0364] Compound 129
[0365] 4-[1-(4-Ethyl-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
278-280.degree. C. MS (ES+): m/e 292.34 (100). MS (ES-): m/e 290.31
(100).
[0366] Compound 130
[0367] 4-(1-Phenyl-1H-pyrol-3-yl)-benzoic acid: m.p.
239-241.degree. C. MS (ES+): m/e 264.27 (100). MS (ES-): m/e 262.32
(100).
[0368] Compound 131
[0369] 4-[1-(4-Trifluoromethoxy-phenyl)-1H-pyrrol-3-yl]-benzoic
acid: m.p. 318-320.degree. C. MS (ES+): m/e 348.30 (100). MS (ES-):
m/e 346.33 (100).
[0370] Compound 150
[0371]
4-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1H-pyrrol-3-yl]-benzoic
acid: m.p. 273-276.degree. C. MS (ES+): m/e 321.34 (100). MS (ES-):
m/e 320.33 (100).
[0372] Compound 151
[0373] 4-[1-(2-Fluoro-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
202-204.degree. C. MS (ES-): m/e 282.3 (100). MS (ES-): m/e 280.3
(100).
[0374] Compound 152
[0375] 4-[1-(3-Fluoro-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
211-213.degree. C. MS (ES+): m/e 282.28 (100). MS (ES-): m/e 280.24
(100).
[0376] Compound 153
[0377] 4-[1-(3,5-Difluoro-phenyl)-1H-pyrrol-3-yl]-benzoic acid:
m.p. 243-245.degree. C. MS (ES+): m/e 300.35 (100). MS (ES-): m/e
298.38 (100).
[0378] Compound 155
[0379] 3-[1-(4-Chloro-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
211-213.degree. C. MS (ES+): m/e 282.28 (100). MS (ES-): m/e 280.24
(100).
[0380] Compound 156
[0381] 3-(1-p-Tolyl-1H-pyrrol-3-yl)-benzoic acid: m.p.
178-181.degree. C. MS (ES+): m/e 278.29 (100). MS (ES-): m/e 276.34
(100).
[0382] Compound 157
[0383] 3-(1-m-Tolyl-1H-pyrrol-3-yl)-benzoic acid: m.p.
201-202.degree. C. MS (ES+): m/e 348.32 (100). MS (ES-): m/e 346.32
(100).
[0384] Compound 158
[0385] 3-[1-(4-Trifluoromethoxy-phenyl)-1H-pyrrol-3-yl]-benzoic
acid: MS (ES+): m/e 348.32 (100). MS (ES-): m/e 346.32 (100).
[0386] Compound 159
[0387] 4-(1-p-Tolyl-1H-pyrrol-3-yl)-benzoic acid: MS (ES+): m/e
278.35 (100). MS (ES-): m/e 276.37 (100).
[0388] Compound 160
[0389] 4-[1-(2-Methoxy-phenyl)-1H-pyrol-3-yl]-benzoic acid: m.p.
200-202.degree. C. MS (ES+): m/e 294.32 (100). MS (ES-): m/e 292.36
(100).
[0390] Compound 194
[0391] 4-(1-m-Tolyl-1H-pyrrol-3-yl)-benzoic acid: m.p.
212-213.degree. C. MS (ES+): m/e 278.29 (100). MS (ES-): m/e 276.33
(100).
[0392] Compound 195
[0393] 4-(1-o-Tolyl-1H-pyrrol-3-yl)-benzoic acid: m.p.
208-209.degree. C. MS (ES+): m/e 278.30 (100). MS (ES-): m/e 276.33
(100).
[0394] Compound 196
[0395] 4-[1-(4-Chloro-phenyl)-1H-pyrol-3-yl]-benzoic acid:
m.p.>350.degree. C. MS (ES+): m/e 298.25 (100). MS (ES-): m/e
296.29 (100).
[0396] Compound 197
[0397] 4-[1-(2-Chloro-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
200-202.degree. C. MS (ES+): m/e 298.25 (100). MS (ES-): m/e 296.30
(100).
[0398] Compound 198
[0399] 3-[1-(2-Chloro-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
198-200.degree. C. MS (ES+): m/e 298.25 (100). MS (ES-): m/e 296.29
(100).
[0400] Compound 199
[0401] 4-[1-(2-Trifluoromethoxy-phenyl)-1H-pyrrol-3-yl]-benzoic
acid: m.p. 164-165.degree. C. MS (ES+): m/e 348.24 (100). MS (ES-):
m/e 346.34 (100).
[0402] Compound 200
[0403] 3-[1-(2-Methoxy-phenyl)-1H-pyrrol-3-yl]-benzoic acid:
m.p.>350.degree. C. MS (ES+): m/e 294.28 (100). MS (ES-): m/e
292.35 (100).
[0404] Compound 240
[0405] 3-(1-o-Tolyl-1H-pyrrol-3-yl)-benzoic acid: m.p.
161-163.degree. C. MS (ES+): m/e 278.27 (100). MS (ES-): m/e 276.29
(100).
[0406] Compound 241
[0407] 3-[1-(3-Fluoro-4-methyl-phenyl)-1H-pyrrol-3-yl]-benzoic
acid: m.p. 205-208.degree. C. MS (ES+): m/e 296.23 (100). MS (ES-):
m/e 294.27 (100).
[0408] Compound 242
[0409] 3-[1-(2,5-Difluoro-phenyl)-1H-pyrrol-3-yl]-benzoic acid:
m.p. 193-194.degree. C. MS (ES+): m/e 300.21 (100). MS (ES-): m/e
298.20 (100).
[0410] Compound 243
[0411] 4-[1-(3-Chloro-phenyl)-1H-pyrol-3-yl]-benzoic acid: m.p.
199-201.degree. C. MS (ES+): m/e 298.19 (100). MS (ES-): m/e 296.27
(100).
[0412] Compound 244
[0413] 4-[1-(3-Fluoro-4-methyl-phenyl)-1H-pyrol-3-yl]-benzoic acid:
m.p. 264-268.degree. C. MS (ES+): m/e 296.23 (100). MS (ES-): m/e
294.23 (100).
[0414] Compound 245
[0415] 4-[1-(2,5-Difluoro-phenyl)-1H-pyrrol-3-yl]-benzoic acid:
m.p. 215-218.degree. C. MS (ES+): m/e 300.21 (100). MS (ES-): m/e
298.20 (100).
[0416] Compound 246
[0417] 3-[1-(3-Benzyloxy-phenyl)-1H-pyrrol-3-yl]-benzoic acid: m.p.
142-144.degree. C. MS (ES+): m/e 370.28 (100). MS (ES-): m/e 368.26
(100).
[0418] Compound 247
[0419] 3-(1-Benzo[1,3]dioxol-5-yl-1H-pyrrol-3-yl)-benzoic acid:
m.p. 177-180.degree. C. MS (ES+): m/e 308.26 (100). MS (ES-): m/e
306.24 (100).
[0420] B. Preparation of Imidazoles
[0421] Imidazoles of the invention may generally be prepared as
follows.
Preparation of 3-[4-(4-Isopropyl-phenyl)-imidazol-yl]-benzoic acid
(Compound 2)
[0422] Part A.
[0423] A solution of isopropylbenzene (50 g) in carbon disulfide
(250 mL) is treated with aluminum chloride (170 g), and the
resulting mixture is cooled to 0.degree. C. Acetyl chloride (33 g)
is added at the rate of 1 mL/min, and the resulting mixture is
stirred overnight. The mixture is pouted into aq. HCl (2N, 400 mL),
and the layers are separated. The aqueous phase is extracted with
ethyl acetate, and the organic phases are combined, washed with
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated to
afford the product, 4-isopropylacetophenone, as an oil (66 g).
[0424] Part B.
[0425] A solution of 4-isopropylacetophenone (65 g) in ethyl
acetate (250 mL) is cooled to 0.degree. C. and treated with bromine
(65 g) dropwise. The mixture is stirred for 5 h, then quenched by
the addition of water (250 mL). The phases are separated, and the
aqueous layer is extracted with ethyl acetate. The organic phases
are washed with satd. aq. NaHCO.sub.3 and brine, combined, dried
over Na.sub.2SO.sub.4, filtered and evaporated to afford the
product, 2-bromo-4'-isopropylacetophenone (64 g, 66%).
[0426] Part C.
[0427] A mixture of 2-bromo-4'-isopropylacetophenone (2.41 g) and
formamide (10 mL) is heated to 180.degree. C. for 1 h. then cooled,
poured into water and extracted with ethyl acetate. The organic
layer is washed with brine, dried over Na.sub.2SO.sub.4. filtered
and evaporated. The residue is purified by column chromatography to
afford the product, 4-(4-isopropyl-phenyl)-1H-imidazole. as a
yellow solid (550 mg).
[0428] Part D.
[0429] A solution of 4-(4-isopropyl-phenyl)-1H-imidazole (190 mg),
3-carbomethoxy-phenylboronic acid (360 mg) and Cu(OAc).sub.2 (300
mg) in dichloromethane (15 mL) is treated with pyridine (160 mg)
and 4 .ANG. molecular sieves (500 mg). The mixture is stirred in
the presence of air for 14 h then filtered through celite, and the
celite pad is washed well with ethyl acetate. The filtrate and
washing are combined and evaporated, and the residual material is
separated by column chromatography to afford the product, methyl
3-[4-(4-isopropyl-phenyl)-imidazol-1-yl]-benzoate, as a yellow
solid (190 mg).
[0430] Part E.
[0431] A solution of methyl
3-[4-(4-isopropyl-phenyl)-imidazol-1-yl]-benzoate (190 mg) in 5 mL.
methanol-1 mL water is treated with lithium hydroxide hydrate (125
mg), and the resulting mixture is heated to reflux for 1 h. The
solution is cooled and neutralized with acetic acid. The resulting
precipitate is collected by filtration, washed with water, dried
under vacuum and recrystallized from acetone to afford the title
product as a white solid (90 mg). m.p. 248-250.degree. C. .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 8.38 (1H, s), 8.31 (1H, s),
8.18 (1H, sa) 7.97 (1H, d, J=8 Hz), 7.91 (1H, d, J=8 Hz), 7.78 (2H,
d, J=8 Hz), 7.66 (1H, t, J=8 Hz), 7.24 (2H, d, J=8 Hz), 2.88 (1H,
heptet, J=7 Hz), 1.20 (6H, d, J=7 Hz). MS (ES+): m/e 308 (21), 307
(100).
[0432] The methods described in the above example are employed
(using appropriate starting materials) in the synthesis of the
following compounds:
[0433] Compound 2
[0434] 3-[1-(4-isopropyl-phenyl)-1H-imidazol-4-yl]-benzoic acid:
m.p. 225-226.degree. C. .sup.1H NMR (400 MHz, DMSO-dr): .delta.
12.94 (1H, br), 8.43 (1H, s), 8.35 (1H, s), 8.30 (1H, s), 8.06 (1H,
d, J=8 Hz), 7.79 (1H, d, J=8 Hz), 7.63 (2H, d, J=8 Hz), 7.51 (1H, t
J=8 Hz), 7.39 (2H, d, J=8 Hz), 2.95 (1H, heptet, J=7 Hz), 1.22 (6H,
d, J=7 Hz). MS (ES+): m/e 308 (18), 307 (100).
[0435] Compound 262
[0436] 3-(4-Phenyl-imidazol-1-yl)-benzoic acid: m.p.
277-279.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.33 (1H, br), 8.42 (1H, d, J=0.5 Hz), 8.39 (1H, d, J=1.5 Hz),
8.19 (1H, t, J=1.8 Hz), 7.98 (1H, ddd, J=8.2 2.3, 1.2 Hz), 7.91
(1H, dt, J=7.9, 1.2 Hz), 7.89-7.85 (21H, m), 7.66 (1H, t, J=7.9
Hz), 7.42-7.35 (2H, m), 7.26-7.20 (1H, m). MS (ES+): m/e 266 (44),
265 (100). MS (ES-): m/e 264 (18), 263 (100).
[0437] Compound 263
[0438] 4-(4-Phenyl-imidazol-1-yl)-benzoic acid: m.p.
263-265.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.11 (1H, br), 8.47 (1H, d, J=1.2 Hz), 8.40 (1H, d, J=1.2 Hz),
8.07 (21H, d, J=8.8 Hz), 7.89-7.84 (4H, m), 7.42-7.36 (2H, m),
7.27-7.21 (1H, m). MS (ES+): m/e 266 (37), 265 (100). MS (ES-): m/e
264 (19), 263 (100).
Preparation of
3-[2-amino-4-(4-isopropylphenyl)-1H-imidazol-1-yl]benzoic acid
(Compound 1)
[0439] Part A.
[0440] To a suspension of methyl 3-aminobenzoate (4.76 g, 31.5
mmol) and K.sub.2CO.sub.3 (6.21 g, 45.0 mmol) in DMF (150 mL), is
added .alpha.-bromo 4-isopropylacetophenone (7.23 g, 30.0 mmol).
The mixture is stirred at room temperature for 24 hr. DMF is
removed in vacuum and the residue is chromatographed to provide the
amino ketone, methyl
3-{[2-(4-isopropylphenyl)-2-oxoethyl]amino}benzoate (2.15 g, 23%).
(ES+): m/e 312.
[0441] Part B.
[0442] Methyl 3-{[2-(4-isopropylphenyl)-2-oxoethyl]amino}benzoate
(0.62 g, 2.0 mmol) is refluxed with cyanamide (1.68 g, 40 mmol) in
EtOH (15 mL) for 48 h, and the solvent is removed in vacuum. The
residue is treated with water. The precipitate is collected by
filtration, dried and chromatographed (silica gel, first with 1:4
ethyl acetate-hexanes, then 50:1 dichloromethane-methanol). The
last fraction (0.26 g) is then treated with NaOH (1 N, 3.0 mL, 3.0
mmol) in THF (10 mL) at 65.degree. C. overnight. After the removal
of the solvent, the residue is treated with water and acidified
with HCl (1 N). The precipitate is collected by filtration and
washed with ethyl acetate thoroughly, dried to furnish desired
product a single component by LC/MS,
3-[2-amino-4-(4-isopropylphenyl)-1H-imidazol-1-yl]benzoic acid
(0.13 g, 20%), m.p. 279-282.degree. C. (decomp.). .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. (ppm) 1.27 (d, 6H), 2.87-2.97 (m,
1H), 4.36 (s, br, 2H), 7.01 (s, 1H), 7.21-7.26 (m, 3H), 7.59-7.69
(m, 3H), 8.05-8.12 (m, 2H). (ES+): m/e 322.
[0443] C. Preparation of 1,3-Pyrazoles
[0444] 1,3-Pyrazoles of the invention may be prepared as
follows.
Preparation of
3-[3-(4-Trifluoromethoxy-phenyl)-pyrazol-1-yl]-benzoic acid
(Compound 95)
[0445] Part A.
[0446] A mixture of 4'-trifluoromethoxyacetophenone (1.50 g) and
dimethylformamide dimethyl acetal (8.6 mL) is heated to 115.degree.
C. for 16 h, then cooled. Volatile components are evaporated, and
the resulting brown oil is used directly in the next step. A
solution of this material (1.90 g) and hydrazine hydrate (1.14 mL)
in acetic acid (10 mL) is heated to 109.degree. C. for 15 h, then
cooled and poured into water (100 mL). This is extracted with ethyl
acetate (2.times.100 mL), and the extracts are washed with brine,
combined, dried over MgSO.sub.4, filtered and evaporated to afford
pure product, 3-(4-trifluoromethoxy-phenyl)-1H-pyrazole, as a
solid; purity as determined by LC/MS 100%.
[0447] Part B.
[0448] A solution of 3-(4-trifluoromethoxy-phenyl)-1H-pyrazole (250
mg), 3-methoxycarbonylphenylboronic acid (540 mg) and pyridine
(0.18 mL) in dimethylformamide (5 mL) is treated with copper (II)
acetate (214 mg) and powdered activated 4 .ANG. molecular sieves
(0.5 g). The resulting mixture is heated to 60.degree. C. for 16 h
and cooled. The reaction mixture is poured into 1M aq. HCl (300
mL), and the resulting mixture is filtered through a glass
microfiber filter pad. The pad is washed with ethyl acetate, and
the filtrate is evaporated to afford the product, methyl
3-[3-(4-trifluoromethoxy-phenyl)-pyrazol-1-yl]-benzoate, as a solid
(204 mg).
[0449] Part C.
[0450] A solution of methyl
3-[3-(4-trifluoromethoxy-phenyl)-pyrazol-1-yl]benzoate (100 mg) and
sodium hydroxide (0.58 mL, 1 M aq. solution) in ethanol (5 mL) is
heated to reflux for 2 d. The mixture is cooled and evaporated, and
the residual material is acidified with 1 M sq. HCl and extracted
with ethyl acetate. The extract is washed with brine, dried over
MgSO.sub.4, filtered and evaporated to afford 91% pure (by LC/MS)
title product (90 mg) as a powder, m.p. 191-194.degree. C. .sup.1H
NMR (300 MHz, DMSO-d.sub.6): .delta. 8.70 (1H, d, J=2.7 Hz), 8.44
(1H, t, J=1.9 Hz), 8.15 (1H, ddd, J=8.2, 2.4, 0.9 Hz), 8.05 (2H, d,
J=8.8 Hz), 7.87 (1H, dt, J=7.7, 1.1 Hz), 7.64 (1H, t, J=8.0 Hz),
7.43 (2H, dd, J=8.8, 0.8 Hz), 7.11 (1H, d, J=2.7 Hz). MS (ES+): m/e
350 (20), 349 (100). MS (ES-): m/e 348 (20), 347 (100).
[0451] Slightly modified versions of this procedure may be used to
prepare the following compounds.
[0452] Compound 78
[0453] 3-[3-(3-Cyano-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
164-166.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.73 (1H, d, J=2.5 Hz), 8.44 (1H, s), 8.37 (1H, s), 8.28 (1H, d,
J=7.9 Hz), 8.17 (1H, dd, J=8.0, 2.2 Hz), 7.88 (1H, d, J=7.7 Hz),
7.82 (1H, d, J=7.7 Hz), 7.69-7.62 (2H, m), 7.22 (1H, d, J=2.7 Hz).
MS (ES+): m/e 291 (20) 290 (100). MS (ES-): m/e 289 (20), 288
(100).
[0454] Compound 79
[0455] 3-(3-Phenyl-pyrazol-1-yl)-benzoic acid: m.p. 180-182.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 8.67 (1H, dd,
J=2.5, 1.4 Hz), 8.43 (1H, m), 8.15 (1H, dt, J=8.2, 1.1 Hz),
7.94-7.91 (2H, m), 7.86 (1H, dd, J=7.7, 1.1 Hz), 7.63 (1H, t, J=8.0
Hz), 7.47-7.32 (3H, m), 7.06 (1H, d, J=2.7 Hz). MS (ES+): m/e 266
(20), 265 (100). MS (ES-): m/e 264 (20), 263 (100).
[0456] Compound 80
[0457] 3-[3-(4-Chloro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
230-235.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.69 (1H, d, J=2.7 Hz), 8.43 (1H, narrow m), 8.16 (1H, dm, J=8 Hz),
7.96 (2H, d, J=8.5 Hz), 7.86 (1H, d, J=7.7 Hz), 7.64 (1H, t, J=8.0
Hz), 7.50 (2H, d, J=8.5 Hz), 7.10 (1H, d, J=2.5 Hz). MS (ES+): m/e
301 (35), 299 (100). MS (ES-): m/e 299 (35), 297 (100).
[0458] Compound 81
[0459] 3-[3-(4-Methoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
210-211.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.63 (1H, d, J=2.5 Hz), 8.41 (1H, t, J=1.7 Hz), 8.13 (1H, dm, J=8
Hz), 7.85 (2H, d, J=8.8 Hz), 7.84-7.80 (1H, m), 7.62 (1H, t, J=8.0
Hz), 7.00 (2H, d, J=8.8 Hz), 6.98 (1H, d, J=2.5 Hz), 3.78 (3H, s).
MS (ES+): m/e 296 (20), 295 (100). MS (ES-): m/e 294 (20), 293
(100).
[0460] Compound 82
[0461] 3-[3-(4-Morpholin-4-yl-phenyl)-pyrazol-1-yl]-benzoic acid:
m.p. 230-235.degree. C. .sup.1H NMR (300 MHz, DMSO-dd): .delta.
8.61 (1H, dd, J=2.6, 1.0 Hz), 8.41 (1H, s), 8.12 (1H, dt, J=8.2,
1.2 Hz), 7.83 (1H, d, J=8 Hz), 7.80 (2H, d, J=8.2 Hz), 7.61 (1H, t,
J=8.0 Hz), 7.07 (2H, d, J=8.2 Hz), 6.96 (1H, dd, J=23, 1.5 Hz),
3.76 (4H, br), 3.19 (4H, br). MS (ES+): m/e 351 (20), 350 (100). MS
(ES-): m/e 349 (20), 348 (100).
[0462] Compound 92
[0463] 3-[3-(4-Fluoro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
237-240 @C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 8.67 (1H,
d, J=2.7 Hz), 8.43 (1H, t, J=1.9 Hz), 8.14 (1H, ddd, J=7.0, 2.5,
1.4 Hz), 7.97 (2H, dd, J=8.8, 5.5 Hz), 7.85 (1H, dt, J=6.6, 1.1
Hz), 7.63 (1H, t, J=7.8 Hz), 7.28 (2H, t, J=8.8 Hz), 7.06 (1H, d,
J=2.5 Hz). MS (ES+): m/e 284 (20), 283 (100). MS (ES-): m/e 282
(20), 281 (100).
[0464] Compound 93
[0465] 3-[3-(3-Fluoro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
173-174.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.70 (1H, d, J=2.5 Hz), 8.42 (1H, t, J=1.8 Hz), 8.16 (1H, ddd,
J=8.2, 2.4, 1.1 Hz), 7.87 (1H, dt, J=7.7, 1.2 Hz), 7.79 (1H, dt,
J=7.9, 1.1 Hz), 7.73 (1H, ddd, J=10.3, 2.5, 1.4 Hz), 7.64 (1H, t,
J=8.0 Hz), 7.51 (1H, d, J=8.3, 6.1 Hz), 7.19 (1H, ddt, J=8, 2, 1
Hz), 7.14 (1H, d, J=2.6 Hz). MS (ES+): m/e 284 (20), 283 (100). MS
(ES-): m/e 282 (20), 281 (100).
[0466] Compound 97
[0467] 3-[3-(4-Trifluoromethyl-phenyl)-pyrazol-1-yl]-benzoic acid:
m.p. 225-227.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.74 (1H, d, J=2.5 Hz), 8.46 (1H, t, J=1.9 Hz), 8.20-8.14
(3H, m), 7.88 (1H, d, J=7.7 Hz), 7.80 (2H, d, J=8.8 Hz), 7.65 (1H,
t, J=8.0 Hz), 7.21 (1H, d, J=2.5 Hz). MS (ES+): m/o 334 (20), 333
(100). MS (ES-): m/e 332 (20), 331 (100).
[0468] Compound 5
[0469] 3-[3-(4-Isopropyl-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
215-216.degree. C. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
13.26 (1H, br), 8.65 (1H, d, J=2 Hz), 8.43 (1H, s), 8.13 (1H, d,
J=8 Hz), 7.87-7.82 (3H, m), 7.63 (1H, t, J=8 Hz), 7.30 (2H, d, J=8
Hz), 7.01 (1H, d, J=2 Hz), 2.90 (1H, heptet, J=7 Hz), 1.20 (6H, d,
J=7 Hz). MS (ES+): m/e 308 (22), 307 (100).
[0470] Compound 137
[0471] 3-(4,5-Dihydro-benzo[g]indazol-2-yl)-benzoic acid: m.p.
191-192.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.25 (1H, br s), 8.44-8.39 (2H, m), 8.114-8.06 (1H, m), 7.84-7.80
(2H, m), 7.61 (1H, dt, J=7.9, 4.1 Hz), 7.32-7.22 (3H, m), 2.92-2.87
(2H, m), 2.83-2.78 (2H, m). MS (ES+): m/e 292 (20), 291 (100). MS
(ES-): m/e 290 (21), 289 (100).
[0472] Compound 138
[0473] 3-(4H-Indeno[1,2-c]pyrazol-2-yl)-benzoic acid: m.p.
249-250.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.24 (1H, br), 8.54 (1H, s), 8.44 (1H, t, J=1.8 Hz), 8.12 (1H, dd,
J=8.0, 2.1 Hz), 7.82 (1H, d, J=7.6 Hz), 7.78 (1H, dd, J=7.9, 1.2
Hz), 7.61 (1H, t, J=7.9 Hz), 7.57 (1H, d, J=7.6 Hz), 7.42-7.32 (2H,
m), 3.76 (2H, s). MS (ES+): m/e 278 (18), 277 (100). MS (ES-): m/e
276 (20), 275 (100).
[0474] Compound 139
[0475] 3-(6-Methoxy-4H-indeno[1,2-]pyrazol-2-yl)-benzoic acid: m.p.
272-273.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.16 (1H, br), 8.47 (1H, s), 8.41 (1H, s), 8.08 (1H, dd, J=8.1,
2.0 Hz), 7.80 (1H, d, J=7.6 Hz), 7.67 (1H, d, J=8.5 Hz), 7.59 (1H,
t, J=7.9 Hz), 7.17 (1H, d, J=2.0 Hz), 6.95 (1H, dd, J=8.5, 2.3 Hz),
3.30 (3H, s), 3.72 (2H, s). MS (ES+): m/e 308 (20), 307 (100). MS
(ES-): m/e 306 (21), 305 (100).
[0476] Compound 140
[0477] 3-(7-Methoxy-4H-indeno[1,2-c]pyrazol-2-yl)-benzoic acid:
m.p. 225-227.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.25 (1H, br), 8.52 (1H, s), 8.45 (1H, s), 8.11 (1H, ddd,
J=8.2, 2.4, 1.2 Hz), 7.82 (1H, d, J=7.6 Hz), 7.61 (1H, t, J=7.9
Hz), 7.45 (1H, d, J=8.5 Hz), 7.34 (1H, d, J=2.3 Hz), 6.90 (1H, dd,
J=8.5, 2.3 Hz), 3.82 (3H, s), 3.67 (2H, s). MS (ES+): m/e 308 (20),
307 (100). MS (ES-): m/e 306 (18), 305 (100).
[0478] Compound 142
[0479] 3-(7-Methoxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic acid:
m.p. 217-218.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.5):
.delta. 13.23 (1H, br), 8.38 (1H, s), 8.37 (1H, d, J=2 Hz), 8.06
(1H, dd, J=8.2, 2.0 Hz), 7.80 (1H, d, J=7.6 Hz), 7.74 (1H, d, J=8.5
Hz), 7.59 (1H, t, J=7.9 Hz), 6.91-6.84 (2H, m), 3.77 (3H, s),
2.92-2.86 (2H, m), 2.78-2.72 (2H, m). MS (ES+): m/e 322 (20), 321
(100). MS (ES-): m/e 320 (21), 319 (100).
[0480] Compound 143
[0481] 3-(8-Methoxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic acid:
m.p. 192-193.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.25 (1H, br), 8.43 (1H, s), 8.38 (1H, t, J=1.8 Hz), 8.09
(1H, dd, J=8.2 2.3 Hz), 7.83 (1H, d, J=7.6 Hz), 7.61 (1H, t, J=7.9
Hz), 7.33 (1H, d, J=3.0 Hz), 7.22 (1H, d, J=8.5 Hz), 6.83 (1H, d,
J=8.5, 3.0 Hz), 3.80 (3H, s), 2.87-2.82 (2H, m), 2.77-2.72 (2H, m).
MS (ES+): m/e 322 (18), 321 (100). MS (ES-): m/e 320 (24), 319
(100).
[0482] Compound 144
[0483] 3-(4H-Chromeno[4,3-c]pyrazol-2-yl)-benzoic acid: m.p.
227-228.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.29 (1H, br), 8.49 (1H, s), 8.39 (1H, t, J=1.9 Hz), 8.09 (1H, dd,
J=8.2, 23 Hz), 7.86 (1H, d, J=7.6 Hz), 7.76 (1H, dd, J=7.4, 1.6
Hz), 7.63 (1H, t, J=7.9 Hz), 7.26 (1H, dt, J=8.0, 1.8 Hz),
7.07-6.96 (2H, m), 5.33 (2H, s). MS (ES+): m/e 294 (17), 293 (100).
MS (ES-): m/e 292 (18), 291 (100).
[0484] Compound 145
[0485] 4-(8-Methoxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic acid:
m.p. 290-292.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 12.98 (1H, br), 8.45 (1H, s), 8.04 (2H, d, J=8.8 Hz), 7.98
(2H, d, J=8.8 Hz), 7.34 (1H, d, J=2.9 Hz), 7.23 (1H, d, J=8.5 Hz),
6.84 (1H, dd, J=8.5, 2.9 Hz), 3.79 (3H, s), 2.86-2.81 (2H, m),
2.78-2.73 (2H, m). MS (ES+): m/e 323 (4), 322 (22), 321 (100). MS
(ES-): m/e 319 (100).
[0486] Compound 147
[0487] 3-(6-Methoxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic acid:
m.p. 232-233.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.25 (1H, br), 8.42 (1H, s), 8.39 (1H, t, J=1.9 Hz), 8.08
(1H, dd, J=8.0, 2.2 Hz), 7.82 (1H, d, J=7.6 Hz), 7.61 (1H, t, J=7.9
Hz), 7.46 (1H, d, J=7.6 Hz), 7.27 (1H, t, J=8.0 Hz), 6.96 (1H, d,
J=8.2 Hz), 3.81 (3H, s), 2.90-2.85 (2H, m), 2.77-2.72 (2H, m). MS
(ES+): m/e 322 (19), 321 (100). MS (ES-): m/e 320 (18), 319
(100).
[0488] Compound 148
[0489] 4-(6-Methoxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic acid:
m.p. 288-290.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 12.97 (1H, br), 8.44 (1H, s), 8.03 (2H, d, J=8.8 Hz), 7.97
(21H, d, J=8.8 Hz), 7.46 (1H, d, J=7.3 Hz), 7.28 (1H, t, J=7.9 Hz),
6.97 (1H, d, J=8.2 Hz), 3.81 (3H, s) 2.90-2.85 (2H, m), 2.78-2.73
(2H, m). MS (ES+): m/e 323 (3), 322 (20), 321 (100).
[0490] Compound 149
[0491] 4-(7-Methoxy-4H-indeno[1,2-c]pyrazol-2-yl)benzoic acid: m.p.
304-306.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.95 (1H, br), 8.55 (1H, s), 8.04 (2H d, J=9.0 Hz), 8.00 (2H, d,
J=9.0 Hz), 7.46 (1H, d, J=8.4 Hz), 7.30 (1H, d J=2.4 Hz), 6.92 (1H,
dd, J=8.4, 2.4 Hz), 3.82 (3H, s), 3.67 (2H, s). MS (ES+): m/e 308
(20), 307 (100).
[0492] Compound 161
[0493] 4-(4,5-Dihydro-benzo[g]indazol-2-yl)-benzoic acid: m.p.
288-290.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.98 (1H, br), 8.45 (1H, s), 8.04 (2H, d, J=8.8 Hz), 7.98 (2H, d,
J=8.8 Hz), 7.82 (1H, dd, J=7.6, 2.0 Hz), 7.34-7.26 (3H, m),
2.95-2.90 (2H, m), 2.81-2.76 (2H, m). MS (ES+): m/e 292 (15), 291
(100). MS (ES-): m/e 290 (20), 239 (100).
[0494] Compound 162
[0495] 4-(4H-Chromeno[4,3-c]pyrazol-2-yl)-benzoic acid: m.p.
303-310.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.03 (1H, br), 8.50 (1H, s), 8.05 (2H, d, J=8.8 Hz), 7.9 (2H, d,
J=8.8 Hz), 7.74 (1H, dd, J=7.5, 1.6 Hz), 7.27 (1H, d, J=7.8, 1.8
Hz), 7.05 (1H, dt, J=7.3, 1.2 Hz), 6.99 (1H, d, J=8.2 Hz), 5.34
(2H, s). MS (ES+): m/e 294 (16), 293 (100). MS (ES-): m/e 292 (22),
291 (100).
[0496] Compound 163
[0497] 4-(7-Met oxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic acid:
m.p. 279-280.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 12.94 (1H, br), 8.41 (1H, s), 3.02 (2H, d, J=8.8 Hz), 7.95
(2H, d, J=3.3 Hz), 7.74 (1H, d, J=8.2 Hz), 6.91 (1H, d, J=2.6 Hz),
6.37 (1H, dd, J=8.2, 2.6 Hz), 3.77 (3H, s), 2.92-2.87 (2H, m),
2.79-2.74 (2H, m). MS (ES+): m/e 322 (20), 321 (100). MS (ES-): m/e
320 (20), 319 (100).
[0498] Compound 169
[0499] 3-[3-(2-Fluoro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
166-167.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.73 (1H, d, J=2.5 Hz), 8.44 (1H, t, J=1.9 Hz), 8.17 (1H, ddd,
J=8.2, 2.3, 1.1 Hz), 8.06 (1H, dt, J=7.7, 1.9 Hz) 7.88 (1H, dt,
J=7.7, 1 Hz), 7.65 (1H, t, J=7.8 Hz), 7.44-7.27 (3H, m), 6.93 (1H,
dd, J=3.9, 2.3 Hz). MS (ES+): m/e 284 (20), 283 (100). MS (ES-):
m/e 282 (20), 281 (100).
[0500] Compound 170
[0501] 3-(3-p-Tolyl-pyrazol-1-yl)-benzoic acid: m.p.
180-182.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.12 (1H, br) 8.54 (1H, d, J=2.5 Hz), 8.47 (1H, t, J=1.8 Hz), 8.13
(1H, dt, J=7.9, 1.8 Hz), 7.90 (1H, dt, J=7.9, 1.3 Hz), 7.30 (2H, d,
J=8.5 Hz), 7.57 (1H, t, J=7.8 Hz) 7.31 (2H, d, J=3.5 Hz), 7.09 (1H,
d, J=2.5 Hz), 2.34 (3H, s). MS (ES+): m/e 280 (14), 279 (100). MS
(ES-): m/e 278 (19), 277 (100).
[0502] Compound 219
[0503] 4-[3-(4-Methoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
263-270.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.65 (1H, d, J=2.5 Hz), 8.05 (2H, d, J=9.1 Hz), 3.01 (2H, d, J=9.1
Hz) 7.87 (2H, d, J=8.5 Hz), 7.02 (1H, d, J=2.5 Hz), 7.01 (2H, d,
J=8.5 Hz), 3.79 (3H, s). MS (ES+): mew 296 (20), 295 (100). MS
(ES-): m/e 294 (23), 293 (100).
[0504] Compound 220
[0505] 3-[3-(3-Methoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
179-180.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.67 (1H, d, J=2.5 Hz), 8.42 (1H, s), 8.15 (1H, d, J=8.0 Hz), 7.86
(1H, d, J=7.7 Hz), 7.64 (1H, t, J=7.8 Hz), 7.51 (1H, d, J=7.7 Hz),
7.46 (1H, s), 7.36 (1H, t, J=7.9 Hz), 7.08 (1H, d, J=2.5 Hz), 6.93
(1H, dd, J=8.2, 2.5 Hz) 3.82 (3H, s). MS (ES+): m/e 296 (20), 295
(100). MS (ES-): m/e 294 (20), 293 (100).
[0506] Compound 221
[0507] 4-[3-(3-Methoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
200-202.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.69 (1H, d, J=2.5 Hz), 8.05 (4H, s), 7.52 (1H, dd, J=7.7, 1 Hz),
7.48 (1H, dd, J=2.6, 1 Hz), 7.37 (1H, t, J=7.9 Hz), 7.12 (1H, d,
J=2.5 Hz), 6.94 (1H, dd, J=7.5, 2.6 Hz), 3.82 (3H, s). MS (ES+):
m/e 296 (20), 295 (100). MS (ES-): m/e 294 (20), 293 (100).
[0508] Compound 222
[0509] 4-(3-Phenyl-pyrazol-1-yl)-benzoic acid: m.p. 244-245.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 8.69 (1H, d, J=2.5
Hz), 8.05 (4H, s), 7.96-7.92 (21H, m), 7.48-7.36 (3H, m) 7.11 (1H,
d, J=2.5 Hz). MS (ES+): m/e 266 (20), 265 (100). MS (ES-): m/e 264
(20), 263 (100).
[0510] D. Preparation of 1,4-Pyrazoles
[0511] 1,4 Pyrazoles of the invention may be prepared as
follows.
Preparation of 3-[4-(4-Methoxy-phenyl)-pyrazol-1-yl]-benzoic acid
(Compound 47)
[0512] A solution of 3-hydrazinobenzoic acid (300 mg, 1.97 mmol)
and 4-methoxyphenylmalondialdehyde (351 mg, 1.97 mmol) in 4 mL
acetic acid is heated for 20 h at 110.degree. C. After being
allowed to cool, the solution developed a tan precipitate, which is
collected by filtration and washed with ethyl acetate and diethyl
ether. The powder is dried under vacuum to afford the title
compound (429 mg, 1.46 mmol, 74%). m.p. 238-239.degree. C. .sup.1H
NMR (300 MHz, DMSO-d.sub.5): .delta. 13.26 (1H, s), 9.02 (1H, s),
8.41 (1H, s), 8.17 (1H, s), 8.12 (1H, d, J=7.9 Hz), 7.85 (1H, d,
J=7.9 Hz), 7.65 (2H, d, J=8.5 Hz), 7.64 (1H, t, J=7.9 Hz), 6.96
(2H, d, J=8.5 Hz), 3.76 (3H, s). MS (ES+): m/e 296 (18), 295 (100).
MS (ES-): m/e 294 (17), 293 (100).
[0513] The following compounds may be prepared following a similar
procedure as just described.
[0514] Compound 48
[0515] 3-(4-p-Tolyl-pyrol-1-yl)-benzoic acid: m.p. 208-209.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 13.26 (1H, s), 9.08
(1H, s), 8.42 (1H, s), 8.21 (1H, s), 8.12 (1H, d, J=8.2 Hz), 7.85
(1H, d, J=7.7 Hz), 7.63 (1H, t, J=8 Hz), 7.62 (2H, d, J=8.2 Hz),
7.20 (2H, d, J=8.2 Hz), 2.30 (3H, s). MS (ES+): m/e 280 (18), 279
(100). MS (ES-): m/e 278 (17), 277 (100).
[0516] Compound 49
[0517] 3-[4-(4-Chloro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
253-254.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.28 (1H, s), 9.17 (1H, s), 8.42 (1H, s), 8.27 (1H, s), 8.11 (1H,
dd, J=8.0, 1.3 Hz), 7.86 (1H, d, J=7.7 Hz), 7.76 (2H, d, J=8.2 Hz),
7.63 (1H, t, J=8.0 Hz), 7.44 (2H, d, J=8.2 Hz). MS (ES+): m/e 301
(35), 300 (19), 299 (100). MS (ES-): m/e 299 (40), 298 (17), 297
(100).
[0518] Compound 50
[0519] 4-[4-(4-Methoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
289-290.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.02 (1H, s), 9.00 (1H, s), 8.20 (1H, s), 8.06 (2H, d, J=8.4 Hz),
7.99 (2H, d, J=8.4 Hz), 7.64 (2H, d, J=8.5 Hz), 6.96 (2H, d, J=8.5
Hz), 3.76 (3H, s). MS (ES+): m/e 296 (16), 295 (100). MS (ES-): m/e
294 (19), 293 (100).
[0520] Compound 51
[0521] 4-(4-p-Tolyl-pyrazol-1-yl)-benzoic acid: m.p.
298-299.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.02 (1H, s), 9.07 (1H, s), 8.25 (1H, s), 8.06 (2H, d, J=8.8 Hz),
8.00 (2H, d, J=8.8 Hz), 7.61 (2H, d, J=8.2 Hz), 7.20 (2H, d, J=8.2
Hz), 2.30 (3H, s). MS (ES+): m/e 280 (20), 279 (100). MS (ES-): m/e
278 (14), 277 (100).
[0522] Compound 52
[0523] 4-[4-(4-Chloro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
300-302.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.03 (1H, s), 9.14 (1H, s), 8.29 (1H, s), 8.06 (2H, d, J=8.8 Hz),
7.98 (2H, d, J=8.8 Hz), 7.73 (2H, d, J=8.5 Hz) 7.44 (2H, J=8.5 Hz).
MS (ES+): m/e 301 (35), 300 (16), 299 (100). MS (ES-): m/e 299
(39), 298 (18), 297 (100).
[0524] Compound 113
[0525] 3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzoic acid: m.p.
243-245.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.29 (1H, s), 8.58 (1H, d, J=5.0 Hz), 8.44 (1H, t, J=1.8 Hz), 838
(1H, s), 8.17 (1H, dd, J=8.0, 1.3 Hz), 7.90-7.87 (3H, m), 7.65 (1H,
t, J=7.9 Hz), 7.30 (1H, q, J=4.4 Hz). MS (ES+): M/e 267 (24), 266
(100). MS (ES-): m/e 265 (19), 264 (100).
[0526] Compound 114
[0527] 4-(4-Pyridin-2-yl-pyrazol-1-yl)-benzoic acid: m.p.
260-262.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.39 (1H, s), 8.61 (1H, dd, J=5.0, 0.6 Hz), 8.50 (1H, s), 8.10-7.95
(6H, m), 7.40 (1H, dt, J=6.0, 1.5 Hz). MS (ES+): m/e 267 (29), 266
(100). MS (ES-): m/e 265 (18), 264 (100).
[0528] Compound 115
[0529] 3-(4-Pyridin-4-yl-pyrazol-1-yl)-benzoic acid: m.p.
300-302.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.37 (1H, s), 8.55 (2H, d, J=5.0 Hz), 8.43 (2H, s), 8.14 (1H, dd,
J=8.2, 1.5 Hz), 7.89 (1H, d, J=7.6 Hz), 7.73 (2H, d, J=6.1 Hz),
7.66 (1H, t, J=7.9 Hz). MS (ES+): m/e 267 (21) 266 (100). MS (ES-):
m/e 265 (18), 264 (100).
[0530] Compound 116
[0531] 4-(4-Pyridin-4-yl-pyrazol-1-yl)-benzoic acid:
m.p.>350.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.36 (1H, s), 8.56 (2H, d, J=6.2 Hz), 8.46 (1H, s), 8.09 (2H, d,
J=8.8 Hz), 8.02 (2H, d, J=8.8 Hz), 7.71 (2H, d, J=62 Hz). MS (ES+):
m/e 267 (30) 266 (100). MS (ES-): m/e 265 (17), 264 (100).
[0532] Compound 117
[0533] 3-(4-Pyrimidin-4-yl-pyrazol-1-yl)-benzoic acid: m.p.
297-299.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.95 (1H, br), 9.45 (1H, s), 9.12 (1H, d, J=1.2 Hz), 8.77 (1H, d,
J 5.2 Hz), 8.47 (1H, s) 8.45 (1H, t, J=1.8 Hz), 8.18 (1H, ddd,
J=8.2, 2.3, 0.9 Hz), 7.94-7.89 (2H, m), 7.66 (1H, t, J=7.9 Hz). MS
(ES+): m/e 268 (15), 267 (100). MS (ES-): m/e 266 (18), 265
(100).
[0534] Compound 118
[0535] 4(4-Pyrimidin-4-yl-pyrazol-1-yl)-benzoic acid:
m.p.>350.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.44 (1H, s), 9.13 (1H, dd, J=4, 1.4 Hz), 8.79 (1H, t, J=4.5 Hz),
8.51 (1H, s), 8.07 (4H, s), 7.90 (1H, m). MS (ES+): m/e 268 (17),
267 (100). MS (ES-): m/e 266 (15), 265 (100).
[0536] Compound 119
[0537] 3-(4-Pyrazin-2-yl-pyrazol-1-yl)-benzoic acid: m.p.
310-311.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.31 (1H, br), 938 (1H, s), 9.13 (1H, d, J=1.4 Hz), 8.60 (1H, dd,
J=2.5, 1.6 Hz), 8.48-8.42 (3H, m), 8.17 (1H, dt, J=7.9, 1.1 Hz),
7.90 (1H, dd, J=6.4, 1.2 Hz), 7.66 (1H, t, J=7.9 Hz). MS (ES+): m/e
268 (13), 267 (100). MS (ES-): m/e 266 (15), 265 (100).
[0538] Compound 120
[0539] 4(4-Pyrazin-2-yl-pyrazol-1-yl)-benzoic acid: m.p.
319-321.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.08 (1H, br), 9.37 (1H, s), 9.12 (1H, d, J=1.6 Hz), 8.62 (1H, dd,
J=2.5, 1.6 Hz), 8.49 (1H, d, J=2.5 Hz), 8.47 (1H, s), 8.08 (21. d,
J=9.0 Hz), 8.05 (2H, d, J=9.0 Hz). MS (ES+): m/e 268 (11), 267
(100). MS (ES-): m/e 266 (13), 265 (100).
[0540] Compound 121
[0541] 3-(4-Benzooxazol-2-yl-pyrazol-1-yl)-benzoic acid: m.p.
331-333.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.31 (1H, br), 9.48 (1H, s), 8.49 (1H, t, J=1.9 Hz), 8.46 (1H, s),
8.23 (1H, dd, J=8.1, 2.3 Hz), 7.93 (1H, d, J=7.9 Hz), 7.77-7.71
(2H, m), 7.67 (1H, t, J=7.9 Hz), 7.42-7.34 (2H, m). MS (ES+): m/e
307 (19), 306 (100). MS (ES-): m/e 305 (22), 304 (100).
[0542] Compound 122
[0543] 3-(4-Quinoxalin-2-yl-pyrazol-1-yl)benzoic acid: m.p.
325-326.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.32 (1H, br), 9.60 (1H, s), 9.46 (1H, s), 8.59 (1H, s), 8.49 (1H,
t, J=1.8 Hz), 8.22 (1H, dt, J=7.9, 1.2 Hz), 8.08-8.03 (2H, m), 7.92
(1H, dt, J=7.7, 1.6 Hz), 7.87-7.75 (2H, m), 7.69 (1H, t, J=7.9 Hz).
MS (ES+): m/e 318 (20), 317 (100). MS (ES-): m/e 316 (22), 315
(100).
[0544] Compound 123
[0545] 3-(4-Quinolin-2-yl-pyrazol-1-yl)-benzoic acid: m.p.
250-252.degree. C. .sup.1H NMR (300 M Hz, DMSO-d.sub.6): .delta.
9.44 (1H, s), 8.51 (1H, s), 8.49 (1H, t, J=1.8 Hz), 8.41 (1H, d, J
8.8 Hz), 8.22 (1H, dt, J=6.7, 1.0 Hz), 8.04 (1H, d, J=8.5 Hz), 8.00
(1H, d, J=8.4 Hz), 7.92 (1H, dt, J=8.2, 1.0 Hz), 7.74 (1H, d,
J=7.8, 1.5 Hz), 7.67 (1H, t, J=7.9 Hz), 7.54 (1H, dt, J=7.9, 1.1
Hz). MS (ES+): m/e 317 (37), 316 (100). MS (ES-): m/e 315 (18), 314
(100).
Preparation of 3-[4-(2-Fluoro-phenyl)-pyrazol-1-yl]-benzoic acid
(Compound 84)
[0546] Part A.
[0547] A flask containing phosphorus oxychloride (3.25 mL, 34.9
mmol) is cooled to ca. 10.degree. C., and dimethylformamide (3.25
mL) is added dropwise. After stirring for 30 min, the resulting
mixture is treated dropwise with a solution of 2-fluorophenylacetic
acid (1.79 g, 11.6 mmol) in dimethylformamide (6 mL). This solution
is heated to 70.degree. C. for 18 h, then cooled and poured into
ice. After being allowed to meth, the mixture is neutralized with
solid NaHCO.sub.3, and then made basic with 50% aq. NaOH solution.
After stirring for 1 h, the mixture is extracted twice with diethyl
ether (100 mL), and the ether extracts are washed with brine,
combined, dried over anhydrous magnesium sulfate, filtered and
evaporated to afford 3-dimethylamino-2-(2-fluorophenyl)-acrolein
(1.72 g, 8.92 mmol, 77%) as a yellow-brown oil. TLC R.sub.F 0.30
(ethyl acetate). .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 9.08
(1H, s), 7.29-7.19 (2H, m), 7.14-7.01 (2H, m), 6.91 (1H, s), 2.88
(6H, br). MS (ES+): m/e 216 (18), 195 (23), 194 (100).
[0548] Part B.
[0549] A solution of 3-dimethylamino-2-(2-fluorophenyl)-acrolein
(812 mg, 4.20 mmol) and 3-hydrazinobenzoic acid (639 mg, 4.20 mmol)
in acetic acid (8 mL) is heated to 110.degree. C. for 18 h and
cooled. The resulting tan-colored precipitate is collected by
filtration, washed with ethyl acetate and diethyl ether, and dried
under vacuum to afford the title product as a powder (833 mg, 2.95
mmol, 70%). m.p. 225-226.degree. C. .sup.1H NMR (300 MHz,
acetone-d.sub.6): .delta. 8.90 (1H, dd, J=1.5, 0.6 Hz), 8.55 (1H,
t, J=1.8 Hz), 8.21 (1H, dd, J=2.0, 0.6 Hz), 8.18 (1H, ddd, J=8.1
2.4, 1.1 Hz), 7.98 (1H, ddd, J=7.9 1.6, 1.0 Hz), 7.90-7.83 (1H, m),
7.65 (1H, t, J=7.7 Hz), 7.35-7.20 (3H, m), 1H missing. MS (ES+):
m/e 285 (2), 284 (18), 283 (100).
[0550] This procedure may be adapted to prepare the following
compounds.
[0551] Compound 85
[0552] 4-[4-(2-Fluoro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
260-261.degree. C. .sup.1H NMR (300 MHz, acetone-d.sub.6): .delta.
8.97 (1H, dd, J=1.5, 0.6 Hz), 8.25 (1H, dd, J=2.0, 0.6 Hz), 8.15
(2H, d, J=9.4 Hz), 8.09 (2H, d, J=9.4 Hz), 7.91-7.85 (1H, m),
7.38-7.23 (31H, m), 1H missing. MS (ES-): m/e 282 (20), 281
(100).
[0553] Compound 88
[0554] 3-[4(3-Bromo-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
177-178.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.24 (1H, s), 8.43 (1H, s), 8.32 (1H, s), 8.13 (1H, dd, J=8.5, 0.5
Hz), 8.00 (1H, s), 7.87 (1H, d, J=7.6 Hz), 7.75 (1H, d, J=7.6 Hz),
7.64 (1H, t, J=7.9 Hz), 7.42 (1H, d, J=8.2 Hz), 7.34 (1H, t, J=7.7
Hz), 1H missing. MS (ES+): m/e 346 (16), 345 (100), 344 (18), 343
(99). MS (ES-): m/e 344 (16), 343 (92), 342 (18), 341 (100).
[0555] Compound 89
[0556] 4-[4-(3-Bromo-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
247-248.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.06 (1H, br), 9.23 (1H, s), 8.36 (1H, s), 8.09-7.98 (5H, m), 7.74
(1H, d, J=7.6 Hz), 7.42 (1H, d, J=7.9 Hz), 7.35 (1H, t, J=7.8 Hz).
MS (ES+): m/e 346 (14), 345 (100), 344 (15), 343 (90). MS (ES-):
m/e 344 (14), 343 (100), 342 (13), 341 (91).
[0557] Compound 90
[0558] 3-(4-m-Tolyl-pyrazol-1-yl)-benzoic acid: m.p.
181-182.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.28 (1H, br), 9.12 (1H, s), 8.44 (1H, t, J=1.9 Hz), 8.24 (1H, s),
8.14 (1H, dt, J=8.2, 1.3 Hz), 7.86 (1H, dd, J=7.9, 1.0 Hz),
7.67-7.51 (3H, m), 7.27 (1H, t, J=7.6 Hz), 7.05 (1H, d, J=7.6 Hz),
2.33 (3H, s). MS (ES+): m/e 280 (19), 279 (100). MS (ES-): m/e 278
(20), 277 (100).
[0559] Compound 91
[0560] 4-(4-m-Tolyl-pyrazol-1-yl)-benzoic acid: m.p.
251-252.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.02 (1H, br), 9.10 (1H, s), 8.27 (1H, s), 8.09-7.99 (4H, m),
7.57-7.50 (2H, m), 7.28 (1H, t, J=7.8 Hz), 7.06 (1H, d, J=7.3 Hz),
2.33 (31H, s). MS (ES-): m/e 280 (19), 279 (100). MS (ES-): m/e 278
(21), 277 (100).
[0561] Compound 98
[0562] 3-(4-Phenyl-pyrazol-1-yl)-benzoic acid: m.p. 225-226.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 13.19 (1H, br s),
9.14 (1H, s), 8.43 (1H, d, J=1.7 Hz), 8.26 (1H, s), 8.14 (1H, dd,
J=7.3, 1.4 Hz), 7.87 (1H, d, J=7.6 Hz), 7.74 (2H, d, J=7.3 Hz),
7.64 (1H, t, J=8.0 Hz), 7.42-7.36 (2H, m), 7.24 (1H, t, J=7.5 Hz).
MS (ES+): m/e 266 (16), 265 (100). MS (ES-): m/e 264 (13), 263
(100).
[0563] Compound 99
[0564] 4-(4-Phenyl-pyrazol-1-yl)-benzoic acid: m.p. 267-269.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 13.04 (1H, br s),
9.13 (1H, s), 8.30 (1H, s), 8.07 (2H, d, J=8.8 Hz), 8.01 (2H, d,
J=8.8 Hz), 7.73 (2H, d, J=7.3 Hz), 7.40 (2H, t, J=7.6 Hz), 7.25
(1H, t, J=7.5 Hz). MS (ES+): m/e 266 (19), 265 (100). MS (ES-): m/e
264 (13), 263 (100).
[0565] Compound 100
[0566] 3-[4-(4-Hydroxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
282-284.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.95 (1H, s), 8.40 (1H, s), 8.12 (1H, s), 8.12-8.09 (1H, m), 7.84
(1H, d, J=7.6 Hz), 7.62 (1H, t, J=7.9 Hz), 7.53 (2H, d, J=8.5 Hz),
6.78 (2H, d, J=8.5 Hz). MS (ES+): m/e 282 (18), 281 (100). MS
(ES-): m/e 280 (17), 279 (100).
[0567] Compound 101
[0568] 3-[4-(4-Nitro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
274-276.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.01 (1H, br s), 9.39 (1H, s), 8.44 (2H, s), 8.25 (2H, d, J=8.8
Hz), 8.14 (1H, dd, J=8.0, 1.7 Hz), 8.01 (2H, d, J=8.8 Hz), 7.89
(1H, d, J=7.6 Hz), 7.66 (1H, t, J=8.0 Hz). MS (ES-): m/e 309 (17),
308 (100).
[0569] Compound 102
[0570] 4-[4-(4-Nitro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
276-277.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.72 (1H, br, s), 9.37 (1H, s), 8.47 (1H, s), 8.26 (2H, d, J=8.8
Hz), 8.09-7.97 (6H, m). MS (ES-): m/e 309 (24), 308 (100).
[0571] Compound 103
[0572] 3-[4-(2,4-Difluoro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
283-285.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.31 (1H, br s), 9.02 (1H, s), 8.42 (1H, s), 8.19 (1H, d, J=1.5
Hz), 8.14 (1H, dt, J=8.0, 1.0 Hz), 7.94-7.86 (2H, m), 7.64 (1H, t
J=7.9 Hz), 7.35 (1H, dt, J=10.1, 2.6 Hz), 7.17 (1H, dt, J=8.5, 2.6
Hz). MS (ES+): m/e 302 (17), 301 (100). MS (ES-): m/e 300 (19), 299
(100).
[0573] Compound 104
[0574] 4-[4-(2,4-Difluoro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
291-293.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.04 (1H, br s), 9.01 (1H, s), 8.23 (1H, d, J=1.7 Hz), 8.06 (2H,
d, J=6.7 Hz), 8.02 (2H, d, J=6.7 Hz), 7.92-7.84 (1H, m), 7.40-7.32
(1H, m), 7.22-7.15 (1H, m). MS (ES+): m/e 302 (21), 301 (100). MS
(ES-): m/e 300 (21), 299 (100).
[0575] Compound 107
[0576] 3-[4-(4-Difluoromethoxy-phenyl)pyrazol-1-yl]-benzoic acid:
m.p. 118-120.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.18 (1H, br s), 9.15 (1H, s), 8.42 (1H, t, J=1.9 Hz),
8.26 (1H, s), 8.13 (1H, dt, J=8.2, 2.3 Hz), 7.86 (1H, dd, J=8.8,
1.2 Hz), 7.80 (2H, d, J=8.8 Hz), 7.65 (1H, t, J=7.9 Hz), 7.25 (1H,
t, J=74.2 Hz), 7.22 (2H, d, J=8.8 Hz). MS (ES+): m/e 332 (20), 331
(100). MS (ES-): m/e 330 (20), 329 (100).
[0577] Compound 108
[0578] 3-[4-(4-Amino-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
209-210.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.85 (1H, s), 8.39 (1H, q, J=2.0 Hz), 8.11-8.06 (1H, m), 8.05 (1H,
s), 7.82 (1H, dt, J=8.2, 1.3 Hz), 7.61 (1H, t, J=8.0 Hz), 738 (2H,
d, J=8.4 Hz), 6.58 (2H, d, J=8.4 Hz). MS (ES+): m/e 281 (32), 280
(100). MS (ES-): m/e 279 (18), 278 (100).
[0579] Compound 109
[0580] 4-[4-(3-Methoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
222-223.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.03 (1H, br s), 9.14 (1H, s), 8.31 (1H, s), 8.07 (2H, d, J=9.0
Hz), 8.01 (2H, d, 0.1-9.0 Hz), 7.34-7.29 (3H, m), 6.85-6.80 (1H,
m), 3.80 (3H, s). MS (ES+): m/e 296 (18), 295 (100). MS (ES-): m/e
294 (19), 293 (100).
[0581] Compound 110
[0582] 3-[4-(4-Dimethylaminophenyl)-pyrazol-1-yl]-benzoic acid:
m.p. 224-225.degree. C. TLC R.sub.F 0.41 (ethyl acetate). .sup.1H
NMR (300 MHz, DMSO-d.sub.6): .delta. 13.27 (1H, br s), 8.93 (1H,
s), 8.40 (1H, J=1.8 Hz), 8.12 (1H, s), 8.11 (1H, ddd, J=8.2 2.3,
1.1 Hz), 7.83 (1H, dd, J=8.0, 1.2 Hz), 7.62 (1H, t, J=7.9 Hz), 7.55
(2H, d, J=8.8 Hz), 6.75 (2H, d, J=8.8 Hz), 2.90 (6H, s). MS (ES+):
m/e 309 (48), 308 (100). MS (ES-): m/e 307 (23), 306 (100).
[0583] Compound 111
[0584] 3-(4-Benzo[1,3]dioxol-5-yl-pyrazol-1-yl)-benzoic acid: m.p.
264-265.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.12 (1H, br s), 9.04 (1H, s), 8.40 (1H, t, J=1.9 Hz), 8.19 (1H,
s), 8.10 (1H, ddd, J=8.2, 2.3, 0.9 Hz), 7.85 (1H, dt, J=7.6, 1.2
Hz), 7.63 (1H, t, J=7.9 Hz), 7.36 (1H, d, J=1.8 Hz), 7.23 (1H, dd,
J=7.9, 1.8 Hz), 6.94 (1H, d, J=7.9 Hz), 6.02 (2H, s). MS (ES+): m/e
310 (18), 309 (100). MS (ES-): m/e 308 (22), 307 (100).
[0585] Compound 112
[0586] 3-[4-(3-Methoxy-phenyl)-pyrazol-1yl]-benzoic acid: m.p.
157-158.degree. C. TLC R.sub.F 0.20 (50:50 ethyl acetate-hexane).
.sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 13.27 (1H, br s), 9.15
(1H, s), 8.43 (1H, t, J=1.9 Hz), 8.27 (1H, s), 8.13 (1H, ddd,
J=8.2, 2.4, 1.2 Hz), 7.86 (1H, dt, J==7.6, 1.2 Hz), 7.64 (1H, t,
J=7.9 Hz), 7.33-7.27 (3H, m), 6.80 (1H, dt, J=6.4, 2.8 Hz), 3.80
(3H, s). MS (ES+): m/e 296 (18), 295 (100). MS (ES-): m/e 294 (20),
293 (100).
[0587] Compound 205
[0588] 4-(4-Benzo[1,3]dioxol-5-yl-pyrazol-1-yl)-benzoic acid: m.p.
286-288.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.03 (1H, s), 8.22 (1H, s), 8.05 (2H, d, J=8.5 Hz), 7.96 (2H, d,
J=8.5 Hz), 7.33 (1H, s), 7.22 (1H, d, J=8.3 Hz), 6.95 (1H, d, J=8.3
Hz), 6.02 (2H, s). MS (ES+): m/e 310 (30), 309 (100). MS (ES-): m/e
308 (20), 307 (100).
[0589] Compound 206
[0590] 4-[4-(3-Hydroxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
273-275.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.47 (1H, s), 9.05 (1H, s), 8.20 (1H, s), 8.06 (2H, d, J=8.8 Hz),
8.00 (2H, d, J=8.8 Hz), 7.17 (2H, m), 7.09 (1H, s), 6.66 (1H, dd,
J=8.6, 1.2 Hz). MS (ES+): m/e 282 (10), 281 (100). MS (ES-): m/e
280 (20), 279 (100).
[0591] Compound 207
[0592] 3-[4-(3-Hydroxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
272-274.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.45 (1H, s), 9.06 (1H, s), 8.43 (1H, s), 8.15 (2H, m), 7.86 (1H,
dd, J=7.7, 1.0 Hz), 7.63 (1H, t, J=7.7 Hz), 7.20 (2H, m), 7.11 (1H,
s), 6.66 (1H, m). MS (ES+): m/e 282 (20), 281 (100). MS (ES-): m/e
280 (20), 279 (100).
[0593] Compound 208
[0594] 4-[4-(3-Trifluoromethoxy-phenyl)-pyrazol-1-yl]-benzoic acid:
m.p. 225-227.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.26 (1H, s), 8.39 (1H, s), 8.08 (2H, d, J=8.8 Hz), 8.00
(2H, d, J=8.8 Hz), 7.78 (2H, m), 7.53 (1H, t, J=8.0 Hz), 7.22 (1H,
m). MS (ES+): m/e 350 (20), 349 (100). MS (ES-): m/e 348 (20), 347
(100).
[0595] Compound 209
[0596] 3-[4-(3-Trifluoromethoxy-phenyl)-pyrazol-1-yl]-benzoic acid:
m.p. 166-168.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.2 (1H, s), 8.43 (1H, s), 8.36 (1H, s), 8.14 (1H, dd,
J=8.0, 1.1 Hz), 7.88 (1H, dd, J=7.7, 0.8 Hz), 7.80 (2H, m), 7.66
(1H, t, J=7.7 Hz), 7.53 (1H, t, J=7.8 Hz), 7.21 (1H, m). MS (ES+):
m/e 350 (30), 349 (100). MS (ES-): m/e 348 (20), 347 (100).
[0597] Compound 210
[0598] 3-[4-(3-Chloro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
178-180.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.25 (1H, s), 8.43 (1H, s), 8.33 (1H, s), 8.13 (1H, dd, J=7.4, 1.0
Hz), 7.87 (2H, m), 7.72 (1H, dd, J=7.7, 1.0 Hz), 7.67 (1H, t, J=8.0
Hz), 7.43 (1H, t, J=8.0 Hz), 7.26 (1H, dd, J=8.0, 0.9 Hz). MS
(ES+): m/e 301 (60), 299 (100). MS (ES-): m/e 299 (30) 297
(100).
[0599] Compound 211
[0600] 4-[4-(3-Chloro-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
252-255.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.23 (1H, s), 8.36 (1H, s), 8.07 (2H, d, J=8.8 Hz), 7.99 (2H, d,
J=8.8 Hz), 7.84 (1H, s), 7.70 (1H, dd, J=7.7, 1.0 Hz), 7.43 (1H, t,
J=8.0 Hz), 7.29 (1H, dd, J=8.0 Hz). MS (ES+): m/e 301 (30), 299
(100). MS (ES-): m/e 299 (30), 297 (100).
[0601] Compound 212
[0602] 4-[4-(3-Fluoro-phenyl)pyrazol-1-yl]-benzoic acid: m.p.
261-265.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.21 (1H, s), 8.36 (1H, s), 8.08 (2H, d, J=8.8 Hz), 8.00 (2H, d,
J=8.8 Hz), 7.59 (2H, m), 7.46 (1H, m), 7.05 (1H, m). MS (ES+): m/e
284 (20), 283 (100). MS (ES-): m/e 282 (20), 281 (100).
[0603] Compound 213
[0604] 3-[4-(3-Fluoro-phenyl)pyrazol-1-yl]-benzoic acid: m.p.
228-230.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.22 (1H, s), 8.43 (1H, s), 8.32 (1H, s), 8.12 (1H, dd, J=9.1, 2.2
Hz), 7.87 (1H, dd, J=7.7, 0.9 Hz), 7.62 (3H, m), 7.41 (1H, m), 7.05
(1H, m). MS (ES+): m/e 284 (30), 283 (100). MS (ES-): m/e 282 (20),
281 (100).
[0605] Compound 214
[0606] 4-[4-(3-Trifluoromethoxy-phenyl)-pyrazol-1-yl]-benzoic acid:
m.p. 220-222.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.21 (1H, s), 8.35 (1H, s) 8.07 (2H, d, J=8.8 Hz), 7.99
(2H, d, J=8.8 Hz), 7.59 (2H, m), 7.45 (1H, t, J=8.0 Hz), 7.28 (1H,
s), 7.05 (1H, m). MS (ES+): m/e 332 (20), 331 (100). MS (ES-): m/e
330 (20), 329 (100).
[0607] Compound 215
[0608] 4-[4-(3-Phenoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
211-213.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.16 (1H, s), 8.31 (1H, s) 8.05 (2H, d, J=9.1 Hz), 7.99 (2H, d,
J=9.1 Hz), 7.51 (2H, m), 7.39 (3H, m), 7.12 (1H, m), 7.05 (2H, m),
6.85 (1H, m). MS (ES+): m/e 358 (25), 357 (100). MS (ES-): m/e 356
(25), 355 (100).
[0609] Compound 216
[0610] 3-[4-(3-Phenoxy-phenyl)-pyrazol-1-yl]-benzoic acid: m.p.
164-165.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.18 (1H, s), 8.43 (1H, t, J=1.2 Hz), 8.27 (1H, s), 8.13 (1H, dd,
J=8.0, 1.3 Hz), 7.86 (1H, dd, J=7.7, 0.9 Hz), 7.63 (1H, t, J=8.0
Hz), 7.56 (2H, m), 7.12 (1H, m), 7.02 (2H, m), 6.84 (1H, dd, J=8.0,
2.5 Hz). MS (ES+): m/e 359 (10), 358 (60), 357 (100). MS (ES-): m/e
356 (25), 355 (100).
Preparation of 3-(4,5-Dihydro-benzo[e]indazol-3-yl)-benzoic acid
(Compound 135)
[0611] A mixture of 2-tetralone (2.00 mL, 14.7 mmol) and
dimethylformamide dimethyl acetal (2.10 mL, 15.0 mmol) is heated to
reflux for 14 h. The mixture is cooled and evaporated, and
approximately half of the residue is dissolved in acetic acid (10
mL) and treated with 3-hydrazinobenzoic acid (750 mL, 4.93 mmol).
The solution is heated to reflux for 12 h, then cooled and poured
into water (100 mL). The resulting precipitate is collected by
filtration, washed with water, and evaporated under high vacuum to
afford the title compound (900 mg, 3.10 mmol, 63%) as a tan solid,
m.p. 273-275.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.30 (1H, br), 8.15 (1H, s), 8.10 (1H, t, J=1.9 Hz), 7.95
(1H, dt, J=7.6, 1.3 Hz), 7.82 (1H, ddd, J=8.0, 2.2, 1.0 Hz), 7.66
(1H, t, J=7.9 Hz), 7.53 (1H, dd, J=7.6, 1.2 Hz), 7.26-7.22 (2H, n),
7.10 (1H, dt, J=7.3, 1.2 Hz), 3.05-3.02 (2H, m), 3.00-2.87 (2H, m).
MS (ES+): m/e 292 (21), 291 (100). MS (ES-): m/e 290 (20), 289
(100).
[0612] Using these procedures, the following compounds may be
prepared.
[0613] Compound 136
[0614] 3-(8H-Indeno[2,1-c]pyrazol-1-yl)-benzoic acid: m.p.
241-243.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.40 (1H, t, J=1.7 Hz), 8.08 (1H dd, J=8.2, 1.4 Hz), 8.01 (1H, s),
7.88 (1H, dt, J=7.9, 1.2 Hz), 7.67 (11 t, J=7.9 Hz), 7.57 (1H, d,
J=7.3 Hz), 7.52 (1H, d, J=8.4 Hz), 7.31 (1H, dt, J=7.9, 0.9 Hz),
7.18 (1H, dt, J=7.6, 1.1 Hz) 4.21 (2H, s). MS (ES+): m/e 278 (19),
277 (100). MS (ES-): m/e 276 (19), 275 (100).
[0615] Compound 141
[0616] 3-(4,5-Dihydro-benzo[e]indazol-2-yl)-benzoic acid: m.p.
233-234.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.1): .delta.
13.22 (1H, br), 8.99 (1H, s), 8.38 (1H, t, J=1.8 Hz), 8.07 (1H, dd,
J=7.9, 2.0 Hz), 7.82 (1H, d, J=7.6 Hz), 7.61 (1H, t, J=7.9 Hz),
7.58 (1H, d, J=7.6 Hz), 7.26 (1H, d, J=7.6 Hz), 7.23 (1H, d, J=7.9
Hz), 7.13 (1H, dr, J=7.9, 1.0 Hz), 3.00-2.95 (2H, m), 2.89-2.84
(2H, m). MS (ES+): m/e 292 (18), 291 (100). MS (ES-): m/e 290 (19),
289 (100).
[0617] Compound 146
[0618] 3.8H-Indeno[2,1-c]pyrazol-2-yl)-benzoic acid: m.p.
246-248.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.24 (1H, br), 8.75 (1H, s), 8.39 (1H, t, J=1.8 Hz), 8.10 (1H, dd,
J=8.0, 2.2 Hz), 7.82 (1H, d, J=7.6 Hz) 7.62 (1H, t, J=7.9 Hz), 7.56
(1H, d, J=7.3 Hz), 7.51 (1H, d, J=7.6 Hz), 7.33 (1H, t, J=7.8 Hz),
7.22 (1H, t, J=7.2 Hz), 3.85 (2H, s). MS (ES+): m/e 278 (18), 277
(100). MS (ES-): m/e 276 (21), 275 (100).
[0619] Compound 183
[0620]
3-(6-Difluoromethoxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic
acid: m.p. 235-237.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.27 (1H, br), 8.47 (1H, s), 8.40 (1H, t, J=1.8 Hz), 8.09
(1H, ddd, J=8.2, 2.3, 1.2 Hz), 7.84 (1H, dt, J=8.2, 1.3 Hz), 7.75
(1H, dd, J=7.6, 1.1 Hz), 7.62 (1H, t, J=7.9 Hz), 7.36 (1H, t, J=7.9
Hz), 7.22 (1H, t, J=74.1 Hz), 7.15 (1H, dd, J=8.2, 0.9 Hz),
2.96-2.90 (2H, m), 2.82-2.77 (2H, m). .sup.19F NMR (300 MHz,
DMSO-d.sub.6): .delta. -81.44 (2F, d, J=74.1 Hz). MS (ES+): m/e 358
(18), 357 (100). MS (ES-): m/e 356 (23), 355 (100).
[0621] Compound 154
[0622] 3-(5-Methoxy-4H-indeno[1,2-c]pyrazol-2-yl)-benzoic acid:
m.p. 277-278.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.24 (1H, br), 8.53 (1H, s), 8.42 (1H, t, J=1.9 Hz), 8.10
(1H, dd, J=8.0, 2.0 Hz), 7.82 (1H, d, J=7.6 Hz), 7.61 (1H, t, J=7.9
Hz), 7.41 (1H, d, J=8 Hz), 7.37 (1H, d, J=8 Hz), 7.03-6.97 (1H, m),
3.87 (3H, s), 3.62 (2H, s). MS (ES+): m/e 308 (24), 307 (100). MS
(ES-): m/e 306 (19), 305 (100).
[0623] Compound 185
[0624] 3-(5-Difluoromethoxy-4H-indeno[1,2-c]pyrazol-2-yl)benzoic
acid: m.p. 240-241.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.27 (1H, br), 8.60 (1H, s), 8.44 (1H, t, J=1.9 Hz), 8.13
(1H, ddd, J=8.2, 2.3, 0.9 Hz), 7.84 (1H, dt, J=7.9, 1.3 Hz), 7.69
(1H, d, J=7.4 Hz), 7.62 (1H, t, J=7.9 Hz), 7.48 (1H, t, J=7.9 Hz),
7.34 (1H, t, J=74.1 Hz), 7.19 (1H, dd, J=7.9, 0.6 Hz), 3.77 (2H,
s). .sup.19F NMR (300 MHz, DMSO-d.sub.6): .delta. -81.57 (2F, d,
J=74.1 Hz). MS (ES+): m/e 344 (23), 343 (100). MS (ES-): m/e 342
(21), 341 (100).
[0625] Compound 186
[0626]
4-(6-Difluoromethoxy-4,5-dihydro-benzo[g]indazol-2-yl)-benzoic
acid: m.p. 282-283.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.00 (1H, br), 8.48 (1H, s), 8.05 (2H, d, J 9.0 Hz), 7.99
(2H, d, J=9.0 Hz), 7.74 (1H, dd, J=7.6, 0.9 Hz), 7.38 (1H, t, J=7.9
Hz) 7.23 (1H, t, J=74.2 Hz), 7.16 (1H, d, J=8.2 Hz), 2.96-2.91 (2H,
m), 2.83-2.77 (2H, m). .sup.19F NMR (300 MHz, DMSO-d.sub.6):
.delta. -81.48 (2F., J=74.2 Hz). MS (ES-): m/e 358 (17), 357 (100).
MS (ES-): m/e 356 (23), 355 (100).
[0627] Compound 187
[0628] 4-(5-Methoxy-4H-indeno[1,2]pyrazol-2-yl)-benzoic acid: m.p.
311-313.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.97 (1H, br), 8.54 (1H, s), 8.04 (2H, d, J=9.0 Hz), 7.99 (2H, d,
J=9.0 Hz), 7.43-7.35 (2H, m), 7.01 (1H, dd, J=7.0, 1.8 Hz), 3.87
(3H, s), 3.63 (2H, s). MS (ES+): m/e 308 (19), 307 (100). MS (ES-):
m/e 306 (22), 305 (100).
[0629] Compound 188
[0630] 4-(5-Difluoromethoxy-4H-indeno[1,2-c]pyrazol-2-yl)-benzoic
acid: m.p. 277-278.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.00 (1H, br), 8.60 (1H, s), 8.05 (2H, d, J=9.4 Hz), 8.01
(2H, d, J=9.4 Hz), 7.66 (1H, d, J=7.4 Hz), 7.49 (1H, t, J=7.9 Hz),
7.34 (1H, t, J=74.0 Hz), 7.20 (1H, d, J=7.6 Hz), 3.77 (2H, s).
.sup.19F NMR (300 MHz, DMSO-d.sub.6): .delta. -81.60 (2F, d, J=74.0
Hz). MS (ES+): m/e 345 (13), 344 (33), 343 (100). MS (ES-): m/e 342
(22), 341 (100).
[0631] Compound 253
[0632] 3-(8-Methoxy-4,5-dihydro-benzo[e]indazol-2-yl)-benzoic acid:
m.p. 239-241.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.01 (1H, s), 8.35 (1H, t, J=1.8 Hz), 8.06 (1H, ddd, J=8.0,
2.3, 0.9 Hz), 7.82 (1H, dt, J=7.6, 1.3 Hz), 7.61 (1H, t, J=7.9 Hz),
7.21 (1H, d, J=2.9 Hz), 7.16 (1H, d, J=8.4 Hz), 6.70 (1H, d, J=8.4,
2.9 Hz), 3.77 (3H, s), 2.93-2.80 (4H, m). MS (ES+): m/e 322 (21),
321 (100). MS (ES-): m/e 320 (23), 319 (100).
[0633] Compound 254
[0634] 3-(8-Methoxy-4,5-dihydrobenzo[e]indazol-3-yl)-benzoic acid:
m.p. 269-271.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.18 (1H, s), 8.09 (1H, t, J=1.9 Hz), 7.94 (1H, dt, J=7.9,
1.3 Hz), 7.81 (1H, ddd, J=8.2, 23, 1.2 Hz), 7.66 (1H, t, J=7.9 Hz),
7.16 (1H, d, J=8.5 Hz), 7.15 (1H, d, J=2.6 Hz), 6.67 (1H, dd,
J=8.5, 2.6 Hz), 3.76 (3H, s) 3.05-2.99 (2H, m), 2.91-2.85 (2H, m).
MS (ES+): m/e 322 (23), 321 (100). MS (ES-): m/e 320 (21), 319
(100).
[0635] E. Preparation of 3,1-Pyrazoles
[0636] 3,1 Pyrazoles of the invention may be prepared as
follows.
Preparation of
3-[1-(4-Difluoromethoxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid
(Compound 124)
[0637] Part A.
[0638] A mixture of 3-acetylbenzonitrile (40.0 g, 276 mmol) and
dimethylformamide dimethyl acetal (321 mL) is heated with stirring
to 100.degree. C. for 72 h. The volatiles are distilled off, and
the crude product (55 g) is taken up in acetic acid (250 mL).
Hydrazine hydrate (42.6 mL) is added, and the mixture is heated to
100.degree. C. for 36 h. The mixture is cooled, and poured into
ethyl acetate (500 mL). This is washed with 1M aq. HCl (1 L) and
said. aq. brine (250 mL). The aqueous phases are back-extracted in
sequence with ethyl acetate (3.times.500 mL), and the extracts are
combined, dried over MgSO.sub.4, filtered and evaporated. The
residual material is filtered to afford the product,
3-(1H-pyrazol-3-yl)-benzonitrile, as an orange solid (45.0 g),
which is 88% pure by HPLC analysis.
[0639] Part B.
[0640] A solution of 4-difluoromethoxy-1-iodobenzene (1.50 g, 5.56
mmol) and triisopropylborate (2.06 mL, 8.89 mmol) in
tetrahydrofuran (50 mL) is cooled to -78.degree. C., and
n-butyllithium (9.8 mL, 1.6 M solution in hexane, 6.11 mmol) is
added dropwise with stirring. After 20 min, the cooling bath is
removed, and the solution is allowed to warm to ambient
temperature. The solvent is evaporated, and the residual material
is taken up in 1M sq. HCl (100 mL). This is extracted with ethyl
acetate (100 mL), and the extract is dried over MgSO.sub.4,
filtered and evaporated. Analysis by HPLC shows the product,
4-difluoromethoxybenzene boronic acid, of sufficient purity for the
next stop (1.02 g).
[0641] Part C.
[0642] A solution of 3-(1H-pyrazol-3-yl)-benzonitrile (400 mg, 2.36
mmol) and 4-difluoromethoxybenzene boronic acid (1.02 g, 5.44 mmol)
in dimethylformamide (20 mL) is treated with copper (II) acetate
(472 mg), pyridine (0.36 mL), and powdered, activated 4 .ANG.
molecular sieves (1 g). The resulting mixture is heated to
35.degree. C. for 3 h, cooled and partially evaporated. The residue
is partitioned between 1 M sq. HCl and ethyl acetate (200 mL each),
and the extract is washed with brine (100 mL), dried over
MgSO.sub.4, filtered and evaporated. The residue is separated by
column chromatography (silica gel, 1:1 CH.sub.2Cl.sub.2-hexane) to
afford
3-[1-(4-difluoromethoxy-phenyl)-1H-pyrazol-3-yl]-benzonitrile (200
mg, 23%).
[0643] Part D.
[0644] A solution of
3-[1-(4-difluoromethoxy-phenyl)-1H-pyrazol-3-yl]-benzonitrile (100
mg) and con. aq. HCl (5 mL) in acetic acid (5 mL) is heated to
reflux for 16 h. The mixture is cooled and poured into water (100
mL). This is extracted with ethyl acetate, and the extract was
washed with brine, dried over MgSO.sub.4, filtered and evaporated.
The residue is separated by column chromatography (silica gel,
1:25:74 acetic acid-CH.sub.2Cl.sub.2-hexane) to afford the title
product (12 mg, 11%) as a powder (m.p. 182-183.degree. C.), after
evaporation. .sup.1H NMR (300 MHz, acetone-d.sub.6): .delta. 11.35
(1H, br s), 8.64 (1H, dt, J=1.6, 0.5 Hz), 8.44 (1H, dd, J=2.6, 1.4
Hz), 8.22 (1H, ddd, J=7.8, 1.9, 1.1 Hz), 8.06-7.99 (3H, m), 7.60
(1H, t, J=8 Hz), 7.38 (2H, d, J=9.1 Hz), 7.09 (1H, d, J 2.6 Hz),
7.07 (1H, t, J=74.0 Hz). MS (ES+): m/r 332 (20), 331 (100). MS
(ES-): m/e 330 (20), 329 (100).
[0645] This procedure may be used in slightly modified forms to
prepare the following compounds
[0646] Compound 36
[0647] 3-[1-(2-Fluoro-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
157-158.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): 1.46 (1H,
t, J=1.6 Hz), 828 (1H, t, J=2.6 Hz), 0.13 (1H, dt, J=3.0, 1.4 Hz),
7.93-7.36 (2H, m), 7.57 (1H, t, J=7.7 Hz), 7.53-7.34 (3H, m), 7.13
(1H, d, J=2.6 Hz). MS (ES+): m/e 254 (20), 233 (100). MS (ES-): m/e
282 (20), 231 (100).
[0648] Compound 57
[0649] 3-(1-Phenyl-1H-pyrazol-3-yl)-benzonitrile: m.p.
73-80.degree. C. MS (ES+): m/e 246 (100).
[0650] Compound 58
[0651] 3-[1-(4-Methoxy-phenyl)-1H-pyrazol-3-yl]-benzonitrile: m.p.
110-112.degree. C. MS (ES+): m/e 276 (100).
[0652] Compound 59
[0653] 3-[1-(3-Methoxy-phenyl)-1H-pyrazol-3-yl]-benzonitrile: m.p.
100-101.degree. C. MS (ES+): m/e 276 (100).
[0654] Compound 60
[0655] 3-(1-Benzo[1,3]dioxol-5-yl-1H-pyrazol-3-yl)-benzonitrile:
m.p. 144-147.degree. C. MS (ES+): m/e 290 (100).
[0656] Compound 61
[0657]
3-[1-(4-Trifluoromethoxy-phenyl)-1H-pyrazol-3yl]-benzonitrile: m.p.
83-84.degree. C. MS (ES 4): m/e 3.30 (100).
[0658] Compound 62
[0659]
3-[1-(4-Trifluoromethyl-phenyl)-1H-pyrazol-3-yl]-benzonitrile: m.p.
70-74.degree. C. MS (ES+): m/e 314 (100).
[0660] Compound 63
[0661] 3-[1-(3,4-Difluoro-phenyl)-1H-pyrazol-3-yl]-benzonitrile:
m.p. 142-145.degree. C. MS (ES+): m/e 232 (100).
[0662] Compound 64
[0663] 3-[3-(3-Cyano-phenyl)-pyrazol-1-yl]-benzoic acid methyl
eater: m.p. 143-145.degree. C. MS (ES+): m/e 304 (100).
[0664] Compound 65
[0665] 3-(1-Phenyl-1H-pyrazol-3-yl)-benzoic acid: m.p.
202-204.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
83.59 (1H, d, J=2.5 Hz), 8.47 (1H, t, J=1.7 Hz), 8.14 (1H, dt,
J=8.0, 1.5 Hz), 7.93 (1H, t, J=1.5 Hz), 7.91-7.88 (1H, m), 7.57
(1H, t, J=7.8 Hz), 7.54, 7.48 (1H, m), 7.32 (1H, tt, J=7.4, 1.1
Hz), 7.11 (1H, d, J=2.5 Hz). MS (ES+): m/e 266 (20), 265 (100). MS
(ES-): m/e 264 (20), 263 (100).
[0666] Compound 74
[0667] 3-[1-(4-Hydroxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
228-230.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.63 (1H, s), 8.44 (1H, t, J=1.7 Hz), 8.38 (1H, d, J=2.5 Hz), 8.10
(1H, dt, J=8.0, 1.5 Hz), 7.88 (1H, dt, J=7.7, 1.4 Hz), 7.67 (2H, d,
J=9.0 Hz), 7.55 (1H, t, J=7.7 Hz), 7.03 (1H, d, J=2.5 Hz), 6.6 (2H,
d, J=9.0 Hz). MS (ES+): m/e 282 (20), 281 (100). MS (ES-): me 280
(20), 279 (100).
[0668] Compound 75
[0669] 3-[1-(3-Hydroxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
178-190.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.80 (1H, s), 8.51 (1H, d, J=2.5 Hz), 8.48 (1H, s), 8.12 (1H, d,
J=7.7 Hz), 7.90 (1H, d, J=7.7 Hz), 7.57 (1H, t, J=7.7 Hz),
7.36-7.25 (3H, m), 7.08 (1H, d, J=2.5 Hr), 6.70 (1H, dt, J=6.9, 2.2
Hz). MS (ES+): m/e 282 (20), 281 (100). MS (ES-): m/e 280 (20), 279
(100).
[0670] Compound 66
[0671] 3-[(1-(4-Trifluoromethoxy-phenyl)-1H-pyrazol-3-yl]-benzoic
acid: m.p. 171-174.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.63 (1H, t, J=2.6 Hz), 8.48 (1H, m), 8.15 (1H, d, J=8.0
Hz) 8.04 (2H, dd, J=9.0, 2.5 Hz), 7.91 (1H, d, J=7.7 Hz) 7.58 (1H,
dd, J=7.7, 2.2 Hz), 7.53 (2H, d, J=9.0 Hz), 7.15 (1H, t, J=2.5 Hz).
MS (ES+): m/e 350 (20), 349 (100). MS (ES-): m/e 348 (20), 347
(100).
[0672] Compound 67
[0673] 3-[1-(4-trifluoromethyl-phenyl)-1H-pyrazol-3-yl]-benzoic
acid: m.p. 225-227.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.75 (1H, d, J=2.5 Hz), 8.50 (1H, t, J=1.5 Hz), 8.20-8.17
(3H, m), 7.94 (1H, dt, J=8.2, 1.4 Hz), 7.88 (2H, 4, J=8.5 Hz) 7.59
(1H, t, J=7.6 Hz), 7.21 (1H, d, J=2.5 Hz). MS (ES+): m/e 334 (20),
333 (100). MS (ES-): m/e 332 (20), 331 (100).
[0674] Compound 68
[0675] 3-[1-(3,4-Difluoro-phenyl)-1H-pyrazol-3-yl]-benzoic acid:
m.p. 240-244.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.62 (1H, d, J=2.5 Hz) 8.47 (1H, t, J=1.7 Hz), 8.15 (1H,
dt, J=8.2, 1.5 Hz) 8.05 (1H, ddd, J=12.1, 7.1, 2.6 Hz) 7.92 (1H,
dt, J=8.0, 1.4 Hz), 7.84-7.78 (1H, m), 7.66-7.55 (2H, m), 7.15 (1H,
d, J=2.5 Hz). MS (ES+): m/e 302 (20), 301 (100). MS (ES-): m/e 300
(20), 299 (100).
[0676] Compound 69**
[0677] 1,3-Bis(3-carboxyphenyl)-1H-pyrazole: m.p.>300.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 8.71 (1H, d, J=1.7
Hz), 8.48 (1H, s), 8.44 (1H, s), 8.16 (2H, d, J=7.2 Hz), 7.93-7.85
(2H, m), 7.64 (1H, t, J=8.0 Hz), 7.57 (1H, t, J=8.2 Hz), 7.14 (1H,
d, J=2.7 Hz). MS (ES+): m/e 310 (20), 309 (100). MS (ES-): m/e 308
(20), 307 (100).
[0678] Compound 76
[0679] 3-[1-(4-Methoxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
160-161.degree. C. .sup.1H NMR (300 MHz, acetone-d.sub.6): .delta.
11.40 (1H, br s), 8.63 (1H, t, J=1.5 Hz), 8.33 (1H, d, J=2.5 Hz),
8.21 (1H, d, J=7 Hz), 8.02 (1H, d, J=7 Hz), 7.86 (2H, d, J=9.1 Hz),
7.59 (1H, t, J=7.7 Hz), 7.09 (2H, d, J=9.1 Hz), 7.03 (1H, d, J=2.5
Hz), 3.87 (3H, s). MS (ES+): m/e 296 (20) 295 (100). MS (ES-): m/e
294 (20), 293 (100).
[0680] Compound 77
[0681] 3-[1-(3-Methoxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
153-154.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.60 (1H, dd, J=2.5, 1.5 Hz), 8.45 (1H, d, J=1.1 Hz), 8.14 (1H, dd,
J=7.9, 1.3 Hz), 7.90 (1H, dd, J=7.7, 1.1 Hz), 7.60-7.38 (4H, m),
7.11 (1H, dd, J=2.5, 1.4 Hz), 6.89 (1H, d, J=8.0 Hz), 3.83 (3H, s).
MS (ES+): m/e 296 (20), 295 (100). MS (ES-): m/e 294 (20), 293
(100).
[0682] Compound 87
[0683] 3-(1-Benzo[1,3]dioxol-5-yl-1H-pyrazol-3-yl)-benzoic acid:
m.p. 210-215.degree. C. .sup.1H NMR (300 MHz, acetone-d.sub.6):
.delta. 8.61 (1H, dt, J=1.7, 0.5 Hz), 8.32 (1H, d, J=2.5 Hz), 8.21
(1H, ddd, J=7.7, 1.7, 1.1 Hz), 8.02 (1H, dt, J=8.3, 1.5 Hz), 7.59
(1H, dt, J=7.7, 0.6 Hz), 7.49 (1H, d, J=2.2 Hz), 7.41 (1H, dd,
J=8.5, 2.2 Hz), 7.03 (1H, d, J=2.7 Hz), 6.98 (1H, d, J=8.3 Hz),
6.11 (2H, s). MS (ES+): m/e 310 (20), 309 (100). MS (ES-): m/e 308
(10), 307 (100).
[0684] Compound 96
[0685] 3-[1-(4-Fluoro-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
245-246.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.57 (1H, d, J=2.5 Hz), 8.47 (1H, t, J=1.8 Hz), 8.14 (1H, dt,
J=7.7, 1.5 Hz), 7.91-7.88 (3H, m), 7.57 (1H, t, J=7.7 Hz), 7.36
(2H, t, J=8.8 Hz), 7.11 (1H, d, J=2.5 Hz). MS (ES+): m/e 284 (20),
283 (100). MS (ES-): m/e 282 (20), 281 (100).
[0686] Compound 4
[0687] 3-[1-(4-Isopropyl-phenyl)-1H-pyrazol-3-yl]-benzoic acid:
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.62 (1H, s), 8.21 (1H,
d, J=8 Hz), 8.08 (1H, d, J=8 Hz), 7.95 (1H, d, J=2 Hz), 7.69 (2H,
d, J=8 Hz), 7.55 (1H, t, J=8 Hz), 7.33 (2H, d, J=8 Hz), 6.84 (1H,
d, J=2 Hz), 2.97 (1 heptet, J=7 Hz), 1.27 (6H, d, J=7 Hz). MS
(ES+): m/e 308 (22), 307 (100).
[0688] The following compounds may be prepared by copper
iodide-catalyzed cross-coupling of a
3-(carbomethoxyphenyl)-1H-pyrazole with an aryl iodide reagent,
followed by hydrolysis of the methyl ester, as described elsewhere
in this invention:
[0689] Compound 160
[0690] 4-[1-(3-Methoxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
190-191.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.99 (1H, br), 8.63 (1H, d, J=2.6 Hz), 8.05 (2H, d, J=8.5 Hz),
7.99 (2H, d, J=8.5 Hz), 7.53-7.48 (2H, m), 7.42 (1H, t, J=7.9 Hz),
7.14 (1H, d, J=2.6 Hz), 6.90 (1H, ddd, J=8, 2.2, 1.2 Hz), 3.84 (3H,
s). MS (ES+): m/e 296 (21), 295 (100).
[0691] Compound 164
[0692] 3-[1-(3-Dimethylamino-phenyl)-1H-pyrazol-3-yl]-benzoic acid:
m.p. 180-183.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.56 (1H, d, J=2.7 Hz), 8.44 (1H, t, J=1.7 Hz), 8.13 (1H,
dt, J=7.9, 1.5 Hz), 7.90 (1H, dt, J=7.7, 1.5 Hz) 7.56 (1H, t, J=7.8
Hz), 7.28 (1H, t, J=8.5 Hz), 7.16 (1H, s), 7.16-7.13 (1H, m), 7.07
(1H, d, J=2.5 Hz), 6.68-6.64 (1H, m), 2.97 (6H, s). MS (ES+): m/e
309 (20), 308 (100). MS (ES-): m/e 307 (15), 306 (100).
[0693] Compound 165
[0694] 3-[1-(3-Bromo-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
180-183.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.68 (1H, d, J=2.5 Hz), 8.47 (1H, s), 8.18-8.15 (2H, m) 7.98-7.90
(2H, m), 7.58 (1H, t, J=7.7 Hz), 7.54-7.44 (2H, m), 7.16 (1H, d,
J=2.5 Hz). MS (ES+): m/e 345 (100), 343 (95). MS (ES-): m/e 343
(98), 341 (100).
[0695] Compound 166
[0696] 3-(1-p-Tolyl-1H-pyrazol-3-yl)-benzoic acid: m.p.
192-193.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): 8.54 (1H,
d, J=2.5 Hz), 8.47 (1H, t, J=2 Hz), 8.13 (1H, dm, J=7.7 Hz), 7.90
(1H, dm, J=8.0 Hz), 7.80 (2H, d, J=8.3 Hz), 7.57 (1H, t, J=7.7 Hz),
7.32 (2H, d, J=8.5 Hz), 7.09 (1H, d, J=2.5 Hz), 2.34 (3H, s). MS
(ES+): m/e 280 (20), 279 (100). MS (ES-): m/e 278 (20), 277
(100).
[0697] Compound 167
[0698] 3-(1-m-Tolyl-1H-pyrazol-3-yl)-benzoic acid: m.p.
162-164.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.56 (1H, d, J=2.5 Hz), 8.47 (1H, t, J=2 Hz), 8.14 (1H, d, J=7.7
Hz), 7.91 (1H, d, J=8.0 Hz), 7.76 (1H, s), 7.70 (1H, d, J=8.0 Hz),
7.57 (1H, t, J=7.7 Hz), 7.39 (1H, t, J=7.8 Hz), 7.13 (1H, d, J=7.2
Hz), 7.10 (1H, d, J=2.5 Hz), 2.40 (3H, s). MS (ES+): m/e 280 (23),
279 (100). MS (ES-): m/e 278 (20), 277 (100).
[0699] Compound 168
[0700] 3-[1-(4-Nitro-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
280-281.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.83 (1H, d, J=2.7 Hz), 8.52 (1H, s), 8.39 (2H, d, J=9.3 Hz), 8.22
(2H, d, J=9.3 Hz), 8.18 (1H, d, J=8 Hz), 7.95 (1H, d, J=8.0 Hz),
7.60 (1H, t, J 8 Hz), 7.27 (1H, d, J=2.5 Hz). MS (ES+): m/e 311
(30), 310 (100). MS (ES-): m/e 309 (20), 308 (100).
[0701] Compound 175
[0702] 3-[1-(3-Benzyloxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid:
m.p. 152-153.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.61 (1H, d, J=2.7 Hz), 8.47 (1H, t, J=1.6 Hz), 8.15 (1H,
dt, J=7.7, 1.2 Hz), 7.91 (1H, dt, J=7.7, 1.2 Hz), 7.60-7.30 (9H,
m), 7.12 (1H, d, J=2.7 Hz), 6.97 (1H, dd, J=7.7, 2.2 Hz), 5.20 (2H,
s). MS (ES+): m/e 372 (25), 371 (100). MS (ES-): m/e 370 (20), 369
(100).
[0703] Compound 176
[0704] 3-[1-(4-Benzyloxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid:
m.p. 210-212.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.47 (1H, d, J=2.5 Hz), 8.45 (1H, t, J=1.8 Hz), 8.12 (1H,
dt, J=7.9, 1.3 Hz), 7.89 (1H, dt, J=7.7, 1.3 Hz), 7.82 (2H, d,
J=9.1 Hz), 7.56 (1H, t, J=7.8 Hz), 7.49-7.30 (5H, m), 7.15 (2H, d,
J=9.1 Hz), 7.07 (1H, d, J=2.5 Hz), 5.15 (2H, s). MS (ES+): m/e 372
(20), 371 (100). MS (ES-): m/e 370 (25), 369 (100).
[0705] Compound 217
[0706] 4-[1-(4-Methoxy-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
252-253.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.49 (1H, d, J=2.5 Hz), 8.03 (2H, d, J=8.7 Hz), 7.99 (2H, d, J=8.7
Hz), 7.2 (2H, d, J=9.0 Hz), 7.09 (1H, d, J=2.5 Hz), 7.07 (2H, d,
J=9.0 Hz), 3.79 (3H, s). MS (ES+): m/e 296 (20), 295 (100). MS
(ES-): m/e 294 (20), 293 (100).
[0707] Compound 218
[0708] 4-[1-(4-Trifluoromethoxy-phenyl)-1H-pyrazol-3-yl]-benzoic
acid: m.p. 214-215.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.66 (1H, d, J=2.5 Hz), 8.06-8.01 (6H, m), 7.54 (2H, d,
J=8.5 Hz), 7.18 (1H, d, J=2.5 Hz). MS (ES+): m/e 350 (20), 349
(100). MS (ES-): m/e 348 (20), 347 (100).
[0709] Compound 255
[0710] 3-[1-(4-Acetyl-phenyl)-1H-pyrazol-pyrazol-3-yl]-benzoic
acid: m.p. 215-216.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 12.99 (1H, br), 8.75 (1H, d, J=2.6 Hz), 8.50 (1H, t, J=1.6
Hz), 8.17 (1H, d, J=8.2, 1.5 Hz), 8.10 (2H, d, J=93 Hz), 8.07 (2H,
d, J=9.3 Hz), 7.93 (1H, dt, J=7.9, 1.5 Hz), 7.59 (1H, t, J=7.9 Hz),
7.20 (1H, d, J=2.6 Hz), 2.60 (3H, s). MS (ES+): m/e 308 (19) 307
(100). MS (ES-): m/e 306 (20), 305 (100).
[0711] Compound 256
[0712] 4-[1-(4-Acetyl-phenyl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
278-279.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.00 (1H, br), 876 (1H, d, J=2.6 Hz), 8.10 (2H, d, J=9.3 Hz), 8.08
(2H, d, J=9.3 Hz), 8.07 (2H, d, J=8.8 Hz), 8.01 (2H, d, J=8.8 Hz),
7.22 (1H, d, J=2.6 Hz), 2.60 (3H, s). MS (ES+): m/e 308 (23), 307
(100). MS (ES-): m/e 306 (20), 305 (100).
[0713] Compound 257
[0714] 4-[1-(1H-Indol-5-yl)-1H-pyrazol-3-yl]-benzoic acid: m.p.
281-282.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.90 (1H, br), 11.27 (1H, br), 8.49 (1H, d, J=2.6 Hz), 8.04 (2H,
d, J=8.8 Hz), 8.03-8.00 (1H, m), 7.99 (2H, d, J=8.8 Hz), 7.64 (1H,
dd, J=8.8, 2.3 Hz), 7.50 (1H, d, J=8.8 Hz), 7.44 (1H, t, J=2.8 Hz),
7.08 (1H, d, J=2.6 Hz), 6.52-6.49 (1H, m). MS (ES+): m/e 305 (19),
304 (100). MS (ES-): m/e 303 (22), 302 (100).
[0715] Compound 258
[0716] 3(1-Thiophen-2-yl-1H-pyrazol-3-yl)-benzoic acid: m.p.
198-199.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.12 (1H, br), 8.48 (1H, d, J=2.4 Hz), 8.42 (1H, s), 8.09 (1H, d,
J=7.6 Hz), 7.91 (1H, d, J=7.9 Hz), 757 (1H, t, J=7.9 Hz), 7.36 (1H,
dd, J=3.8, 1.1 Hz), 7.31 (1H, d, J=5.2 Hz), 7.11 (1H, d, J=2.4 Hz),
7.03 (1H, dd, J=5.2, 3.8 Hz). MS (ES+): m/e 273 (8), 272 (21), 271
(100). MS (ES-): m/e 271 (6), 270 (16), 269 (100).
[0717] Compound 259
[0718] 4-(1-Thiophen-2-yl-1H-pyrazol-3-yl)-benzoic acid: m.p.
200-202.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.97 (1H, 1w), 8.50 (1H, d, J=2.6 Hz), 8.00 (2H, d, J=9.3 Hz),
7.97 (2H, d, J=9.3 Hz), 7.38 (1H, dd, J=3.8, 1.4 Hz), 7.32 (1H, dd,
J=5.6, 1.5 Hz), 7.13 (1H, d, J=2.6 Hz), 7.03 (1H, dd, J=5.6, 3.8
Hz). MS (ES+): m/e 273 (5), 272 (15), 271 (100). MS (ES-): m/e 271
(5), 270 (16), 269 (100).
[0719] Compound 260
[0720] 3-(1-Pyridin-3-yl-1H-pyrazol-3-yl)-benzoic acid: m.p.
235-236.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.12 (1H, br), 9.18 (1H, d, J=2.6 Hz), 8.69 (1H, d, J=2.6 Hz),
8.53 (1H, dd, J=4.7, 1.2 Hz) 8.49 (1H, t, J=1.6 Hz), 8.31 (1H, ddd,
J=8.5, 2.6, 1.5 Hz), 8.17 (1H, d, J=8.2, 1.6 Hz), 7.93 (1H, dt,
J=7.9, 1.6 Hz), 7.59 (1H, t, J=7.9 Hz), 7.56 (1H, ddd, J=8.2, 4.7,
0.6 Hz), 7.19 (1H, d, J=2.6 Hz). MS (ES+): m/e 267 (34), 266 (100).
MS (ES-): m/e 265 (17), 264 (100).
[0721] Compound 261
[0722] 4-(1-Pyridin-3-yl-1H-pyrazol-3-yl)-benzoic acid: m.p.
280-282.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
12.99 (1H, br), 9.21 (1H, br), 8.71 (1H, d, J=2.6 Hz), 8.56 (1H,
br), 8.32 (1H, br d, J=9.0 Hz), 8.07 (2H, d, J=8.8 Hz), 8.01 (2H,
d, J=8.8 Hz), 7.60-7.55 (1H, br m), 7.21 (2H, d, J=2.6 Hz). MS
(ES+): m/e 267 (30), 266 (100). MS (ES-): m/e 265 (20), 264
(100).
[0723] F. Preparation of 4,1-Pyrazoles
[0724] 4,1-pyrazoles of the invention may be prepared as
follows.
Preparation of
6-[1-(4-Methoxy-phenyl)-1H-pyrazol-4-yl]-pyridine-2-carboxylic acid
(Compound 53)
[0725] A solution of 6-(diformylmethyl)-pyridin-2-carboxylic acid
(315 mg, 1.63 mmol), 4-methoxyphenylhydrazine hydrochloride (285
mg, 1.63 mmol) and sodium acetate (134 mg, 1.63 mmol) in acetic
acid (5 mL) is heated to 110.degree. C. for 18 h. After being
allowed to cool, the solution is filtered. The solid product is
washed with ethyl acetate and diethyl ether, and dried under vacuum
to afford the title product (294 mg, 0.99 mmol, 61%) as a beige
powder. m.p. 122-123.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 9.11 (1H, s), 8.38 (1H, s), 7.99 (2H, d,
J=4.7 Hz), 7.86 (1H, t, J=4.4 Hz), 7.80 (2 d, J=9.1 Hz), 7.08 (2H,
d, J=9.1 Hz), 3.80 (3H, s), 1H missing. MS (ES+): m/e 297 (18), 296
(100). MS (ES-): m/e 295 (14), 294 (100).
[0726] The procedure above may be slightly modified to prepare the
following compounds.
[0727] Compound 54
[0728]
6-[1-(4-Chloro-phenyl)-1H-pyrazol-4-yl]-pyridine-2-carboxylic acid:
m.p. 194-196.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.25 (1H, s), 8.45 (1H, s), 8.01-7.86 (5H, m), 7.59 (2H, d,
J=8.5 Hz), 1H missing. MS (ES+): m/e 302 (36), 301 (16), 300 (100).
MS (ES-): m/e 300 (36), 299 (16), 298 (100).
[0729] Compound 55
[0730] 3-[1-(4-Methoxy-phenyl)-1H-pyrazol-4-yl]-4-nitro-benzoic
acid: m.p. 249-250.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.68 (1H, H br s), 8.81 (1H, s), 8.20 (1H, s), 8.02 (2H,
s), 7.79 (2H, d, J=9.1 Hz), 7.79 (1H, s), 7.06 (2H, d, J=9.1 Hz),
3.79 (3H, s). MS (ES+): m/e 341 (20), 340 (100). MS (ES-): m/e 339
(21), 338 (100).
[0731] Compound 56
[0732] 3-[1-(4-Chlorphenyl)-1H-pyrazol-4-yl]-4-nitro-benzoic acid:
m.p. 270-271.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.70 (1H, br s), 8.96 (1H, s), 8.20 (1H, s), 8.03 (2H, s),
7.92 (2H, d, J=8.8 Hz), 7.86 (1H, s), 7.57 (2H, d, J=8.8 Hz). MS
(ES+): m/e 346 (37), 345 (14), 344 (100). MS (ES-): m/e 344 (42),
343 (15), 342 (100).
Preparation of 3-[1-(4-Chloro-phenyl)-1H-pyrazol-4-yl]-benzoic acid
(Compound 83)
[0733] Part A.
[0734] A solution of 4-chlorophenylhydrazine hydrochloride (2.02 g,
11.3 mmol), 1,1,3,3-tetramethoxypropane (2.00 mL, 12.1 mmol) and
sodium acetate (1.00 g, 12.2 mmol) in acetic acid (25 mL) is heated
to gentle reflux overnight. The solution is cooled and poured into
water (125 mL). Solid sodium bicarbonate is added in portions until
the pH of the mixture is slightly basic. This is then extracted
twice with ethyl acetate (125 mL), and the extracts are washed with
brine, combined, dried over anhydrous magnesium sulfate, filtered
and evaporated to afford 1-(4-chlorophenyl)pyrazol in two crops
(1.13 g+0.24 g, 7.65 mmol, 68%). m.p. 50-53.degree. C. TLC R.sub.F
0.19 (10:90 ethyl acetate-hexane). .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 7.89 (1H, dd, J=2.4, 0.6 Hz), 7.72 (1H, d,
J=1.5 Hz), 7.64 (2H, d, J=8.7 Hz), 7.42 (2H, d, J=8.7 Hz), 6.47
(1H, dd, J=2.4, 1.8 Hz). MS (ES+): m/e 182 (3), 181 (34), 180(6),
179 (100).
[0735] Part B.
[0736] A solution of 1(4-chlorophenyl)pyrazole (834 mg, 4.67 mmol)
in acetic acid (10 mL) is treated with bromine (0.26 mL, 5.08
mmol). After stirring for 18 h. the solution is diluted with 40 mL
water, and satd. aq. NaHSO.sub.3 solution is added until the
bromine color had dissipated. Then, solid sodium bicarbonate is
added until a neutral pH is obtained. This mixture is extracted
with ethyl acetate (2.times.50 mL), and the extracts are washed
with brine, combined, dried over MgSO.sub.4, filtered and
evaporated. The solid residue is recrystallized from cyclohexane to
afford pure product, 4-bromo-1-(4-chlorophenyl)-pyrazole (797 mg,
3.10 mmol, 66%). m.p. 75-76.degree. C. (cyclohexane). .sup.1H NMR
(300 MHz, CDCl.sub.3): .delta. 7.89 (1H, s), 7.66 (1H, s), 7.57
(2H, d, J=9.0 Hz), 7.41 (2H, d, J=9.0 Hz). MS (ES+): m/e 261 (26),
259 (100), 257 (77).
[0737] Part C.
[0738] A solution of 4-bromo-1-(4-chlorophenyl)-pyrazole (422 mg,
1.64 mmol), 3-carboxybenzeneboronic acid (326 mg, 1.96 mmol),
palladium acetate (20 mg, 0.089 mmol), triphenylphosphine (93 mg,
0.355 mmol) and sq. Na.sub.2CO.sub.3 solution (2.50 mL, 2.0 M, 5.00
mmol) in dimethoxyethane (25 mL) is degassed by three cycles of
vacuum pumping/nitrogen purging. The solution is then heated to
reflux for 18 h. The resulting black mixture is allowed to cool,
filtered through celite and poured into 120 mL HCl (0.5 N). This is
extracted with ethyl acetate (2.times.120 mL), and the extracts we
washed with brine, combined, dried over MgSO.sub.4, filtered and
partially evaporated. A small amount (50 mg) of a solid product is
collected by filtration, which is pure title product by
spectroscopic analysis. m.p. 205-206.degree. C. .sup.1H NMR (300
MHz, acetone-d.sub.6): .delta. 9.03 (1H, s), 8.32 (1H, t, J=1.6
Hz), 8.26 (1H, s), 8.01 (2H, d, J=9.0 Hz), 7.97-7.87 (2H, m), 7.56
(2H, d, J=9.0 Hz), 7.53 (1H, t, J=8.2 Hz), 1H missing. MS (ES+):
m/e 302 (4), 301 (31), 300 (19), 299 (100). MS (ES-): m/r 300 (2),
299 (31), 298 (23), 297 (100).
[0739] The procedure above may be slightly modified to prepare the
following compounds.
[0740] Compound 97
[0741] 3-[1-(4-Methoxy-phenyl)-1H-pyrazol-4yl]-benzoic acid: m.p.
223-225.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
13.07 (1H, s), 9.01 (1H, s), 8.24 (1H, s), 8.22 (1H, s), 7.94 (1H,
d, J=7.6 z), 7.82 (2H, d, J=9.9 Hz), 7.81 (1H, d, J=7.8 Hz), 7.52
(1H, t, J=7.7 Hz), 7.06 (2H d, J=9.9 Hz), 3.79 (3H, s). MS (ES+):
m/e 296 (19), 295 (100). MS (ES-): m/e 294 (17), 293 (100).
[0742] Compound 133
[0743]
3-(.parallel.-(4-Trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 213-215.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.18 (1H, s), 8.32 (1H, s), 8.26 (1H, s), 7.99 (3H, m),
7.81 (1H, d, J=6.3 Hz), 7.53 (3H, m). MS (ES+): m/e 350 (20), 349
(100). MS (ES-): m/e 348 (20), 347 (100).
[0744] Compound 134
[0745] 4-[1-(4-Trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 246-248.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.18 (1H, s), 8.35 (1H, s), 8.01 (2H, d, J=8.9 Hz), 7.96
(2H, d, J=8.2 Hz), 7.83 (2H, d, J=8.2 Hz), 7.55 (2H, d, J=8.9 Hz).
MS (ES+): m/r 350 (20), 349 (100). MS (ES-): m/e 348 (20), 347
(100).
[0746] Compound 171
[0747] 4-[1-(3-Methoxy-phenyl)-1H-pyrazol-4-yl]-benzoic acid: m.p.
211-212.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.16 (1H, s), 8.31 (1H, s), 7.95 (2H, d, J=8.5 Hz), 7.83 (2H, d,
J=8.5 Hz), 7.44 (3H, m), 6.90 (1H, m), 3.84 (3H, s). MS (ES+): m/e
297 (5), 296 (45), 295 (100). MS (ES-): m/e 294 (20), 293
(100).
[0748] Compound 172
[0749] 3-[1-(3-Trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 179-181.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.21 (1H, s), 8.33 (1H, s), 8.27 (1H, s), 7.95 (1H, dd,
J=8.0, 1.2 Hz), 7.80 (3H, m), 7.55 (2H, m), 7.35 (1H, s), 7.12 (1H,
m). MS (ES+): m/e 332 (60), 331 (100). MS (ES-): m/e 330 (20), 329
(100).
[0750] Compound 173
[0751] 4-[1-(3-Trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 255-257.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.20 (1H, s), 8.34 (1H, s), 7.96 (2H, d, J=8.5 Hz), 7.82
(2H, d, J=8.5 Hz), 7.77 (1H, m), 7.73 (1H, m), 7.57 (1H, m), 7.36
(1H, s), 7.14 (1H, m). MS (ES+): m/e 333 (10), 332 (60), 331 (100).
MS (ES-): m/e 330 (20), 329 (100).
[0752] Compound 174
[0753] 3-([1-(3-Methoxy-phenyl)-1H-pyrazol-4-yl]-benzoic acid: m.p.
156-157.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.15 (1H, s), 8.27 (2H, s, overlapping), 7.96 (1H, dd, J=7.7, 1.1
Hz), 7.81 (1H, dd, J=7.4, 1.1 Hz), 7.50 (3H, m), 7.43 (1H, m), 6.88
(1H, dd, J=8.0, 1.1 Hz), 3.83 (3H, s). MS (ES+): m/e 296 (20), 295
(100). MS (ES-): m/e 294 (20), 293 (100).
[0754] Compound 177
[0755] 3-(1-p-Tolyl-1H-pyrazol-4-yl)-benzoic acid: m.p.
229-231.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.07 (1H, s), 8.25 (2H, s, overlapping), 7.94 (1H, d, J=7.4 Hz),
7.78 (3H, m), 7.51 (1H, t, J=7.4 Hz), 730 (2H, d, J=8.0 Hz), 2.33
(311H, s). MS (ES+): m/280 (20), 279 (100). MS (ES-): m/e 278 (20),
277 (100).
[0756] Compound 178
[0757] 4-(1-p-Tolyl-1H-pyrazol-4-yl)-benzoic acid: m.p.
280-282.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.08 (1H, s), 8.28 (1H, s), 7.95 (2H, d, J=8.3 Hz), 7.83 (2H, d,
J=8.3 Hz), 7.77 (2H, d, J=8.6 Hz), 7.32 (2H, d, J=8.6 Hz), 2.33
(3H, s). MS (ES+): m/e 280 (20), 279 (100). MS (ES-): m/e 278 (20),
277 (100).
[0758] Compound 179
[0759] 3-[1-(2,4-Difluoro-phenyl)-1H-pyrazol-4-yl]-benzoic acid:
m.p. 200-202.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.74 (1H, d, J=1.9 Hz), 8.32 (1H, s), 821 (1H, s), 7.87
(3H, m), 7.58 (21H, m), 7.28 (1H, m). MS (ES+): m/e 302 (20), 301
(100). MS (ES-): m/e 300 (20), 299 (100).
[0760] Compound 180
[0761] 4-[1-(2,4-Difluoro-phenyl)-1H-pyrazol-4-yl]-benzoic acid:
m.p. 258-260.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.76 (1H, d, J=2.2 Hz), 8.36 (1H, s), 7.94 (2H, d, J=8.3
Hz), 7.88 (1H, m), 7.83 (2H, d, J=8.3 Hz), 7.61 (1H, m), 7.29 (1H,
m). MS (ES+): m/e 302 (20), 301 (100). MS (ES-): m/e 300 (20), 299
(100).
[0762] Compound 181
[0763] 3-[1-(4-Fluoro-phenyl)-1H-pyrazol-4-yl]-benzoic acid: m.p.
235-237.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.11 (1H, s), 8.26 (2H, d, J=6.3 Hz), 7.94 (3H, m), 7.81 (1H, d,
J=7.7 Hz), 7.52 (1H, t, J=7.7 Hz), 7.36 (2H, m). MS (ES+): m/e 284
(40), 283 (100). MS (ES-): m/e 282 (20), 281 (100).
[0764] Compound 182
[0765] 4-[1-(4-Fluo-phenyl)-1H-pyrazol-4-yl]-benzoic acid: m.p.
266-268.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.11 (1H, s), 8.31 (1H, s), 7.95 (2H, d, J=8.4 Hz), 7.92 (2H, m),
7.83 (2H, d, J=8.4 Hz), 7.38 (2H, m). MS (ES+): m/e 284 (40), 283
(100). MS (ES-): m/e 282 (20), 281 (100).
[0766] Compound 223
[0767] 3-[1-(3-Trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 143-145.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.30 (1H, s), 8.21 (1H, s), 8.03 (2H, m), 7.76 (1H, dd,
J=6.9, 1.0 Hz), 7.65 (2H, m), 7.49 (2H, m), 7.17 (1H, dd, J=8.3,
1.3 Hz). MS (ES+): m/e 350 (30), 349 (100). MS (ES-): m/e 348 (20),
347 (100).
[0768] Compound 224
[0769] 4-[1-(3-Trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 230-231.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.24 (1H, s), 7.90 (1H, s), 7.86 (2H, m), 7.53 (21. m),
7.45 (2H, m), 7.33 (1H, m), 6.98 (1H, m). MS (ES+): m/e 350 (30),
349 (100). MS (ES-): m/e 348 (20), 347 (100).
[0770] Compound 225
[0771]
3-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 201-203.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.01 (1H, s), 8.23 (1H, s), 8.20 (1H, s), 7.91 (1H, dd,
J=7.7, 1.1 Hz), 7.79 (1H, dd, J=7.4, 1.0 Hz), 7.50 (1H, t, J=7.7
Hz), 7.36 (2H, m), 6.97 (1H, d, J=8.8 Hz), 4.28 (4H, t, J=1.2 Hz).
MS (ES+): m/e 324 (20), 323 (100). MS (ES-): m/e 322 (20), 321
(100).
[0772] Compound 226
[0773]
4-[1-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 238-240.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.01 (1H, s), 8.23 (1H, s), 7.93 (2H, d, J=8.3 Hz), 7.75
(2H, d, J=8.3 Hz), 7.36 (2H, m), 6.98 (1H, d, J=8.8 Hz), 4.28 (4H,
t, J=1.9 Hz). MS (ES+): m/e 324 (20), 323 (100). MS (ES-): m/e 322
(20), 321 (100).
[0774] Compound 227
[0775] 4-(1-Benzo[1,3]dioxol-5-yl-1H-pyrazol-4-yl)-benzoic acid:
m.p. 266-268.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.00 (1H, s, 8.25 (1H, s), 7.94 (2H, d, J=8.2 Hz), 7.80
(2H, d, J=8.2 Hz), 7.47 (1H, d, J=2.2 Hz), 7.35 (1H, dd, J=8.5, 2.2
Hz), 7.04 (1H, d, J=8.5 Hz), 6.09 (2H, s). MS (ES+): m/e 310 (20),
309 (100). MS (ES-): m/e 308 (15), 307 (70), 242 (100).
[0776] Compound 228
[0777] 3-[1-(4-Isopropyl-phenyl)-1H-pyrazol-4-yl]-benzoic acid:
m.p. 212-215.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.06 (1H, s), 8.25 (1H, t, J=2.2 Hz), 8.24 (1H, s) 7.94
(1H, dd, J=7.1, 1.1 Hz), 7.81 (21H, d, J=8.6 Hz), 7.79 (1H, s),
7.51 (1H, m), 7.36 (2H, d, J=8.6 Hz), 2.91 (1H, heptet, J=6.9 Hz),
1.21 (6H, d, J=6.9 Hz). MS (ES+): m/e 308 (20), 307 (100). MS
(ES-): m/e 306 (20), 305 (100).
[0778] Compound 229
[0779] 4-[1-(4-Isopropyl-phenyl)-1H-pyrazol-4-yl]-benzoic acid:
m.p. 215-218.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.08 (1H, s), 8.28 (1H, s), 7.94 (2H, d, J=8.3 Hz), 7.83
(2H, d, J=83 Hz), 7.79 (2H, d, J=8.5 Hz), 7.38 (2H, d, J=8.5 Hz),
2.93 (1H, heptet, J=6.9 Hz), 1.21 (6H, d, J=6.9 Hz). MS (ES+): m/e
308 (20), 307 (100). MS (ES-): m/e 306 (20), 305 (100).
[0780] Compound 230
[0781] 3-[1-(3-Chloro-4-methyl-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 209-211.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.16 (1H, s), 8.33 (1H, s), 7.93 (3H, m), 7.85 (2H, m),
7.58 (21H, m), 2.31 (3H, s). MS (ES+): m/e 315 (30), 313 (100). MS
(ES-): m/e 313 (30), 311 (100), 277 (10).
[0782] Compound 231
[0783] 4-[1-(3-Chloro-4-methyl-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 285-288.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.5):
.delta. 9.17 (1H, s), 8.31 (1H, s), 7.97 (1H, s), 7.94 (2H, d,
J=8.3 Hz), 7.81 (2H, d, J=8.3 Hz), 7.77 (1H, d, J=8.5 Hz), 7.49
(1H, d, J=8.3 Hz), 2.34 (3H, s). MS (ES+): m/e 315 (30), 313 (100).
MS (ES-): m/e 313 (30), 311 (100).
[0784] Compound 232
[0785] 3-[1-(3,4-Dichloro-phenyl)-1H-pyrazol-4-yl]-benzoic acid:
m.p. 135-138.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.24 (1H, s), 8.34 (1H, s), 8.27 (1H, s), 8.23 (1H, d,
J=2.5 Hz), 7.93 (2H, m), 7.80 (2H, m), 7.51 (1H, t, J=7.7 Hz). MS
(ES+): m/e 337 (10), 335 (60), 333 (100). MS (ES-): m/e 335 (10),
333 (60), 331 (100).
[0786] Compound 233
[0787] 4-[1-(3,4-Dichloro-phenyl)-1H-pyrazol-4-yl]-benzoic acid:
m.p. 286-289.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.23 (1H, s), 8.36 (1H, s), 8.19 (1H, d, J=1.1 Hz), 7.95
(2H, d, J=7.2 Hz), 7.90 (1H, m), 7.82 (2H, d, J=7.2 Hz), 7.80 (1H,
s). MS (ES+): m/e 337 (10), 335 (50), 333 (100). MS (ES-): m/e 335
(10), 333 (60), 331 (100).
[0788] Compound 234
[0789] 4-[1-(4-Chloro-phenyl)-1H-pyrazol-4-yl]-benzoic acid: m.p.
259-261.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.16 (1H, s) 8.33 (1H, s), 7.95 (2H, d, J=7.6 Hz), 7.91 (2H, d,
J=8.5 Hz), 7.82 (2H, d, J=7.6 Hz), 7.58 (2H, d, J=8.5 Hz). MS
(ES+): m/e 301 (30) 299 (100). MS (ES-): m/e 299 (30), 297
(100).
[0790] Compound 235
[0791] 3-[1-(4-Trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 218-220.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.30 (1H, s), 8.38 (1H, s), 8.30 (1H, s), 8.15 (2H, d,
J=8.1 Hz), 7.96 (1H, dd, J=7.7, 1.1 Hz), 7.89 (21H, d, J=8.1 Hz),
7.83 (1H, dd, J=7.8, 1.2 Hz), 7.53 (1H, m). MS (ES+): m/e 334 (20),
333 (100). MS (ES-): m/e 332 (20), 331 (100).
[0792] Compound 236
[0793] 4-[1-(4-Trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-benzoic
acid: m.p. 271-273.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.28 (1H, s), 8.40 (1H, s), 8.10 (2H, d, J=7.7 Hz), 7.96
(2H, d, J=7.7 Hz), 7.89 (4H, m). MS (ES+): m/e 334 (20), 333 (100).
MS (ES-): m/e 332 (20), 331 (100), 287 (10).
[0794] Compound 237
[0795] 3-[1-(3,4-Dimethyl-phenyl)-1H-pyrazol-1-yl]-benzoic acid:
m.p. 196-197.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.03 (1H, s), 8.25 (1H, s), 8.22 (1H, s), 7.91 (1H, d,
J=7.4 Hz), 7.80 (1H, dd, J=7.2, 1.1 Hz), 7.72 (1H, s), 7.60 (1H,
dd, J=8.3, 2.2 Hz) 7.49 (1H, m), 7.23 (1H, d, J=8.0 Hz), 2.29 (3H,
s), 2.23 (3H, s). MS (ES+): m/e 294 (20), 293 (100). MS (ES-): m/e
292 (20), 291 (100).
[0796] Compound 238
[0797] 4-[1-(3,4-Dimethyl-phenyl)-1H-pyrazol-4-yl]-benzoic acid:
m.p. 254-256.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.05 (1H, s), 8.25 (1H, s), 7.93 (2H, d, J=6.9 Hz), 7.88
(2H, d, J=6.9 Hz), 7.68 (1H, s), 7.57 (1H, d, J=8.0 Hz), 725 (1H,
d, J=8.0 Hz), 2.28 (3H, s), 2.23 (3H, s). MS (ES+): m/e 294 (20),
293 (100). MS (ES-): m/e 292 (20), 291 (100), 247 (10).
[0798] Compound 239
[0799] 3-(1-Benzo[1,3]dioxol-5-yl-1H-pyrazol-4-yl)-benzoic acid:
m.p. 221-223.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.01 (1H, s), 8.23 (1H, t, J=1.7 Hz), 8.22 (1H, s), 7.92
(1H, d, J=7.7 Hz), 7.79 (1H, dd, J=7.7, 1.1 Hz), 7.53-7.48 (2H, m),
7.37 (1H, dd, J=8.3, 2.2 Hz), 7.03 (1H, d, J=8.3 Hz), 6.09 (2H, s).
MS (ES+): m/e 310 (20), 309 (100). MS (ES-): m/e 308 (20), 307
(100).
[0800] G. Preparation of 1,2,4-Triazoles
Preparation of
3-[1-(4-Methoxy-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid
(Compound 12)
[0801] Part A.
[0802] A solution of methyl 3-cyanobenzoate (1.06 g, 6.58 mmol) in
methanol (8 mL) is cooled to 0.degree. C., and treated dropwise
with acetyl chloride (10.0 mL, 140 mmol). The resulting mixture is
stirred for 6 h and allowed to warm to ambient temperature. The
solution is evaporated of volatile components, and the resulting
white solid is purified by washing with diethyl ether. After drying
under vacuum, the solid is used immediately in the next step.
[0803] Part B.
[0804] 4-Methoxyphenylhydrazine hydrochloride (1.30 g, 7.44 mmol)
is treated with said. aq. NaHCO.sub.3 solution (15 mL), and stirred
for 10 min. This is extracted with ethylene dichloride (2.times.20
mL), and the extracts are washed with brine, combined, dried over
MgSO.sub.4, filtered and evaporated to afford the free base as a
white powder. This is suspended in 1,4-dioxane (10 mL), and the
imidate salt prepared in Part A above is added. The resulting
solution is heated to 110.degree. C. for 3.5 h and allowed to cool.
The mixture is diluted with diethyl ether, and the resulting white
precipitate is collected by filtration and dried under vacuum to
afford methyl
3-[imino(2-(4-methoxyl)phenylhydrazino)methyl]benzoate (0.48 g,
21%). MS (ES+): m/e 300 (100).
[0805] Part C.
[0806] A solution of methyl
3-[imino(2-(4-methoxyl)phenylhydrazino)methyl]benzoate (0.28 g,
0.94 mmol) is treated with conc. sq. formic acid (3.5 mL). The
solution is heated to reflux for 12 h, cooled, poured into water,
and stirred for 1 h. A white solid (methyl
3-[1-(4-methoxy-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoat) forms,
which is collected by filtration, washed with water and hexane, and
dried under vacuum (0.22 g, 76%). MS (ES+): m/e 310.
[0807] Part D.
[0808] A mixture of methyl
3-[1-(4-methoxy-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoate (0.21 g,
6.8 mmol) and aq. NaOH solution (5 mL) in THF (5 mL) is heated to
reflux for 5 h. The solution is cooled and evaporated. and the
residue is treated with 1 N HCl until the pH is slightly acidic.
This causes the precipitation of a white solid, which is
recrystallized from ethanol/water to afford the title product (0.13
g, 65%). m.p. 230-232.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 9.26 (1H, s), 8.64 (1H, s), 8.29 (1H, d, J=8
Hz), 8.00 (1H, d, J=8 Hz), 7.84 (2H, d, J=8.8 Hz), 7.63 (1H, t, J=8
Hz), 7.12 (2H, d, J=8.8 Hz), 3.82 (3H, s). MS (ES+): m/e 297 (20),
296 (100). MS (ES-): m/e 295 (20), 294 (100).
[0809] This procedure may be used in the synthesis of the following
compounds.
[0810] Compound 8
[0811] 3-(3-Phenyl-[1,2,4]triazol-1-yl)-benzoic acid: m.p.
268-271.degree. C. .sup.1H NMR (300 MHz, acetone-d.sub.6): .delta.
9.27 (1H, s), 8.57 (1H, t, J=1.9 Hz), 826-8.19 (3H, m), 8.09 (1H,
dt, J=7.9, 1.3 Hz), 7.75 (1H, t, J=7.9 Hz), 7.54-7.43 (3H, m). MS
(ES+): m/e 267 (18), 266 (100). MS (ES-): m/e 265 (17), 264 (100).
Analysis calculated for
C.sub.15H.sub.11N.sub.3O.sub.2.1.52H.sub.2O: C, 61.57; H, 4.83; N,
14.36. found: C, 62.79; H, 4.27; N, 13.00.
[0812] Compound 9
[0813] 3-[3-(4-Hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid:
m.p. 307-311.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.41 (1H, s), 8.41 (1H, s), 8.16 (1H, dd, J=7.9, 2.0 Hz),
7.95-7.84 (3H, m), 7.68 (1H, t, J=7.9 Hz), 6.87 (2H, d, J=8.5 Hz).
MS (ES+): m/e 283 (18), 282 (100). MS (ES-): m/e 281 (18), 280
(100). Analysis calculated for
C.sub.15H.sub.11N.sub.3O.sub.3.2.03H.sub.2O: C, 56.69; H, 4.78; N,
13.22. found: C, 56.38; H, 3.66; N, 13.02.
[0814] Compound 10
[0815] 3-[3-(4-Benzyloxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid:
m.p. 259-261.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.37 (1H, br s), 9.42 (1H, s), 8.42 (1H, s), 8.16 (1H,
ddd, J=8.1, 2.3, 1.2 Hz), 8.03 (2H, d, J=9.2 Hz), 7.95 (1H, dt,
J=7.9, 1.0 Hz), 7.69 (1H, t, J=7.8 Hz), 7.48-7.32 (5H, m), 7.13
(2H, d, J=9.2 Hz), 5.16 (2H, s). MS (ES+): m/e 373 (21), 372 (100).
MS (ES-): m/e 371 (23), 370 (100). Analysis calculated for
C.sub.22H.sub.17N.sub.3O.sub.3.0.18H.sub.2O: C, 70.54; H, 4.67; N,
11.22. found: C, 70.55; H, 4.46; N, 11.07.
[0816] Compound 11
[0817] 3-[3-(4-Methoxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid:
m.p. 268-270.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 13.36 (1H, brs), 9.42 (1H, s), 8.42 (1H, s), 8.17 (1H, dt,
J=8.1, 1.1 Hz), 8.03 (2H, d, J=8.2 Hz), 7.94 (1H, dd, J=7.8, 1.1
Hz), 7.69 (1H, t, J=7.6 Hz), 7.05 (2H, d, J=8.2 Hz), 3.81 (3H, s).
MS (ES+): r/c 297 (23), 296 (100). MS (ES-): m/e 295 (17), 294
(100). Analysis calculated for
C.sub.16H.sub.13N.sub.3O.sub.3.0.17H.sub.2O: C, 64.42; H, 4.51; N,
14.08. found: C, 64.69; H, 4.43; N, 13.77.
[0818] Compound 13
[0819] 3-[1-(4-Fluoro-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p.>310.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.31 (1H, s), 8.60 (1H, s), 8.25 (1H, d, J=6.6 Hz), 8.00-7.90 (31H,
m), 7.59 (1H, t, J=7.5 Hz), 7.42-7.36 (2H, m). MS (ES+): m/e 285
(25), 284 (100). MS (ES-): m/e 283 (20), 282 (100).
[0820] Compound 14
[0821] 3-(1-p-Tolyl-1I-[1,2,4]triazol-3-yl)-benzoic acid: m.p.
263-265.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.26 (1H, d), 8.57 (1H), 8.21 (1H), 7.91 (1H), 7.73 (1H), 7.55 (1H,
d), 7.29 (2H), 2.30 (3H, s). MS (ES+): m/e 281 (25), 280 (100). MS
(ES-): m/e 279 (20), 278 (100).
[0822] Compound 16
[0823] 3-[1-(2,4-Difluoro-phenyl)-1-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 290-292.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.09 (1H, t, J=1.9 Hz), 8.63 (1H, d, J=1.4 Hz), 8.28 (1H,
d, J=6.3 Hz), 8.03-7.90 (2H, m), 7.71-7.61 (2H, m), 7.34 (1H, t,
J=7 Hz). MS (ES+): m/e 303 (20), 302 (100). MS (ES-): m/e 301 (20),
300 (100).
[0824] Compound 15
[0825] 3-[1-(4-Isopropyl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 173-175.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.25 (1H), 8.58 (1H), 8.22 (1H), 7.92 (1H), 7.75 (2H), 7.56
(1H), 7.34 (2H), 2.89 (1H), 1.15 (6H). MS (ES+): m/e 309 (40), 308
(100). MS (ES-): m/e 307 (20), 306 (100).
[0826] Compound 17
[0827] 3-[1-(2-Fluoro-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p. 239-241.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.12 (1H, s), 8.66 (1H, s), 8.31 (1H, d, J=7.4 Hz), 8.03
(1H, d, J=7.1 Hz), 7.91 (1H, t, J=7.5 Hz), 7.64 (1H, t, J=7.7 Hz),
7.60-7.50 (2H, m), 7.43 (1H, br). MS (ES+): m/e 285 (20), 284
(100). MS (ES-): m/e 283 (20), 282 (100).
[0828] Compound 18
[0829]
3-[1-(4-Trifluoromethyl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 141-143.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.55 (1H, s), 8.67 (1H, s), 8.32 (1H, d, J=7.7 Hz), 8.19
(2H, d, J=8.5 Hz), 8.02 (1H, d, J=7.7 Hz), 7.95 (21H, d, J=8.5 Hz),
7.65 (1H, t, J=7.7 Hz). MS (ES+): m/e 335 (20), 334 (100). MS
(ES-): m/e 333 (20), 332 (100).
[0830] Compound 19
[0831]
3-[1-(4-Trifluoromethoxy-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 219-221.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.43 (1H, s), 8.66 (1H, s), 8.28 (1H, d, J=7.4 Hz),
8.13-8.00 (3H, m), 7.67-7.58 (3H, m). MS (ES+): m/e 351 (15), 350
(100). MS (ES-): m/e 349 (15), 348 (100).
[0832] Compound 20
[0833]
3-[1-(3,5-Bis-trifluoromethyl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzo-
ic acid: m.p. 271-273.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 9.68 (1H, s), 8.65 (1H, s), 8.62 (2H, s),
8.34 (1H, d, J=7.7 Hz), 8.16 (1H, s), 8.02 (1H, d, J=7.7 Hz), 7.63
(1H, t, J=7.7 Hz). MS (ES+): m/e 403 (25), 402 (100).
[0834] Compound 21
[0835] 3-[1-(2-Ethyl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p. 176-178.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.96 (1H, s), 8.64 (1H, s), 8.28 (1H, dd, J=7.7, 1.1 Hz),
8.01 (1H, dd, J=7.7, 1.1 Hz), 7.63 (1H, t, J=7.7 Hz), 7.52-7.40
(4H, m), 2.55 (2H, q, J=7.7 Hz), 1.06 (3H, t, J=7.7 Hz). MS (ES+):
m/e 295 (30), 294 (100).
[0836] Compound 22
[0837] 3-[1-(4-Bromo-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p.>310.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.39 (1H, s), 8.65 (1H, s), 8.03-7.93 (4H, m), 7.76 (2H, d, J=8.2
Hz), 7.40 (1H, t, J=7.3 Hz). MS (ES+); awe 347 (15), 346 (100), 345
(15), 344 (100).
[0838] Compound 23
[0839] 3-[1-(4-Nitro-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p. 284-286.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.41 (1H, s), 8.65 (1H, s), 8.31 (1H, d, J=7.7 Hz),
8.30-8.25 (1H, m), 8.05-7.95 (2H, m), 7.70-7.60 (3H, m). MS (ES+):
m/e 312 (20), 311 (100).
[0840] Compound 25
[0841]
3-[1-(3-Chloro-4-fluoro-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 270-272.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.42 (1H, s), 8.65 (1H, s), 8.31 (1H, dd, J=7.7, 1.1 Hz),
8.25-8.22 (1H, m), 8.04-7.95 (2H, m), 7.68-7.61 (2H, m). MS (ES+):
m/e 320 (35), 318 (100).
[0842] Compound 29
[0843] 3-[1-(3-Fluoro-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p. 266-268.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.45 (1H, s), 8.66 (1H, s), 831 (1H, d, J=7.8 Hz), 8.02
(1H, d, J=7.6 Hz), 7.89-7.80 (2H, m), 7.66-7.58 (2H, m), 7.28 (1H,
t, J=8.3 Hz). MS (ES-): m/e 285 (20), 284 (100).
[0844] Compound 30
[0845] 3-[1-(2-Bromo-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p. 245-247.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.04 (1H, s), 8.62 (1H, d, J=1.2 Hz), 8.27 (1H, dd, J=7.8,
1.2 Hz), 8.00 (1H, dd, J=7.8, 13 Hz), 7.90 (1H, dt, J=8.0, 2.2 Hz),
7.74-7.49 (4H, m). MS (ES+): m/e 347 (20), 346 (100), 345 (20) 344
(100).
[0846] Compound 31
[0847] 4-[3-(3-Carboxy-phenyl)[1,2,4]triazol-1-yl]-benzoic acid:
m.p.>300.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.53 (1H, s), 8.67 (1H, s), 8.32 (1H, d, J=7.6 Hz), 8.10 (4H, s),
8.02 (1H, d, J=7.6 Hz), 7.65 (1H, t, J=7.6 Hz). MS (ES+): m/e 311
(20), 310 (100).
[0848] Compound 35
[0849] 3-[1-(3-Bromo-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic acid:
m.p. 253-255.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.48 (1H, s), 8.67 (1H, s), 8.33 (1H, d, J=7.8 Hz), 8.22
(1H, s), 8.05-7.97 (21H, m), 7.68-7.62 (2H, m), 7.54 (1H, t, J=7.8
Hz). MS (ES+): m/e 347 (20), 346 (100), 345 (20), 344 (100). MS
(ES-): m/e 345 (15), 344 (95), 343 (15), 342 (100).
[0850] Compound 36
[0851] 3-(1-Pyridin-2-yl-1H-[1,2,4]triazol-3-yl)-benzoic acid: m.p.
241-244.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.47 (1H, s), 8.68 (1H, s), 8.56 (1H, br), 8.34 (1H, d, J=7.3 Hz),
8.10-7.98 (3H, m), 7.66 (1H, t, J=7.3 Hz), 7.50 (1H, br). MS (ES+):
m/e 268 (25), 267 (100). MS (ES-): m/e 266 (20), 265 (100).
[0852] Compound 37
[0853] 3-(1-Phenyl-1H-[1,2,4]triazol-3-yl)-benzoic acid: m.p.
257-259.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.41 (1H, s), 8.68 (1H, s), 8.33 (1H, d, J=7.6 Hz), 8.03 (1H, d,
J=7.6 Hz), 8.01-7.93 (2H, m), 7.68-7.55 (3H, m), 7.44 (1H, t, J=7.1
Hz). MS (ES+): m/e 267 (25), 266 (100). MS (ES-): m/e 265 (20) 264
(100).
[0854] Compound 38
[0855]
3-[1-(3-Chloro-4-methyl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 269-272.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.43 (1H, s), 8.66 (1H, s), 8.32 (1H, d, J=6.8 Hz), 8.06
(1H, s), 8.02 (1H, d, J=7.5 Hz), 7.85 (1H, t, J=7.6 Hz), 7.65 (1H,
t J=7.5 Hz), 7.57 (1H, d, J=8.5 Hz), 2.39 (3H, s). MS (ES+): m/e
314 (100). MS (ES-): m/e 312 (100).
[0856] Compound 39
[0857] 3-(1-m-Tolyl-1H-[1,2,4]triazol-3-yl)-benzoic acid: m.p.
223-225.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.37 (1H, s), 8.66 (1H, s), 8.31 (1H, d, J=7.5 Hz), 8.01 (1H, d,
J=7.5 Hz) 7.78 (1H, s), 7.73 (1H, d, J=8.3 Hz), 7.64 (1H, t, J=7.5
Hz), 7.45 (1H, t, J=7.8 Hz), 7.24 (1H, d, J=7.5 Hz), 2.41 (31H, s).
MS (ES+): m/e 281 (30), 280 (100). MS (ES-): m/e 279 (20), 278
(100).
[0858] Compound 40
[0859] 3-(1-o-Tolyl-1H-[1,2,4]triazol-3-yl)-benzoic acid: m.p.
209-211.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.98 (1H, s), 8.64 (1H, s), 8.29 (1E, d, J=7.3 Hz), 8.01 (1H, d,
J=7.3 Hz), 7.63 (1H, 1, J=7.3 Hz), 7.53-7.41 (4H, m), 2.27 (3H, s).
MS (ES+): m/e 280 (100).
[0860] Compound 45
[0861] 4-[1-(3-Methoxy-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 203-205.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.43 (1H, s), 8.21 (2H, d, J=8 Hz), 8.06, 2H, d, J=8 Hz),
7.51-7.47 (3H, m), 7.02-6.99 (1H, m), 3.85 (3H, s). MS (ES+): m/e
297 (20), 296 (100). MS (ES-): m/e 295 (20), 294 (100).
Preparation of 3-(1-Biphenyl-4-yl-1H-[1,2,4]triazol-3-yl)-benzoic
acid (Compound 24)
[0862] A 10 mL glass tube with a stirbar is charged with methyl
3-[1-(4-bromo-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoate (265 mg,
0.74 mmol), benzeneboronic acid (90.2 mg, 0.74 mmol), sodium
carbonate (235 mg), tetrabutylammonium iodide (273 mg). palladium
acetate (0.8 mg) and 6 mL water. The vessel is sealed and placed
into the reaction cavity of a microwave reactor. The reaction is
performed with 60 W power at 150.degree. C. with monitoring by
LC/MS. After the reaction is determined to be complete, the mixture
is filtered through celite and acidified using 1N HCl until the pH
of the medium is less than 7. The resulting solid is collected by
filtration and recrystallized to purity from THF-hexane to afford
the title product (200 mg, 79%) as a white powder, m.p.
263-265.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
9.47 (1H, s), 8.69 (1H, s), 8.34 (1H, d, J=7.5 Hz), 8.05-739 (11H,
m). MS (ES+): m/e 343 (30), 342 (100).
[0863] The following examples may be prepared using the above
procedure, slightly modified as necessary.
[0864] Compound 26
[0865]
3-[1-(4-Benzofuran-2-yl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 293-295.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.50 (1H, s), 8.69 (R.sub.1Hz), 8.34 (1H, d, J=7.8 Hz),
8.14-7.99 (4H, m), 7.66 (2H, t, J=7.8 Hz), 7.56 (1H, s), 7.36-7.24
(4H, m). MS (ES+): m/e 383 (25), 382 (100).
[0866] Compound 27
[0867]
3-[1-(4'-Methoxy-biphenyl-4-yl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 243-246.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.44 (1H, s), 8.68 (1H, s), 8.29 (1H, d, J=7.5 Hz), 8.01
(1H, d, J=7.7 Hz), 7.99 (2H, d, J=8.8 Hz), 7.82 (2H, d, J=8.8 Hz),
7.68 (2H, d, J=8.8 Hz), 7.61 (1H, t, J=7.7 Hz), 7.04 (2H, d, J=8.8
Hz), 3.80 (3H, s). MS (ES+): m/e 373 (30), 372 (100).
[0868] Compound 28
[0869]
3-[1-(4'-Isopropyl-biphenyl-4-yl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 225-228.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.44 (1H, s), 8.69 (1H, s), 8.26 (1H, d, J=7.3 Hz), 8.01
(2H, d, J=8.0 Hz), 8.00 (1H, obscured), 7.84 (2H, d, J=8.5 Hz),
7.64 (2H, d, J=8.1 Hz), 7.62 (1H, t, J=7.7 Hz), 7.34 (2H, d, J=7.8
Hz), 2.95 (1H, heptet, J=6.6 Hz), 1.22 (6H, d, J=6.6 Hz). MS (ES+):
m/e 385 (25), 384 (100).
[0870] Compound 32
[0871]
3-[1-(4'-Fluoro-biphenyl-4-yl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 272-275.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.46 (1H, s), 8.68 (1H, s), 8.33 (1H, d, J=7.8 Hz),
8.05-7.60 (911H, m), 7.31 (1H, t, J=8.7 Hz). MS (ES+): m/e 361
(25), 360 (100). MS (ES-): m/e 359 (25), 358 (100).
Preparation of
3-[1-(3-Fluoro-phenyl)-5-methyl-1H-[1,2,4]triazol-3-yl]-benzoic
acid (Compound 34)
[0872] A solution of methyl
3-[imino-2-(3-fluorophenylhydrazino)methyl]benzoate (0.43 g, 1.50
mmol) and triethyl orthoacetate (6.07 g, 37.4 mmol) in ethanol (8
mL) is heated to reflux overnight. After cooling, the solution is
poured into water, and the resulting solid is collected by
filtration. This ester compound (230 mg, 0.73 mmol) is then
subjected to hydrolysis (3 mL 1N sq. sodium hydroxide in 3 mL THF,
reflux, 3 h). After evaporation and acidification of the reaction
mixture, the resulting residue is collected by filtration and dried
under vacuum to afford the solid product (153 mg 70%), m.p.
236-238.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.61 (1H, s), 8.24 (1H, d, J=7.6 Hz), 7.99 (1H d, J=7.6 Hz),
7.68-7.53 (4H, m), 7.39 (1H, t, J=7.6 Hz), 2.57 (3H, s).
[0873] The following compound may be prepared by this method.
[0874] Compound 33
[0875]
3-[1-(4-Bromo-phenyl)-5-methyl-1H-[1,2,4]triazol-3-yl]-benzoic
acid: m.p. 295-298.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.60 (1H, s), 8.24 (1H, d, J=7 Hz), 7.98 (1H, d, J=7 Hz),
7.78 (2H, d, J=8 Hz), 7.66 (2H, d, J=8 Hz), 7.64 (1H, t, J=7 Hz),
2.55 (3H, s). MS (ES+): m/e 361 (15), 360 (100), 359 (15), 358
(100). MS (ES-): m/e 359 (15), 358 (100), 357 (15), 356 (95).
Preparation of
3-(5-Oxo-1-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-benzoic acid
(Compound 41)
[0876] Part A.
[0877] A solution of methyl
3-[imino-2-(2-methylphenylhydrazino)methyl]benzoate (1.13 g, 36.4
mmol) in toluene (8 mL) is treated with N,N'-carbonyldiimidazole
(0.61 g, 37.6 mmol). The solution is heated to reflux for 14 h with
stirring and monitoring by TLC. After cooling, the reaction mixture
is poured into water (50 mL) and extracted with ethyl acetate
(2.times.50 mL). The extracts are combined, dried over magnesium
sulfate, filtered and evaporated. The residual solid is suspended
in diethyl ether, collected by filtration and dried under vacuum to
afford methyl
3-(5-oxo-1-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-benzoate as
a white powder (92.0 mg).
[0878] Part B.
[0879] A solution of methyl
3-(5-oxo-1-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-benzoate (92
mg, 0.30 mmol) and lithium iodide (478 mg, 3.57 mmol) in pyridine
(3 mL) is heated at reflux for 12 h. The cooled reaction mixture is
poured into water and acidified by the addition of 1 N HCl. The
resulting solid is collected by filtration, washed with water and
ether, and dried under vacuum to afford the title product (72.8 m,
83%) as a white powder, m.p.>310.degree. C. .sup.1H NMR (300
MHz, DMSO-d.sub.6): .delta. 8.80 (1H, br), 8.44 (1H, s), 8.29 (1H,
t, J=7.7 Hz), 8.15-8.05 (2H, m), 7.85-7.75 (1H, m), 7.64 (1H, t,
J=7.8 Hz), 7.42-7.30 (3H, m), 2.25 (3H, s). MS (ES+): m/e 297 (20),
296 (100). MS (ES-): m/e 295 (29), 294 (100).
[0880] The above method may be used to produce the following
compound.
[0881] Compound 42
[0882]
3-[1-(3-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-be-
nzoic acid: m.p.>310.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 8.68 (1H, s), 8.03 (2H, d, J=7.5 Hz), 7.86
(2H, d, J=73 Hz), 7.56-7.46 (2H, m), 7.04 (1H, t, J=8.0 Hz). MS
(ES+): m/e 301 (15), 300 (100). MS (ES-): m/e 299 (15), 298
(100).
Preparation of
3-{1-[4-(2-Oxo-pyrrolidin-1-yl)-phenyl]-1H-[1,2,4]triazol-3-yl}-benzoic
acid (Compound 43)
[0883] Part A.
[0884] A 50 mL culture tube containing methyl
3-[1-(4-bromophenyl)-1H-[1,2,4]triazol-3-yl]benzoate (407 mg, 1.14
mmol), copper (I) iodide (10.8 mg, 0.057 mmol), pyrrolidin-2-one
(121 mg, 1.42 mmol) and potassium carbonate (138 m& 2.28 mmol)
is evacuated and back charged with nitrogen.
N,N'-Dimethylethylenediamine (10 mg, 0.12 mmol) and toluene (5 mL)
are added, the tube is sealed with a PTFE cap, and the reaction
mixture is heated to 110.degree. C. with stirring for 12 h. The
cooled reaction mixture is partitioned between water and ethyl
acetate, and the organic extract is washed with water. dried over
MgSO.sub.4, filtered and evaporated. The residual material is
separated by column chromatography (silica gel, 1:20
methanol-dichlormethane) to provide methyl
3-{1-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-1H-[1,2,4]triazol-3-yl}-be-
nzoate as a tan solid (380 mg, 92%).
[0885] Part B.
[0886] A solution of methyl
3-{1-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-1H-[1,2,4]triazol-3-yl}-benzoate
(101.6 mg, 0.28 mmol) and lithium iodide (451 mg, 3.37 mmol) in
pyridine (3 mL) is heated under dry N.sub.2 atmosphere to reflux
for 6 h, then cooled and poured into 1N sq. HCl. The resulting
solid is collected by filtration, washed with water and ether, and
dried under vacuum to afford the title product as a tan solid (75.3
mg, 77%), m.p. 270-273.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 9.36 (1H, s), 8.66 (1H, s), 8.31 (1H, d,
J=7.6 Hz), 8.02 (1H, d, J=7.1 Hz), 7.93 (2H, d, J=8.5 Hz), 7.86
(2H, d, J=8.5 Hz), 7.64 (1H, t, J=7.8 Hz), 3.88 (2H, m), 2.53 (2H,
m), 2.08 (2H, m). MS (ES+): m/e 350 (30), 349 (100). MS (ES-): m/e
348 (25), 347 (100).
[0887] The following compound may be prepared using a minor
modification of the procedure above.
[0888] Compound 44
[0889]
3-(1-[4-(2-Oxo-azetidin-1-yl)-phenyl]-1H-[2,4]triazol-3-yl)-benzoic
acid: m.p. 295-297.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 9.33 (1H, s), 8.65 (1H, s), 8.31 (1H, d, J=7.8 Hz), 8.01
(1H, d, J=6.8 Hz), 7.93 (2H, d, J=8.0 Hz), 7.64 (1H, t, J=7.3 Hz),
7.51 (2H, d, J=8.0 Hz), 3.68 (2H, br), 3.11 (2H, br). MS (ES+): m/e
336 (30), 335 (100). MS (ES-): m/e 334 (20), 333 (100).
Preparation of
3-[1-(4-Pyrrolidin-1-yl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoic
acid (Compound 45)
[0890] Part A.
[0891] A solution of methyl
3-(1-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-1H-[1,2,4]triazol-3-yl)-benzoate
(278 mg, 0.77 mmol) in THF (5 mL) is treated with
borane.tetrahydrofuran complex (3.85 mmol) at ambient temperature.
The resulting solution is stirred for 16 h, and quenched by the
addition of 6N sq. HCl. After being allowed to stir for 30 min, the
mixture is made basic with the addition of 1N aq. sodium hydroxide
solution. The mixture is partially evaporated until a precipitate
formed, which is collected by filtration, washed with water, and
dried under vacuum to afford 226 mg (84%) of methyl
3-[1-(4-pyrrolidin-1-yl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoate.
[0892] Part B.
[0893] The lithium iodide-pyridine ester cleavage method described
above is employed to convert methyl
3-[1-(4-pyrolidin-1-yl-phenyl)-1H-[1,2,4]triazol-3-yl]-benzoate to
the title compound, m.p. 263-265.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 9.14 (1H, s), 8.64 (1H, s), 8.28 (1H, d,
J=7.3 Hz), 7.98 (1H, d, J=6.9 Hz), 7.68-7.59 (3H, m), 6.64 (2H, d,
J=8.5 Hz), 3.26 (4H, s), 1.96 (4H, s). MS (ES+): m/e 336 (40), 335
(100). MS (ES-): m/e 334 (30), 333 (100).
Preparation of
3-(5H-4-Oxa-1,3,9b-triaza-cyclopenta[a]naphthalen-2-yl)-benzoic
acid (Compound 46)
[0894] Part A.
[0895] A suspension of methyl
3-(5-oxo-1-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-benzoate
(0.58 g, 1.88 mmol). N-bromosuccinimide (368 mg, 2.07 mmol) and
azoisobutyronitrile (5 mg) in 2:1 CCl.sub.4/CHCl.sub.3 (23 mL) is
heated to reflux for 3 d. After cooling, the solution is
partitioned between water and ethyl acetate, and the organic
extract is dried over magnesium sulfate, filtered and evaporated.
The residual material (0.62 g) is taken up in tetrahydrofuran (6
mL), and treated with sodium hydride (7 mg of 60% w/w suspension in
mineral oil, 0.29 mmol). The resulting mixture is heated to reflux
for 6 h, cooled and evaporated. The residue is separated by column
chromatography (5:95 ethyl acetate-hexane) to afford the cyclized
compound (66 mg).
[0896] Part B.
[0897] A solution of the eater compound of Part A above (66 mg) in
1:1 aq. tetrahydrofuran (6 mL) is treated with lithium hydroxide
(7.7 mg), and the resulting mixture is heated to reflux for 1 h.
The solution is cooled and poured into 1 N HCl. The resulting solid
is collected by filtration and separated by column chromatography
to afford the title product (2.2 mg). .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 8.50 (1H, s), 8.00 (1H, d, J=7.8 Hz), 7.80
(1H, d, J=7.5 Hz), 7.43 (1H, d, J=7.8 Hz), 7.28-7.21 (2H, m),
7.03-6.99 (2H, m), 5.31 (2H, s). MS (ES+): m/e 295 (30), 294 (100).
MS (ES-): m/e 293 (20), 292 (100).
[0898] H. 1,2,3-Triazoles
[0899] 1,2,3-triazoles of the invention may be prepared as
follows.
Preparation of 4-[4-(3-Methoxyphenyl)-[1,2,3]triazol-1-yl]benzoic
acid (Compound 204)
[0900] To a solution of 1-ethynyl-3-methoxybenzene (396 mg, 3.00
mmol, Aldrich) in 50% tert-butanol/water (4.0 mL) is added 300
.mu.L (0.30 mmol) of an aqueous solution of sodium ascorbate (594
mg in 3 mL H.sub.2O), 100 .mu.L (0.030 mmol) of an aqueous
CuSO.sub.4.5H.sub.2O solution (75 mg in 1 mL H.sub.2O), followed by
4-azidobenzoic acid (489 mg, 3 mmol). The resulting mixture is
stirred for 7 days, the resulting suspension filtered and washed
with H.sub.2O (3.times.30 mL), Et.sub.2O (2.times.15 mL), and
hexanes (3.times.30 mL). The solid is dried overnite in vacuo
(70.degree. C., 10 torr) to afford 880 mg (99%) of
4-[4-(3-methoxy-phenyl)-[1,2,3]triazol-1-yl]benzoic acid as a pale
yellow powder. m.p. 276-277.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.44 (s, 1H), 8.16 (d, J=8.5 Hz, 2H), 8.08
(d, J=8.3 Hz, 2H), 7.52 (m, 2H), 7.40 (t, J=7.8 Hz, 1H), 6.95 (ddd,
J=8.3, 2.5, 0.8 Hz, 1H), 3.82 (s, 3H). MS m/z 296.29, calcd for
C.sub.16H.sub.13N.sub.3O.sub.3 (M+H.sup.+) 296.
[0901] This method may be used in the synthesis of the following
compounds.
[0902] Compound 201
[0903] 4-(4-p-Tolyl-[1,2,3]triazol-1-yl)-benzoic acid: m.p.
302-303.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 9.40
(s, 1H), 8.15 (d, J=8.5 Hz, 2H), 8.08 (d, J=8.5 Hz, 2H), 7.82 (d,
J=8.0 Hz, 2H), 7.30 (d, J=8.0 Hz, 2H), 2.33 (s, 3H). MS (ES+): m/e
250.36 (100).
[0904] Compound 202
[0905] 4-[4-(4-Trifluoromethyl-phenyl)-[1,2,3]triazol-1-yl]-benzoic
acid: m.p. 305-306.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.60 (s, 1H), 3.14 (m, 61H), 7.87 (m, 2H). MS (ES+): m/e
334.30 (100).
[0906] Compound 203
[0907] 4-[4-(4-Methoxy-phenyl)-[1,2,3]triazol-1 yl]-benzoic acid:
m.p. 294-295.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
9.30 (s, 1H), 8.11 (m, 4H), 7.86 (d, J=8.5 Hz, 2H), 7.05 (d, J=8.3
Hz, 2H), 3.79 (a, 3H). MS (ES+): m/e 296.35 (100).
[0908] Compound 264
[0909] 4-[4-(2-Fluoro-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 292-294.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.17
(1H, s), 8.15 (5H, m), 7.90 (3H, m). MS (ES+) m/e 234.20 (100).
[0910] Compound 265
[0911] 4-[4-(3-Fluoro-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 327-328.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.49
(1H, s), 8.16 (2H, d, J=8.5 Hz), 8.07 (2H, d, J=8.5 Hz), 7.76 (2H,
m), 7.54 (1H, m), 7.22 (1H, tm, J=7.6 Hz). MS (ES+) m/e 284.22
(100).
[0912] Compound 266
[0913] 4-[4-(4-Fluoro-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 321-323.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.41
(1H, s), 8.16 (2H, d, J=8.5 Hz), 8.07 (2H, d, J=8.5 Hz), 7.97 (2H,
m), 7.34 (2H, t, J=8.3 Hz). MS (ES+) m/e 284.26 (100).
[0914] Compound 267
[0915] 4-[4-(4-Bromo-2-fluoro-phenyl)-[1,2,3]triazol-1-yl]-benzoic
acid: m.p. 327-328.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta.
9.21 (1H, s), 8.14 (5H, m), 7.76 (1H, dm, J=9.9 Hz), 7.57 (1H, dm,
J=7.4 Hz). MS (ES+) m/e 366 (100), 364.15 (100).
[0916] Compound 268
[0917] 4-[4-(2,4-Difluoro-phenyl)-[1,2,3]triazol-1-yl]-benzoic
acid: m.p. 312-313.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta.
9.17 (1H, s), 8.14 (5H, m), 7.97 (2H, tm, J=9.5 Hz), 7.25 (1H, m).
MS (ES+) m/e 302.19 (100).
[0918] Compound 269
[0919] 4-[4-(4-Chloro-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 313-314.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.46
(1H, s), 8.16 (2H, d, J=8.4 Hz), 8.07 (2H, d, J=8.4 Hz), 7.95 (2H,
d, J=8.4 Hz), 7.56 (2H, d, J=8.4 Hz). MS (ES+) m/e 300.29
(100).
[0920] Compound 270
[0921] 4-[4-(2-Bromo-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 261-262.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.32
(1H, s), 8.14 (4H, m), 7.90 (1H, d, J=6.6 Hz), 7.78 (1H, d, J=7.7
Hz), 7.52 (1H, t, J=7.5 Hz), 7.37 (1H, t, J=7.7 Hz). MS (ES+) m/l
346.11 (100), 348 (100).
[0922] Compound 271
[0923] 4-(4-Naphthalen-1-yl-[1,2,3]triazol-1-yl)-benzoic acid: m.p.
265-266.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.38 (1H,
s), 8.53 (1H, m), 8.18 (4H, m), 8.00 (2H, m), 7.86 (1H, m) 7.59
(3H, m). MS (ES+) m/e 316.23 (100).
[0924] Compound 272
[0925] 4-[4-(3,4-Diethoxy-phenyl)-[1,2,3]triazol-1-yl]-benzoic
acid: m.p. 253-254.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta.
9.33 (1H, s), 8.15 (1H, d, J=8.0 Hz), 8.07 (1H, d, J=8.0 Hz), 7.48
(2H, m), 7.06 (1H, d, J=8.3 Hz), 3.83 (3H, s), 3.78 (3H, s). MS
(ES+) m/e 326.23 (100).
[0926] Compound 273
[0927] 4-[4-(4-Ethoxy-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 310-311.degree. C. MS (ES+) m/e 310 (100).
[0928] Compound 274
[0929]
4-[4-(4-Methoxy-2-methyl-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 244-245.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.04
(1H, s), 8.16 (4H, m), 7.71 (2H, d, J=8.0 Hz), 6.89 (2H, m), 3.77
(3H, s), 2.48 (3H, s). MS (ES+) m/e 310.26 (100).
[0930] Compound 275
[0931] 4-[4-(4-Isopropyl-phenyl)-[1,2,3]triazol-1-yl]-benzoic acid:
m.p. 311-312.degree. C. .sup.1H NMR (DMSO-d.sub.6): .delta. 9.36
(1H, s), 8.15 (2H, d, J=8.5 Hz), 8.09 (2H, d, J=8.5 Hz), 7.85 (2H,
d, J=8.0 Hz), 7.36 (2H, d, J=8.2 Hz), 2.91 (1H, heptet, J=6.9 Hz),
1.21 (6H, d, J=6.9 Hz). MS (ES+) m/e 308.26 (100).
[0932] I. Preparation of Oxadiazolones
[0933] Oxadiazolones of the invention may be prepared as
follows.
Preparation of
4-[5-(3-cyanophenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]benzoic acid
(Compound 280)
[0934] Part A.
[0935] At 0.degree. C., to a suspension of 3-cyanobenzoic acid
(0.62 g, 4.2 mmol) in dichloromethane (15 mL) is added THF dropwise
until the system became homogenous, which is followed by the
addition of 1-hydroxybenzotriazole (0.57 g, 4.2 mmol) and
dicyclohexylcarbodiimide (0.87 g, 4.2 mmol). The mixture is brought
to room temperature slowly and stirred for 0.5 h. To the mixture,
methyl 4-hydrazinobenzoate (0.63 g, 3.8 mmol) is added and the
mixture is stirred for 2 hr. The precipitate is then removed by
filtration and washed with dichloromethane. The filtrate is washed
with water and brine, dried over anhydrous Na.sub.2SO.sub.4, which
is discarded later. The crude product obtained after the removal of
the solvent is separated by column chromatography (silica gel, 1:19
ethyl acetate-dichloromethane) to provide the intermediate, methyl
4-[2-(3-cyanobenzoyl)hydrazino]benzoate (0.68 g, 61%). MS (ES+)
m/z: 296.
[0936] Part B.
[0937] Methyl 4-[2-(3-cyanobenzoyl)hydrazino]benzoate (0.59 g, 2.0
mmol) and carbonyldiimidazole (0.49 g, 3.0 mmol) are stirred at
80.degree. C. in dichloroethane (20 mL) overnight, and the mixture
is then subjected to chromatography directly (silica gel, 1:9 ethyl
acetate-dichloromethane) to provide methyl
4-[5-(3-cyanophenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]benzoate (0.63
g, 98%). MS (ES+) m/z: 322.
[0938] Part C.
[0939] Methyl
4-[5-(3-cyanophenyl)-2-oxo-3,4-oxadiazol-3(2H)-yl]benzoate (0.60 g,
1.87 mmol) is then treated with boron tribromide (1M in
dichloromethane, 5.6 mL, 5.6 mmol) in dichloromethane (20 mL) at
room temperature overnight. The volatiles are removed in vacuum and
the residue is treated with water. The crude product is separated
by column chromatography (silica gel, 1:9 methanol-dichloromethane)
to furnish the desired product,
4-[5-(3-cyanophenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]benzoic acid
(0.46 g, 81%). m.p. 294-295.degree. C. (decomp.). .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. (ppm) 7.47 (t, 1H), 7.77 (d, 2H),
7.88-8.00 (m, 4H). (ES+) m/z: 307.
[0940] The following compounds may be prepared in the same fashion
as described above. For thio-1,3,4-oxadizolone analogues,
thiocarbonyldiimidazole may be used instead of carbonyldiimidazole.
Compound 276 is also prepared similarly by using
4-methoxycarbonylbenzoic acid and 4-isopropylphenylhydrazine as the
starting materials.
[0941] Compound 276
[0942]
4-[4-(4-Isopropyl-phenyl)-5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl]--
benzoic acid: m.p. 263-267.degree. C. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 1.15 (d, 2H), 2.80-2.88 (m, 1H), 7.20 (d, 2H),
7.69 (d, 2H), 7.87 (d, 2H), 8.05 (d, 2H). MS (ES-): m/e 323.
[0943] Compound 277
[0944]
4-[5-(4-Isopropyl-phenyl)-2-oxo-[1,3,4]oxadiazol-3-yl]-benzoic
acid: m.p. 252-254.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3):
.delta. 1.19 (d, 2H), 2.82-2.96 (m, 1H), 7.25 (d, 2H), 7.76 (d,
2H), 7.93 (d, 2H), 8.04 (d, 2H). MS (ES-): m/e 323.
[0945] Compound 279
[0946]
3-[5-(4-Isopropyl-phenyl-2-oxo-[1,3,4]oxadiazol-3-yl]-benzoic acid:
m.p. 218-220.degree. C. (decomp.). .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 1.31 (d, 2H), 2.93-3.08 (m, 1H), 7.37 (d, 2H),
7.60 (t, 1H), 7.89 (d, 2H), 8.00-8.05 (m, 1H), 8.27-8.31 (m, 1H),
8.66 (t, 1H). MS (ES-): m/e 323.
[0947] Compound 283
[0948]
3-[5-(4-Isopropyl-phenyl)-2-thioxo-[1,3,4]oxadiazol-3-yl]-benzoic
acid: m.p. 215-217.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3):
.delta. 1.31 (d, 2H), 2.95-3.05 (m, 1H), 7.40 (d, 2H), 7.66 (t,
1H), 7.97 (d, 2H), 8.14-8.19 (m, 1H), 8.55-8.60 (m, 1H), 8.90 (t,
1H). MS (ES-): m/e 339.
[0949] Compound 285
[0950]
4-[5-(4-Isopropyl-phenyl)-2-thioxo-[1,3,4]oxadiazol-3-yl]-benzoic
acid: m.p. 239-240.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3):
.delta. 1.30 (d, 2H), 2.96-3.05 (m, 1H), 7.41 (d, 2H), 7.96 (d,
2H), 8.28 (d, 2H), 8.46 (d, 2H). MS (ES-): m/e 339.
Preparation of
4-[5-(4-Isopropylphenyl)-2-oxo-1,3,4-thiadiazol-3(2H)-yl]benzoic
acid (Compound 281)
[0951] Part A.
[0952] To a toluene (25 mL) solution of methyl
4-[2-(4-isopropylbenzoyl)hydrazino]benzoate (0.94 g, 3.0 mmol),
prepared from 4-methoxycarbonylphenylhydrazine and
4-isopropylbenzoic acid using the coupling technique described
above, is added Lawesson's Reagent (1.82 g, 4.5 mmol). The mixture
is stirred at 120.degree. C. for 10 hr and cooled to room
temperature. The precipitate is removed and the filtrate is
concentrated, chromatographed (silica gel, 1:9 ethyl acetate.
hexane) to give an intermediate compound, MS (ES+): m/e 496. The
intermediate is then treated with NaOH (1.25N, 2.63 mL, 3.3 mmol)
in THF (20 mL) at 65.degree. C. for 1 h. The solvent is then
replaced with ether (50 mL), and the mixture is washed with water,
dried and chromatographed to provide the thiohydrazide, methyl
4-{2-[(4-isopropylphenyl)carbonothioyl]hydrazino}benzoate (0.82 g,
81%). MS (ES+): m/e 329.
[0953] Part B.
[0954] Methyl
4-{2-[(4-isopropylphenyl)carbonothioyl]hydrazino}benzoate (0.26 g,
0.8 mmol) and carbonyldiimidazole (0.19 g, 1.2 mmol) are stirred at
80.degree. C. in dichloroethane (20 mL) overnight, and the mixture
is subjected to chromatography directly (silica gel, 4:1 ethyl
acetate-hexanes) to provide methyl
4-[5-(4-isopropylphenyl)-2-oxo-1,3,4-thiadiazol-3(2H)-yl]benzoate
(0.21 g, 75%). MS (ES+): m/e 355.
[0955] Part C.
[0956] Methyl
4-[5-(4-isopropylphenyl)-2-oxo-1,3,4-thiadiazol-3(2H)-yl]benzoate
(0.20 g, 0.56 mmol) in dichloromethane (10 mL) is then treated with
boron tribromide (1M in dichloromethane, 1.7 mL, 1.7 mmol) at room
temperature overnight. The volatiles are removed in vacuum and the
residue is treated with water. The precipitate is collected and
washed thoroughly with water to furnish the desired product,
4-[5-(4-isopropylphenyl)-2-oxo-1,3,4-thiadiazol-3(2H)-yl]benzoic
acid (0.19 g, 100%). m.p. 205-208.degree. C. .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. (ppm) 1.30 (d, 6H) 2.92-3.06 (m, 1H),
7.35 (d, 2H), 7.70 (d, 2H), 8.11-8.23 (m, 4H). (ES+) m/z: 341.
[0957] The following compounds may be prepared in the same fashion
as described above. For thio-1,3,4-thiadiazolone analogues,
thiocarbonyldiimidazole is used in stead of
carbonyldiimidazole.
[0958] Compound 282
[0959]
4-[5-(4-Isopropyl-phenyl)-2-thioxo-[1,3,4]thiadiazol-3-yl]-benzoic
acid: m.p. 176-179.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3):
.delta. 1.19 (d, 2H), 2.83-2.92 (m, 1H), 7.24 (d, 2H), 7.55 (d,
2H), 7.87 (d, 2H), 8.01 (d, 2H), 12.35 (s, 1H). MS (ES-): m/e
355.
[0960] Compound 284
[0961]
3-[5-(4-Isopropyl-phenyl)-2-oxo-[1,3,4]thiadiazol-3-yl]-benzoic
acid: m.p. 220-221.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3):
.delta. 1.29 (d, 2H), 2.93-3.03 (m, 1H), 7.34 (d, 2H), 7.59 (t,
1H), 7.71 (d, 2H), 8.05-8.08 (m, 1H), 8.21-8.25 (m, 1H), 8.63 (t,
1H). MS (ES-): m/e 339.
Preparation of
4-{[5-(4-isopropylphenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]methyl}benzoic
acid (Compound 278)
[0962] Part A.
[0963] At 0.degree. C., to a solution of 4-isopropylbenzoic acid
(3.28 g, 20.0 mmol), triethylamine (2.12 g, 2.93 mL, 21.0 mmol) in
dichloromethane/THF (15 mL/5 mL), is added isobutylchloroformate
(2.87 g, 2.72 mL, 21.0 mmol). The mixture is stirred at 0.degree.
C. for 20 min. with warming to room temperature over 2 hr., and
then treated with ethyl hydrazinoacetate (2.18 g, 21.0 mmol) and
stirred overnight. The mixture is then washed with water, brine and
dried over Na.sub.2SO.sub.4. The crude product obtained after the
removal of the solvent is chromatographed (silica gel, 5:1
dichloromethane-ethyl acetate) to provide ethyl
[2-(4-isopropylbenzoyl)hydrazino]acetate (4.85 g, 97%). MS (ES+):
m/e 251.
[0964] Part B.
[0965] Ethyl [2-(4-isopropylbenzoyl)hydrazino]acetate (4.85 g, 19.4
mmol) is treated with phosphorus oxychloride (50 mL), heated to
reflux for 3 h, and then poured onto ice. The precipitate is
collected and washed thoroughly with water and dried in the air to
furnish 5-(4-isopropylphenyl)-1,3,4-oxadiazol-2(3H)-one (2.30 g,
58%) MS (ES+): m/e 205.
[0966] Part C.
[0967] 5-(4-Isopropylphenyl)-1,3,4-oxadiazol-2(3H)-one (0.41 g, 2.0
mmol) is dissolved in dichloromethane (5 mL) and stirred vigorously
with methyl 4-bromomethylbenzoate (0.50 g, 2.2 mmol) in the
presence of sodium hydroxide (1.25 N, 1.76 mL, 2.2 mmol) and
tetra-n-butylammonium bromide (0.07 g, 0.022 mmol) at room
temperature overnight. The solvent is removed in vacuum, and the
residue is treated with water. The precipitate is collected by
filtration, washed with hexanes thoroughly and dried in the air to
provide methyl
4-{[5-(4-isopropylphenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]methyl}benzoate
(0.65 g, 93%). (ES+): m/e 353.
[0968] Part D.
[0969] Methyl
4-{[5-(4-isopropylphenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]methyl}benzoate
(50 mg, 0.14 mmol) is refluxed with lithium iodide (0.19 g, 1.4
mmol) in pyridine (5 mL) for 48 h and the mixture is diluted with
water (30 mL) after cooling to room temperature. The precipitate is
collected by filtration, washed with dichloromethane and dried in
the air to furnish the desired product
4-{[5-(4-isopropylphenyl)-2-oxo-1,3,4-oxadiazol-3(2H)-yl]methyl}benzoic
acid (31 mg, 66%), m.p. 217-219.degree. C. .sup.1H NMR (CDCl.sub.3,
300 MHz) .delta. (ppm) 1.13 (d, 6H) 2.70-2.90 (m, 1H), 4.86 (s,
2H), 7.17 (d, 2H), 7.30 (d, 2H), 7.59 (d, 2H), 7.89 (d, 2H). MS
(ES+): m/e 339.
Preparation of
3-[4-(2,4-Difluoro-phenyl)-5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl]-benzo-
ic acid (Compound 286)
[0970] Part A.
[0971] A suspension of isophthalic acid monobenzyl ester (prepared
according to the procedure published in J. Med. Chem. 2001, 44,
1491-1508) (1.72 g, 6.71 mmol) in diethyl ether (30 mL) is treated
with pyridine (550 .mu.L, 6.80 mmol), and then a solution of
cyanuric fluoride (1 equiv.) in ether (10 mL) is delivered by
cannula dropwise over 15 min. A gummy precipitate forms, and the
resulting mixture is made homogeneous by partial evaporation of the
ether and addition of dichloromethane (50 mL). After 3 hrs., the
solution is diluted with dichloromethane and poured over ice. The
organic layer is washed with brine. The aqueous layers are
back-extracted with dichloromethane, and the organic extracts are
combined, dried over MgSO.sub.4, filtered and evaporated to afford
benzyl isophthaloyl fluoride (1.68 g, 97%), which is taken on
directly to the next step.
[0972] Part B.
[0973] A 16.times.100 mm screw-cap tube containing
2,4-difluorophenylhydrazine (41.5 mg, 0.29 mmol), polystyrene-NMM
resin (0.303 g, 2 equiv.), and anhydrous dimethylformamide (5 mL)
is treated with a solution of benzyl isophthaloyl fluoride (0.289
mmol) in dimethylformamide (1 mL). The tube is sealed, and mixed at
ambient temperature for 5.5 d. The contents of the tube are
filtered into another tube, and the resin is washed with additional
dimethylformamide. The solution is heated to 80.degree. C. and
treated with portions of carbonyldiimidazole (100 mg each) until
analysis by LC/MS showed complete consumption of starting material.
The tube is allowed to cool and the solvent is evaporated. The
residual material is eluted through a short column of silica gel
with a gradient of 10:90 to 40:60 ethyl acetate-chloroform, and the
fractions containing the product, benzyl
3-[4-(2,4-difluoro-phenyl)-5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl]-benzo-
ate, are collected and evaporated.
[0974] Part C.
[0975] Benzyl
3-[4-(2,4-difluoro-phenyl)-5-oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl]-benzo-
ate from Part B is treated with a 45% solution of hydrogen bromide
in acetic acid. After 1 h, ether is added (5 mL), and the resulting
solution is stirred for an additional 1 h. The solvents are
evaporated, and analysis by LC/MS of the residual material shows
the presence of unconverted starting material. The residue is taken
up in chloroform (10 mL), cooled to 0.degree. C., and treated with
a solution of boron tribromide (1 mL, 1.0 M). After stirring for 17
h, the solution is evaporated, and the residue is suspended in 10
mL cold water. This mixture is sonicated to achieve a homogeneous
suspension and filtered. The resulting solution is separated by
HPLC to afford pure title product. MS (ES+): m/r 320 (20), 319.13
(100).
[0976] In summary, certain preferred compounds of the invention are
prepared in a manner similar to those described above as
follows:
TABLE-US-00002 TABLE 1 Compound Melting Point Mass Spec Data 1
279-282 322 2 248-250 307 3 225-226 307 4 307 5 215-216 307 6
210-215 306 8 268-271 266 9 307-311 282 10 259-261 372 11 268-270
296 12 230-232 296 13 >310 284 14 263-265 280 15 173-175 308 16
290-291 302 17 239-241 284 18 141-143 334 19 219-221 350 20 271-273
402 21 176-178 294 22 >310 344 23 284-286 311 24 263-265 342 25
270-272 318 26 293-295 382 27 243-246 372 28 225-228 384 32 272-275
360 33 295-298 358 34 236-238 41 >310 296 42 >310 300 43
270-273 349 44 295-297 335 45 263-265 335 46 294 47 238-239 295- 48
208-209 279 49 253-254 299 50 289-290 295 51 298-299 279 52 300-302
299 53 122-123 296 54 194-196 300 55 249-250 240 56 270-271 244 57
78-80 246 58 110-112 276 59 100-101 276 60 144-147 290 61 83-84 330
62 70-74 314 63 142-145 282 64 143-145 304 65 202-204 265 66
171-174 349 67 225-227 333 68 240-244 301 74 228-230 281 75 178-179
281 76 160-161 295 77 153-154 295 78 164-166 290 79 180-182 265 80
230-235 299 81 210-211 295 82 230-235 350 83 205-206 299 84 225-226
283 85 260-261 281 (ES-) 86 157-158 283 87 210-215 309 88 177-178
343 89 247-248 343 90 181-182 279 91 251-252 279 92 237-240 283 93
173-174 283 94 225-227 333 95 191-194 349 96 245-246 283 97 223-225
295 98 225-226 265 99 267-269 265 100 282-284 281 101 274-276 308
(ES-) 102 276-277 308 (ES-) 103 283-285 301 104 291-293 301 105
315-317 332 106 240-243 306 107 118-120 331 108 209-210 280 109
222-223 295 110 224-225 308 111 264-265 309 112 157-158 295 113
243-245 266 114 260-262 266 115 300-302 266 116 >350 266 117
297-299 267 118 >350 267 119 310-311 267 120 319-321 267 121
331-333 306 122 325-326 317 123 250-252 316 124 182-183 331 125
190-192 292 126 178-180 294 127 231-233 300 128 209-211 332 129
278-280 292 130 239-241 264 131 318-320 348 132 203-205 296 133
213-215 349 134 246-248 249 135 273-275 291 136 241-243 277 137
191-192 291 138 249-250 277 139 272-273 307 140 225-227 307 141
233-234 291 142 217-218 321 143 192-193 321 144 227-228 293 145
290-292 321 146 246-248 277 147 232-233 321 148 288-290 321 149
304-306 307 150 273-276 321 151 202-204 282 152 211-213 282 153
243-245 300 154 224-226 332 155 211-213 282 156 178-181 278 157
201-202 348 158 348 159 278 160 190-191 295 161 288-290 291 162
308-310 293 163 279-280 321 164 180-183 308 165 180-183 343 166
192-193 279 167 162-164 279 168 280-281 310 169 166-167 283 170
180-182 279 171 211-212 295 172 179-181 331 173 255-257 331 174
156-157 295 175 152-153 371 176 210-212 371 177 229-231 279 178
280-282 279 179 200-202 301 180 258-260 301 181 235-237 283 182
266-268 283 183 235-237 357 184 277-278 307 185 240-241 343 186
282-283 357 187 311-313 307 188 277-278 344 193 200-202 294 194
212-213 278 195 208-209 278 196 >350 298 197 200-202 298 198
198-200 298 199 164-165 348 200 >350 294 201 302-303 280 202
305-306 334 203 294-295 296 204 276-277 296 205 286-288 309 206
273-275 281 207 272-274 281 208 225-227 349 209 166-168 349 210
178-180 299 211 252-255 299 212 261-265 283 213 228-230 283 214
220-222 331 215 211-213 357 216 164-165 357 217 252-253 295 218
214-215 349 219 268-270 295 220 179-180 295 221 200-202 295 222
244-245 265 223 143-145 349 224 230-231 349 225 201-203 323 226
238-240 323 227 266-268 309 228 212-215 307 229 215-218 307 230
209-211 313 231 285-288 313 232 135-138 333 233 286-289 333 234
259-261 299 235 218-220 333 236 271-273 333 237 196-197 293 238
254-256 293 239 221-223 309 240 161-163 278 241 205-208 296 242
193-194 300 243 199-201 298 244 264-268 296 245 215-218 300 246
142-144 370 247 177-180 308 253 239-241 321 254 269-271 321 255
215-216 307 256 278-279 307 257 281-282 304 258 198-199 271 259
200-202 272 260 235-236 266 261 280-282 266 262 277-279 263 263
263-265 263 264 292-294 284 265 327-328 284 266 321-323 284 267
327-328 364 268 312-313 302 269 313-314 300
270 261-262 346 271 265-266 316 272 253-254 326 273 310-311 310 274
244-245 310 275 311-312 308 276 263-267 323 277 252-254 323 278
217-219 339 279 218-220 323 280 294-295 307 281 205-208 341 282
176-179 355 (ES-) 283 215-217 339 (ES-) 284 220-221 339 (ES-) 285
239-240 339 (ES-) 286 319-320 287 244-245 306.22 288 289 290 291
292 230-232 293 >310 294 263-265 295 173-175 296 290-292 297
239-241 298 141-143 299 219-221 300 271-273 301 176-178 302 >300
303 284-286 304 263-265 305 270-272 306 293-295 307 243-246 308
225-228 309 266-268 310 245-247 311 >330 312 272-275 313 295-298
314 236-238 315 253-255 316 241-244 317 257-259 318 269-272 319
223-225 320 209-211 321 >310 322 >310 323 270-273 324 295-297
325 263-265 326 327 203-205 328 223-225 329 220-223 330 221-223 331
250-253 332 169-170 333 276-278 334 203-206 335 255-258 336 165-168
337 188-191 338 209-211 339 252-255 340 225-227 341 280-282 342
296-298 343 193-194 344 >320 345 191-193 346 282.40 347 205-208
348 195-199 349 163-165 350 184-187 351 183-186 352 188-189 353
204-205 354 200-204 355 239-240 356 249-250 357 237-239 358 212-214
359 230-232 360 173-178 361 180-185 362 193-195 363 230-235 364
169-170 365 210-212 366 246-247 367 275-246 368 215-216 369 266-268
370 274-276 371 259-260 372 251-252 373 259-260 374 205-207 375
274-276 376 171-172 377 176-177 378 330-332 379 295-296 380 305-307
381 271-272 382 291-292 383 238-240 384 251-252 385 266.5-267.5 386
277-278 387 256-257 388 225-226 389 216-217 390 276-277 391 262-263
392 235.5-237.sup. 393 211-213 394 275-277 395 158-160 396 162-164
397 197-199 398 241-243 399 295-298 400 247-249 401 >300 402
187-189 403 257-259 404 233-235 405 127-129 406 142-144 407 199-200
408 175-177 409 172-173 410 202-204 411 283-285 412 284-285 413
217-219 414 155-157 415 167-169 416 290-292 417 292-293 418 223-225
419 283-285 420 153-154 421 156-158 422 220-223 423 208-210 424
269-270 425 247-249 426 207-209 427 273-275 428 241-243 429 297-299
430 207-209 431 257-259 432 268-270 433 174-176 434 210-211 435
251-252 436 212-213 437 227-228 438 192-193 439 >320 440 272-273
441 212-213 442 263-265 443 226-227 444 262-263 445 .sup. 247-248.5
446 285-287 447 291-292 448 245-250 449 203-205 450 165-170 451
280-283 452 282-284 453 286-287 454 455 177-180 456 171-174 457
246-250 458 183-186 459 135-138 460 209-211 461 267-270 462 286-289
463 256-258 464 260-262 465 250-252 466 283-285 467 265-267 468
253-255 469 263-265 470 267-269 471 269-271 472 271-273 473 291-293
474 293.28
Example 2
Nonsense Suppression Activity
[0977] A functional, cell-based translation assay based on
luciferase-mediated chemoluminescence (International Application
PCT/US2003/023185, filed on Jul. 23, 2003, hereby incorporated by
reference in its entirety) permits quantitative assessment of the
level of nonsense suppression. Human embryonic kidney cells (293
cells) are grown in medium containing fetal bovine serum (FBS).
These cells can be stably transfected with the luciferase gene
containing a premature termination codon at amino acid position
190. In place of the threonine codon (ACA) normally present in the
luciferase gene at this site, each of the 3 possible nonsense
codons (TAA, TAG, or TGA) and each of the 4 possible nucleotides
(adenine, thymine, cytosine, or guanine) at the contextually
important downstream +1 position following the nonsense codon are
introduced by site-directed mutagenesis. As such, amino acid 190 in
the luciferase gene containing a premature termination codon is
either TAA, TAG, or TGA. For each stop codon. the nucleotide
following amino acid 190 of luciferase gene containing a premature
termination codon can be replaced with an adenine, thymine,
cytosine, or guanine (A, T, C, G) such that these mutations do not
change the reading flame of the luciferase gene. Schematics of
these constructs are depicted in FIG. 1.
[0978] The nonsense suppression activity from a cell-based
luciferase reporter assay of the present invention as described
above shown in the table below (Table 2). Human Embryonic Kidney
293 cells are stably transfected with a luciferase reporter
construct comprising a UGA nonsense mutation at position 190. which
is followed, in-frame by an adenine nucleotide (UGAA).
[0979] Activity measurements in Table 2 are determined in a
cell-based luciferase reporter assay of the present invention
construct containing a UGA premature termination codon which is
followed, in-frame by an adenine nucleotide (UGAA).
[0980] Gentamicin, an aminoglycoside antibiotic known to allow read
rough of premature termination codons, is used as an internal
standard. Activity measurements re based on the qualitative ratio
between the minimum concentration of compound required to produce a
given protein in a cell versus the amount of protein produced by
the cell at that concentration. Compounds which are found to have
either or both very high potency and very high efficacy of protein
synthesis are classified as "******". Compounds which are found to
have intermediate potency and/or efficacy of protein synthesis are
classified as "****"; "***"; or "**". Similarly, compounds which
are found to have lower potency and/or efficacy of protein
synthesis are classified as "*".
TABLE-US-00003 TABLE 2 Compound UGAA 1 * 2 ** 3 *** 4 **** 5 **** 6
**** 8 * 9 * 10 * 11 ** 12 *** 13 *** 14 **** 15 **** 16 ** 17 ***
18 **** 19 ***** 20 *** 21 *** 22 ***** 23 **** 24 **** 25 **** 26
**** 27 ** 28 ** 29 ***** 30 *** 31 * 32 *** 33 * 34 * 35 **** 36
*** 37 *** 38 **** 39 ***** 40 *** 41 * 42 * 43 * 44 * 45 *** 46
**** 47 *** 48 *** 49 *** 50 *** 51 ***** 52 *** 53 ** 54 ** 55 *
56 * 57 ** 58 ** 59 ** 60 ** 61 ** 62 ** 63 * 64 * 65 **** 66 ****
67 **** 68 **** 69 * 70 ** 71 ** 72 ** 73 * 74 **** 75 **** 76
***** 77 **** 78 *** 79 *** 80 *** 81 **** 82 *** 83 **** 84 ****
85 ***** 86 **** 87 **** 88 *** 89 ** 90 **** 91 *** 92 *** 93 ***
94 *** 95 *** 96 *** 97 **** 98 *** 99 ***** 100 *** 101 **** 102
*** 103 **** 104 **** 105 ***** 106 ***** 107 *** 108 *** 109 *****
110 *** 111 *** 112 *** 113 *** 114 * 115 * 116 * 117 * 118 * 119 *
120 * 121 ** 122 *** 123 *** 124 **** 125 ***** 126 ***** 127 ***
128 *** 129 ***** 130 *** 131 **** 132 ***** 133 **** 134 ** 135 **
136 * 137 *** 138 **** 139 **** 140 *** 141 *** 142 *** 143 * 144
** 145 * 146 **** 147 *** 148 **** 149 * 150 ***** 151 ** 152 **
153 ** 154 **** 155 ***** 156 **** 157 **** 158 *** 159 **** 160
*** 161 ** 162 ** 163 * 164 **** 165 **** 166 ***** 167 **** 168
*** 169 *** 170 **** 171 *** 172 *** 173 ** 174 **** 175 *** 176
**** 177 ***** 178 **** 179 ***** 180 ** 181 **** 182 ** 183 ***
184 *** 185 *** 186 *** 187 **** 188 *** 189 * 190 ** 191 * 192 **
193 *** 194 ***** 195 *** 196 ***** 197 **** 198 **** 199 *** 200
**** 201 **** 202 **** 203 *** 204 *** 205 **** 206 **** 207 ***
208 *** 209 *** 210 *** 211 **** 212 **** 213 **** 214 **** 215 *
216 ** 217 *** 218 **** 219 *** 220 **** 221 ** 222 * 223 *** 224
** 225 **** 226 ***** 227 *** 228 **** 229 **** 230 **** 231 ***
232 **** 233 ** 234 *** 235 **** 236 *** 237 ***** 238 *** 239
***** 240 **** 241 ***** 242 **** 243 ** 244 ***** 245 *** 246
****
247 **** 248 ** 249 **** 250 **** 251 * 252 * 253 * 254 * 255 ****
256 *** 257 *** 258 ***** 259 * 260 **** 261 * 262 * 263 * 264 *
265 * 266 *** 267 *** 268 ** 269 *** 270 * 271 *** 272 *** 273 ****
274 *** 275 **** 276 *** 277 **** 278 * 279 *** 280 * 281 ** 282 **
283 *** 284 **** 285 *** 286 * 287 * 288 * 289 * 290 * 291 * 292
**** 293 *** 294 **** 295 **** 296 ** 297 ** 298 **** 299 ***** 300
*** 301 *** 302 **** 303 *** 304 *** 305 *** 306 **** 307 * 308 **
309 ***** 310 **** 311 * 312 *** 313 * 314 * 315 **** 316 ** 317
*** 318 **** 319 **** 320 *** 321 * 322 * 323 * 324 * 325 *** 326
**** 327 ***** 328 *** 329 ***** 330 * 331 **** 332 **** 333 * 334
*** 335 *** 336 **** 337 * 338 *** 339 * 340 **** 341 *** 342 *****
343 ** 344 * 345 ** 346 **** 347 **** 348 **** 349 *** 350 **** 351
** 352 ***** 353 ***** 354 ***** 355 ***** 356 **** 357 **** 358
**** 359 ***** 360 **** 361 **** 362 **** 363 ** 364 *** 365 ****
366 ** 367 *** 368 ** 369 *** 370 *** 371 *** 372 *** 373 *** 374
** 375 *** 376 **** 377 *** 378 * 379 * 380 ** 381 *** 382 ** 383 *
384 **** 385 *** 386 *** 387 *** 388 *** 389 ** 390 *** 391 ** 392
** 393 ***** 394 ***** 395 * 396 * 397 ***** 398 ** 399 *** 400 **
401 402 **** 403 * 404 **** 405 **** 406 **** 407 * 408 * 409 * 410
* 411 **** 412 * 413 * 414 *** 415 **** 416 * 417 *** 418 **** 419
* 420 * 421 *** 422 **** 423 ** 424 *** 425 ** 426 **** 427 ** 428
**** 429 **** 430 **** 431 ** 432 *** 433 ** 434 *** 435 **** 436
**** 437 **** 438 **** 439 * 440 *** 441 *** 442 **** 443 *** 444
*** 445 *** 446 ** 447 *** 448 *** 449 *** 450 *** 451 * 452 * 453
* 454 *** 455 *** 456 *** 457 *** 458 **** 459 *** 460 ** 461 ****
462 * 463 **** 464 * 465 *** 466 ***** 467 **** 468 **** 469 ****
470 **** 471 ***** 472 **** 473 **** 474 ****
[0981] Nonsense suppression activity in an assay as described above
is shown in the Table 3 below, for a construct with a UGA nonsense
mutation at position 190, followed by a cytosine nucleotide
in-frame, (UGAC); for a construct with UAG nonsense mutation at
position 190, followed by an adenine nucleotide in-frame, (UAGA);
for a construct with UAA nonsense mutation at position 190,
followed by an adenine nucleotide in-frame, (UAAA); and a construct
with a UAA nonsense mutation at position 190, followed by an
cytosine nucleotide in-frame, (UAAC). Also included in Table 3 is a
column ("western blot") indicating whether treatment of cells with
the Indicated compound suppresses the nonsense mutation in a
specific codon context (UGAA, UGAC, UAAA or UAAC) in luciferase and
results in production of luciferase protein as determined by a
positive signal on a western blot. A positive result in the western
blot assay is indicated by a "+" and the nonsense codon and context
of the codon that Is suppressed.
TABLE-US-00004 TABLE 3 Compound No. UGAC UAAA UAAC UAGA western
blot 47 * * 48 * * 65 ** *** 66 ** *** +UGAC; UAAC 67 **** **** 68
*** **** 76 **** **** 81 *** *** 83 *** * 84 * * 85 * * +; UGAC 86
* * 90 * * 91 * * 92 * * 93 * * 95 * * 96 *** ** 97 *** ** 98 ***
99 * * 100 * 101 * 102 * 103 * ** 104 * * 105 * *** +; UGAA; UGAC;
UAAA 106 ***** *** **** 109 ***** * * 131 * * 133 * * 135 * * 136
*** * 137 *** * 138 ***** * ** * 139 ***** * * * 140 ***** ** * ***
141 *** * 142 *** * *** *** 143 * * 144 ** * 145 * * 146 ***** * **
* 147 *** ** 148 *** * * *** 149 * * 150 * * 154 * *** 155 ** ***
156 * * 157 ** * 159 * * 164 ** ** 177 ** ** 179 * ** 196 * * 198 *
* 205 * * 214 * * 225 ** *** 228 ** ** 230 ** ** 232 * * 235 ** **
237 *** ** +; UGAC 239 * * 241 *** ** 242 ** ** 249 * * 255 **
**
Example 3
Readthrough Assay
[0982] A functional, cell-based translation assay based on
luciferase-mediated chemoluminescence (International Application
PCT/US2003/023185, filed on Jul. 23, 2003 and incorporated by
reference in its entirety) permits assessment of
translation-readthrough of the normal stop codon in a mRNA. Human
embryonic kidney cells (293 cells) are grown in medium containing
fetal bovine serum (FBS). These cells are stably transfected with
the luciferase gene containing a premature termination codon at
amino acid position 190. In place of the threonine codon (ACA)
normally present in the luciferase gene at this site, each of the 3
possible nonsense codons (TAA, TAG, or TGA) and each of the 4
possible nucleotides (adenine, thymine, cytosine, or guanine) at
the contextually important downstream +1 position following the
nonsense codon are introduced by site-directed mutagenesis. As
such, amino acid 190 in the luciferase gene containing a premature
termination codon is either TAA, TAG, or TGA. For each stop codon,
the nucleotide following amino acid 190 of luciferase gene
containing a premature termination codon are replaced with an
adenine, thymine, cytosine, or guanine (A, T, C, G) such that these
mutation do not change the reading frame of the luciferase gene.
Schematics of these constructs are depicted above in FIG. 1.
[0983] Another assay of the present invention can evaluate
compounds that promote nonsense mutation suppression. The
luciferase constructs described above in FIG. 1 are engineered to
harbor two epitope tags in the N-terminus of the luciferase
protein. Based on luciferase protein production, these constructs
qualitatively assess the level of translation-readthrough. The
presence of the full-length luciferase protein produced by
suppression of the premature termination codon is measured by
immunoprecipitation of the suppressed luciferase protein (using an
antibody against a His tag) followed by western blotting using an
antibody against the second epitope (the Xpress.TM. epitope;
Invitrogen.RTM.; Carlsbad, Calif.). These constructs are depicted
in FIG. 2.
[0984] Cells that harbor the constructs of FIG. 2 show increased
full-length protein production when treated with a compound of the
present invention. After treatment for 20 hours, cells containing
the constructs of FIG. 2 are collected and an antibody recognizing
the His epitope is used to immunoprecipitate the luciferase
protein. Following immunoprecipitation, western blotting is
performed using the antibody to the Xpress.TM. epitope
(Invitrogen.RTM.; Carlsbad, Calif.) to detect the truncated
luciferase (produced when no nonsense suppression occurs) and to
detect the full-length protein (produced by suppression of the
nonsense codon). Treatment of cells with a test compound produces
full-length protein and not a readthrough protein (See e.g., FIG.
3). The readthrough protein is produced if suppression of the
normal termination codon occurs. Compounds of the present invention
suppress the premature, i.e. nonsense mutation, but not the normal
termination codon in the luciferase mRNA.
[0985] Compounds of the present invention selectively act on
premature termination codons but not normal termination codons in
mammals.
[0986] Rats and dogs are administered high doses of compound (up to
1800 mg/kg) by gavage (oral) once daily for 14 days. After the
treatment, tissues are collected, lysates are prepared, and Western
blot analysis is performed. Selection of the proteins for
evaluation of normal termination codon readthrough is based
primarily on the corresponding mRNA having a second stop codon in
the 3'-UTR that is in-frame with the normal termination codon.
Between these 2 stop codons, each selected protein has an
intervening sequence of nucleotides that codes for an extension of
the protein in the event of ribosomal readthrough of the first
termination codon. If the compound has the capacity to induce
nonspecific, ribosomal readthrough, an elongated protein is
differentiated from the wild-type protein using Western blot.
Tissues are collected from rats and are analyzed for suppression of
the normal termination codon (UAA) in the vimentin mRNA. No
evidence of suppression is apparent. Tissues are collected from
dogs treated with compounds of the present invention. There is no
evidence of suppression of the normal termination codon of beta
actin, which harbors a UAG stop codon.
[0987] In healthy human volunteers, a single dose of a compound of
the present invention (200 mg/kg) is administered orally. Blood
samples are collected, plasma is prepared, and a Western blot is
conducted using plasma samples from female and male subjects.
C-reactive protein (CRP), which harbors a UGA termination codon, is
used to determine if treatment of subjects with compounds of the
present invention result in suppression of the normal termination
codon in the CRP mRNA. A luciferase assay in combination with a
premature termination assay demonstrates selective suppression of
premature termination codons but not normal termination codons.
Example 4
Animal Models
[0988] Animal model systems can also be used to demonstrate the
safety and efficacy of a compound of the present invention. The
compounds of the present invention are tested for biological
activity using animal models for a disease, condition, or syndrome
of interest. These include animals engineered to contain the target
RNA element coupled to a functional readout system, such as a
transgenic mouse.
Cystic Fibrosis
[0989] Examples of animal models for cystic fibrosis include, but
are not limited to, cfr(-/-) mice (see, e.g., Freedman et al.,
2001, Gastroenterology 121(4):950-7), cftr(tm1HGU/tm1HGU) mice
(see, e.g., Bernhard et al., 2001, Exp Lung Res 27(4):349-66),
CFTR-deficient mice with defective cAMP-mediated Cl(-) conductance
(see, e.g., Stotland et al., 2000, Pediatr Pulmonol 30(5):413-24),
and C57BL/6-Cftr(m1UNC)/Cftr(m1UNC) knockout mice (see, e.g.,
Stotland et al., 2000, Pediatr Pulmonol 30(5):413-24).
Muscular Dystrophy
[0990] Examples of animal models for muscular dystrophy include,
but are not limited to, mouse, hamster, cat, dog, and C. elegans.
Examples or mouse models for muscular dystrophy include, but are
not limited to, the dy-/- mouse (see, e.g., Connolly et al., 2002,
J Neuroimmunol 127(1-2):80-7), a muscular dystrophy with myositis
(mdm) mouse mutation (see, e.g., Garvey et al., 2002. Genomics
79(2):146-9), the mdx mouse (see, e.g., Nakamura et al., 2001,
Neuromuscul Disord 11(3):251-9), the utrophin-dystrophin knockout
(dko) mouse (see. e.g., Nakamura et al., 2001, Neuromuscul Disord
11(3):251-9), the dy/dy mouse (see, e.g., Dubowitz et al., 2000,
Neuromuscul Disord 10(4-5):292-8), the mdx(Cv3) mouse model (see,
e.g., Pillers et al., 1999, Laryngoscope 109(8):1310-2), and the
myotonic ADR-MDX mutant mice (see, e.g., Kramer et al., 1998,
Neuromuscul Disord 8(8):542-50). Examples of hamster models for
muscular dystrophy include, but me not limited to,
sarcoglycan-deficient hamsters (see, e.g., Nakamura et a., 2001, Am
J Physiol Cell Physiol 281(2):C690-9) and the BIO 14.6 dystrophic
hamster (see, e.g., Schlenker & Burbach, 1991, J Appl Physiol
71(5):1655-62). An example of a feline model for muscular dystrophy
includes, but is not limited to, the hypertrophic feline muscular
dystrophy model (see, e.g., Geachen & Burgunder, 2001. Acta
Neuropathol (Berl) 101(6):591-600). Canine models for muscular
dystrophy include, but are not limited to, golden retriever
muscular dystrophy (see, e.g., Fletcher et al., 2001, Neuromuscul
Disord 11(3):239-43) and canine X-linked muscular dystrophy (see.
e.g., Valentine et al., 1992. Am J Med Genet 42(3):352-6). Examples
of C. elegans models for muscular dystrophy are described in
Chamberlain & Benian, 2000, Curr Biol 10(21):R795-7 and Culette
& Sattelle, 2000, Hum Mol Genet 9(6):869-77.
Familial Hypercholesterolemia
[0991] Examples of animal models for familial hypercholesterolemia
include, but are not limited to, mice lacking functional LDL
receptor genes (see, e.g., Aji et al., 1997, Circulation
95(2):430-7), Yoshida rats (see, e.g., Fantappie et al., 1992, Life
Sci 50(24):1913-24), the JCR:LA-cp rat (see, e.g., Richardson et
al., 1998, Atherosclerosis 138(1):135-46), swine (see, e.g.,
Hasler-Rapacz et al., 1998, Am J Med Genet 76(5):379-86), and the
Watanabe heritable hyperlipidaemic rabbit (see, e.g., Tsutsumi et
al., 2000, Arzneimittelforschung 50(2): 118-21; Harsch et al.,
1998. Br J Pharmacol 124(2):227-82; and Tanaka et al., 1995,
Atherosclerosis 114(1):73-82).
Human Cancer
[0992] An example of an animal model for human cancer, in general
includes, but is not limited to, spontaneously occurring tumors of
companion animals (see, e.g., Vail & MacEwen, 2000, Cancer
Invest 18(8):781-92). Examples of animal models for lung cancer
include, but are not limited to, lung cancer animal models
described by Zhang & Roth (1994, In Vivo 8(5):755-69) and a
transgenic mouse model with disrupted p53 function (see, e.g.,
Morris et al., 1998, J La State Med Soc 150(4):179-85). An example
of an animal model for breast cancer includes, but is not limited
to, a transgenic mouse that overexpresses cyclin D1 (see, e.g.,
Hosokawa at al., 2001, Transgenic Res 10(5):471-8). An example of
an animal model for colon cancer includes, but is not limited to, a
TCRbeta and p53 double knockout mouse (see, e.g., Kado et al.,
2001, Cancer Res 61(6):2395-8). Examples of animal models for
pancreatic cancer include, but are not limited to, a metastatic
model of Panc02 murine pancreatic adenocarcinoma (see, e.g., Wang
et a., 2001, Int J Pancreatol 29(1):37-46) and nu-nu mice generated
in subcutaneous pancreatic tumours (see, e.g., Ghaneh et al., 2001,
Gene Ther 8(3):199-208). Examples of animal models for
non-Hodgkin's lymphoma include, but are not limited to, a severe
combined immunodeficiency ("SCID") mouse (see, e.g., Bryant et al.,
2000, Lab Invest 80(4):553-73) and an IgHmu-HOX11 transgenic mouse
(see, e.g., Hough et al., 1998, Proc Natl Acad Sci USA
95(23):13853-8). An example of an animal model for esophageal
cancer includes, but is not limited to, a mouse transgenic for the
human papillomavirus type 16 E7 oncogene (see, e.g. Herber et al.,
1996, J Virol 70(3):1873-81). Examples of animal models for
colorectal carcinomas include, but am not limited to, Apc mouse
models (see, e.g., Fodde & Smits, 2001, Trends Mol Med
7(8):369-73 and Kuraguchi et al., 2000, Oncogene 19(50):5755-63).
An example of an animal model for neurofibromatosis includes, but
is not limited to, mutant NF1 mice (see, e.g., Cichowski et al.,
1996, Semin Cancer Biol 7(5):291-8). Examples of animal models for
retinoblastoma include, but are not limited to, transgenic mice
that expression the simian virus 40 T antigen in the retina (see.
e.g. Howes et al., 1994. Invest Ophthalmol Vis Sci 35(2):342-51 and
Windle et al, 1990, Nature 343(6259):665-9) and inbred rats (see,
e.g., Nishida et al., 1981, Curr Eye Res 1(1):53-5 and Kobayashi et
al., 1982. Acta Neuropathol (Berl) 57(2-3):203-8). Examples of
animal models for Wilm's tumor include, but are not limited to, a
WT1 knockout mice (see, e.g., Scharnhorst et al., 1997, Cell Growth
Differ 8(2):133-43), a rat subline with a high incidence of
neuphroblastoma (see. e.g., Mesfin & Breech, 1996. Lab Anim Sci
46(3):321-6), and a Wistar/Furth rat with Wilms' tumor (see. e.g.,
Murphy et al., 1987, Anticancer Res 7(4B):717-9).
Retinitis Pigmentosa
[0993] Examples of animal models for retinitis pigmentosa include,
but are not limited to, the Royal College of Surgeons ("RCS") rat
(see, e.g., Vollrath et al., 2001, Proc Natl Acad Sci USA 98(22);
12584-9 and Hanitzsch et al., 1998, Acta Anat (Basel) 162(2-3):
119-26), a rhodopsin knockout mouse (see, e.g., Jaissle et al.,
2001. Invest Ophthalmol Vis Sci 42(2):506-13), and Wag/Rij rats
(see, e.g., Li et al., 1980, Am J Pathol 98(1):281-4).
Cirrhosis
[0994] Examples of animal models for cirrhosis include, but are not
limited to, CCl.sub.4-exposed rats (see, e.g., Kloehn et al., 2001,
Horm Metab Res 33(7):394-401) and rodent models instigated by
bacterial cell components or colitis (see, e.g., Vierling, 2001,
Best Pract Res Clin Gastroenterol 15(4):591-610).
Hemophilia
[0995] Examples of animal models for hemophilia include, but are
not limited to, rodent models for hemophilia A (see. e.g., Reipert
et al., 2000, Thromb Haemost 84(5):826-32; Jarvis et al., 1996,
Thromb Haemost 75(2):318-25; and Bi et al., 1995, Nat Genet
10(1):119-21), canine models for hemophilia A (see, e.g.,
Gallo-Penn et al., 1999, Hum Gene Ther 10(11):1791-802 and Connelly
et al, 1998, Blood 91(9); 3273-81), murine models for hemophilia B
(see, e.g., Snyder et al., 1999. Nat Med 5(1):64-70; Wang e al.,
1997, Proc Natl Acad Sci USA 94(21):11563-6; and Fang et al., 1996,
Gene Ther 3(3):217-22), canine models for hemophilia B (see, e.g.,
Mount et al., 2002, Blood 99(8):2670-6; Snyder et al., 1999, Nat
Med 5(1):64-70; Fang et al., 1996, Gene Ther 3(3):217-22); and Kay
t al., 1994, Proc Natl Acad Sci USA 91(6):2353-7), and a rhesus
macaque model for hemophilia B (see, e.g., Lozier at a., 1999,
Blood 93(6):1875-81).
Von Willebrand Disease
[0996] Examples of animal models for von Willebrand disease
include, but are not limited to, an inbred mouse strain RIIIS/J
(see, e.g., Nichols et al., 1994, 83(1):3225-31 and Sweeney et al.,
1990, 76(11):2258-65), rats injected with botrocetin (see, e.g.,
Sanders et al., 1988, Lab Invest 59(4):443-52), and porcine models
for von Willebrand disease (see, e.g., Nichols et al., 1995. Proc
Natl Acad Sci USA 92(7):2455-9; Johnson & Bowie, 1992, J Lab
Clin Med 120(4):553-8); and Brinkhous et al., 1991, Mayo Clin Proc
66(7):733-42).
.beta.-Thalassemia
[0997] Examples of animal models for .beta.-thalassemia include,
but are not limited to, murine models with mutations in globin
genes (see, e.g., Lewis et al., 1998, Blood 91(6):2152-6; Raja et
al., 1994, Br J Haematol 86(1):156-62; Popp et al., 1985,
445:432-44; and Skow et al., 1983, Cell 34(3):1043-52).
Kidney Stones
[0998] Examples of animal models for kidney stones include, but am
not limited to, genetic hypercalciuric rats (see, e.g., Bushinsky
et al., 1999, Kidney Int 55(1):234-43 and Bushinsky et al., 1995,
Kidney Int 41(6):1705-13), chemically treated rats (see, e.g.,
Grases et al., 1998, Scand J Urol Nephrol 32(4):261-5; Burgess et
al., 1995, Urol Res 23(4):239-42; Kumar et al., 1991, J Urol
146(5):1384-9; Okada et al., 1985, Hinyokika Kiyo 31(4):565-77; and
Bluestone et al., 1975, Lab Invest 33(3):273-9), hyperoxaluric rats
(see, e.g., Jones et al., 1991, J Urol 145(4):868-74), pips with
unilateral retrograde flexible nephroscopy (see, e.g., Seifmah et
al., 2001, 57(4):832-6), and rabbits with an obstructed upper
urinary tract (see, e.g., Itatani et a., 1979, Invest Urol
17(3):234-40).
Ataxia-Telangiectasia
[0999] Examples of animal models for ataxia-telangiectasia include,
but are not limited to, murine models of ataxia-telangiectasia
(see, e.g., Barlow et al., 1999, Proc Natl Acad Sci USA
96(17):9915-9 and Inoue et al., 1986, Cancer Res
46(8):3979-82).
Lysosomal Storage Diseases
[1000] Examples of animal models for lysosomal storage diseases
include, but are not limited to, mouse models for
mucopolysaccharidosis type VII (see, e.g., Brooks et al., 2002,
Proc Natl Acad Sci USA. 99(9):6216-21; Monroy et al., 2002. Bone
30(2):352-9; Vogler et al., 2001, Pediatr Dev Pathol. 4(5):421-33;
Vogler et al., 2001, Pediatr Res. 49(3):342-8; and Wolfe et al.,
2000. Mol Ther. 2(6):552-6), a mouse model for metachromatic
leukodystrophy (see, e.g., Matzner et al., 2002. Gene Ther.
9(1):53-63), a mouse model of Sandhoff disease (see, e.g., Sango et
al., 2002, Neuropathol Appl Neurobiol. 28(1):23-34), mouse models
for mucopolysaccharidosis type III A (see, e.g., Bhattacharyya et
al., 2001, Glycobiology 11(1):99-10 and Bhaumik et al., 1999,
Glycobiology 9(12):1389-96.), arylsulfatase A (ASA)-deficient mice
(see, e.g., D'Hooge et al., 1999, Brain Res. 847(2):352-6 and
D'Hooge at al, 1999, Neurosci Lett. 273(2):93-6); mice with an
aspartylglucosaminuria mutation (see, e.g., Jalanko et al., 1998,
Hum Mol Genet. 7(2):265-72); feline models of mucopolysaccharidosis
type VI (see, e.g., Crawley et al., 1998, J Clin Invest.
101(1):109-19 and Norrdin et al., 1995, Bone 17(5):485-9); a feline
model of Niemann-Pick disease type C (see. e.g., March et al.,
1997, Acta Neuropathol (Berl), 94(2):164-72); acid
sphingomyelinase-deficient mice (see, e.g., Otterbach &
Stoffel, 1995, Cell 81(7):1053-6), and bovine mannosidosis (see,
e.g., Jolly et al., 1975, Birth Defects Orig Arctic Ser. 11(6)
273-8).
Tuberous Sclerosis
[1001] Examples of animal models for tuberous sclerosis ("TSC")
include, but are not limited to, a mouse model of TSC1 (see, e.g.,
Kwiatkowski et al., 2002, Hum Mol Genet. 11(5):525-34), a Tsc1
(TSC1 homologue) knockout mouse (see, e.g., Kobayashi et al., 2001,
Proc Natl Acad Sci USA. 2001 Jul. 17; 98(15):8762-7), a TSC2 gene
mutant(Eker) rat model (see, e.g., Hino 2000, Nippon Rinsho
58(6):1255-61; Mizuguchi et al., 2000, J Neuropathol Exp Neurol.
59(3):188-9; and Hino et al., 1999, Prog Exp Tumor Res. 35:95-108);
and Tsc2(+/-) mice (see, e.g., Onda et al., 1999, J Clin Invest.
104(6):687-95).
Example 5
mdx Mouse, an Animal Model Study
[1002] The mutation in the mdx mouse that causes premature
translation termination of the 427 kDa dystrophin polypeptide has
been shown to be a C to T transition at position 3185 in exon 23
(Sicinski et al., Science 244(4912):1578-1580(1989)). Mouse primary
skeletal muscle cultures derived from 1-day old mdx mice are
prepared as described previously (Barton-Davis et al., J. Clin.
Invert. 104(4):375-381(1999)). Cells are cultured for 10 days in
the presence of a compound of the invention. Culture medium is
replaced every four days and the presence of dystrophin in myoblast
cultures is detected by immunostaining as described previously
(Barton-Davis et al., J. Clin. Invest. 104(4):375-381(1999), hereby
incorporated by reference in its entirety). A primary monoclonal
antibody to the C-terminus of the dystrophin protein is used
undiluted and rhodamine conjugated anti-mouse IgG is used as the
secondary antibody. The antibody detects the full-length protein
produced by suppression of the nonsense codon. Staining is viewed
using a Leica DMR microscope, digital camera, and associated
imaging software.
[1003] As previously described (Barton-Davis et al., J. Clin.
Invest. 104(4):375-381(1999), a compound is delivered by Alzet
osmotic pumps implanted under the skin of anesthetized mice. Two
doses of a compound of the invention are administered. Gentamicin
serves a positive control and pumps filled with solvent only serve
as the negative control. Pumps are loaded with appropriate compound
such that the calculated doses to which tissue is exposed are 10 mM
and 20 mM. The gentamicin concentration is calculated to achieve
tissue exposure of approximately 200 mM. In the initial experiment,
mice are treated for 14 days, after which animals are anesthetized
with ketamine and exsanguinated. The tibialis anterior (TA) muscle
of the experimental animals is then excised, frozen, and used for
immunofluorescence analysis of dystrophin incorporation into
striated muscle. The presence of dystrophin in TA muscles is
detected by immunostaining, as described previously (Barton-Davis
et al., J. Clin. Invest. 104(4):375-381(1999).
Western Blot Analysis
[1004] Quadricep muscles from an mdx mouse treated with a compound
of the present invention for 4 weeks are analyzed by western blot
using a commercially available antibody to dystrophin. Protein
extracted from the quadriceps of a wild-type mouse serve as a
positive control. Production of full-length dystrophin is observed
in the treated animal. The amount of full-length dystrophin
produced, as a result of nonsense suppression, but not limited by
this theory, is approximately 10% of wild-type levels of
expression.
Immunofluorescence
[1005] Male mdx mice (age 9-11 weeks) are treated with different
compounds of the present invention (n-2 at least for each
compound). These compounds are injected SQ once per day for two
weeks at 25 mg/k. After 2 weeks of treatment, mice are sacrificed
for the removal of muscles to determine dystrophin readthrough
efficiency.
[1006] Immunofluorescence (IF) is performed on 10 .mu.m
cryosections using a dystrophin antibody. The antibody recognizes
an epitope C-terminal to the premature stop mutation found in mdx
mice. Image analysis is performed in an identical manner in all
sections. Images from treated and untreated mice are analyzed and a
signal greater than the signal on the untreated control is deemed
positive and indicates that suppression of the premature
termination codon in the dystrophin mRNA occurred.
Muscle Mechanics
[1007] Isolated whole muscle mechanics is performed on EDL muscles
from animals. Optimum muscle length (Lo) is defined as the length
that produced maximum twitch tension. Maximum tetanic force at Lo
is measured using a 120 Hz, 500 msec pulse at supramaximal voltage.
Protection against mechanical injury, induced by a series of 5
eccentric tetanic contractions, is monitored. These measurements
are performed using a 700 msec stimulation period during which the
muscle is held in an isometric contraction for the first 500 msec
followed by a stretch of 8 or 10% Lo at a rate of 0.5Lo/sec.
Protection against mechanical injury is evaluated at 80 Hz
stimulation frequency. Damage is determined as the loss in force
between the first and last eccentric contraction. Treatment with
compounds of the present invention result in protection from damage
induced by eccentric contractions of the EDL muscle compared to the
untreated control.
Example 6
Suppression of a Nonsense Mutation in the p53 Gene
[1008] For an animal model system, CAOV-3 cells (1.times.10.sup.7)
are injected into the flanks of nude/nude mice. After 12 days, mice
are randomized (10 mice per group) and treated subcutaneously (5
days per week) with 3 mg/kg of a compound of the present invention
or intraperitonealy (1 day per week) with 30 mg/kg of a compound of
the present invention. Tumor volumes are measured weekly.
Suppression of nonsense mutations in the p53 gene by a compound of
the present invention can inhibit cancer growth in vivo.
Example 7
Access to Specific Nucleotides of the 28S rRNA is Modified by
Compounds of the Present Invention
[1009] Previous studies have demonstrated that gentamicin and other
members of the aminoglycoside family that decrease the fidelity of
translation bind to the A site of the 16S rRNA. By chemical
footprinting, UV cross-linking and NMR, gentamicin has been shown
to bind at the A site (comprised of nucleotides 1400-1410 and
1490-1500, E. coli numbering) of the rRNA at nucleotides 1406,
1407, 1494, and 1496 (Moazed & Noller, Nature 327(6121):389-394
(1978); Woodcock et al., EMBO J. 10(10):3099-3103 (1991); and
Schroeder et al., EMBO J. 19:1-9 (2000).
[1010] Ribosomes prepared from HeLa cells are incubated with the
small molecules (at a concentration of 100 mM), followed by
treatment with chemical modifying agents (dimethyl sulfate [DMS]
and kethoxal [KE]). Following chemical modification, rRNA is
phenol-chloroform extracted, ethanol precipitated, analyzed in
primer extension reactions using end-labeled oligonucleotides
hybridizing to different regions of the three rRNAs and resolved on
6% polyacrylamide gels. Probes for primer extension cover the
entire 18S (7 oligonucleotide primers), 28S (24 oligonucleotide
primers), and 5S (one prima) rRNAs. Controls in these experiments
include DMSO (a control for changes in rRNA accessibility induced
by DMSO), paromomycin (a marker for 18S rRNA binding), and
anisomycin (a marker for 28S rRNA binding).
[1011] All publications and patent applications cited herein are
incorporated by reference to the same extent as if each individual
publication or patent application was specifically and individually
indicated to be incorporated by reference.
[1012] Although certain embodiments have been described in detail
above, those having ordinary skill in the art will clearly
understand that many modifications are possible in the embodiments
without departing from the teachings thereof. All such
modifications are intended to be encompassed within the claims of
the invention.
* * * * *